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1 Summary (English/German) 
English: 
Precursor T lymphoblastic lymphoma (T-LBL) is the second most common subtype of Non-
Hodgkin Lymphoma (NHL) in children and adolescents. Favorable survival rates have been 
achieved with current combination chemotherapy regimens; however failure of frontline 
treatment is still fatal for the majority of patients. Currently there are no strong prognostic criteria 
known that would allow the minority of patients at risk of failure to be identified early enough to 
expose them to a more intense or new therapy.  
Cytogenetic data from four index patients from clinical trial NHL-BFM 95 exhibited a common 
deleted region at chromosomal band 6q15-q16. Interestingly, all four patients suffered from a 
relapse. In the literature, chromosome 6q deletions have been reported for various 
hematological malignancies, but the prognostic impact is still inconclusive.  
In the present study the frequency of chromosome 6q deletions in T-LBL, the common deleted 
region and the prognostic impact was analyzed. Secondly, identical analyses were performed in 
pediatric precursor T leukemia (T-ALL) patients as T-LBL and T-ALL are considered to be 
biologically closely related. Both groups were treated uniformly according to an ALL-BFM-type 
treatment strategy.  
6q deletions were examined by loss-of-heterozygosity analysis (LOH) of 25 microsatellite 
markers on chromosome 6q14-q24. A total of 1,671 markers were successfully analyzed from 
108 T-LBL patients. LOH was detectable in 21 patients. Markers D6S1682 and D6S468 flanked 
a chromosomal region which was affected by deletion in 13 cases. The cumulative incidence of 
relapse was 9±3% for LOH negative versus 63±12% for LOH positive patients (P < 0.001). In 
comparison, a total of 3,109 markers were successfully analyzed from 127 T-ALL patients. LOH 
was detected in 16 patients, with proximal interstitial deletions in 15 cases. Markers D6S1627 
and D6S1644 flanked the 4.3-Mb common deleted region. LOH at 6q was not associated with 
outcome.  
Thus, we conclude that LOH on chromosome 6q14-q24 was associated with a high risk of 
relapse in children with T-LBL and that the pattern of 6q deletions and the prognostic impact 
differed between pediatric T-LBL and T-ALL. These results might indicate differences in the 
biology of the cells in pediatric T-LBL and T-ALL. 
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German: 
Bei Kindern und Jugendlichen sind lymphoblastische T-Zell Lymphome (T-LBL) der zweit 
häufigste Subtyp der Non-Hodgkin Lymphome. Mit modernen Chemotherapie-Regimen werden 
bei diesen Patienten hohe Überlebenswahrscheinlichkeiten erzielt. Im Falle eines Rezidivs sind 
die Überlebenswahrscheinlichkeiten jedoch sehr gering. Bisher konnten keine Risikofaktoren 
etabliert werden, die eine frühzeitige Identifizierung der Hoch-Risiko-Patienten erlauben 
würden, um diese frühzeitig mit intensiverer Therapie behandeln zu können. 
Bei der Auswertung zytogenetischer Befunde von Patienten der Studie NHL-BFM 95 konnten 
vier Index-Patienten identifiziert werden, die alle vier eine Deletion im Chromosom 6q 
aufwiesen. Die gemeinsame Verlustregion der vier Fälle umfasst die chromosomalen Banden 
6q15-q16. Interessanterweise erlitten alle vier Patienten ein Rezidiv. Die Literaturanalyse ergab, 
dass 6q Deletionen bereits bei einer Vielzahl hämatologischer Erkrankungen berichtet wurden, 
die prognostische Bedeutung bisher aber ungeklärt ist. 
In der vorliegenden Studie wurden die Häufigkeit, die gemeinsame Verlustregion und die 
prognostische Bedeutung von 6q Deletionen bei Kindern und Jugendlichen mit T-LBL 
untersucht. In einem zweiten Schritt wurden die gleichen Analysen bei Kindern und 
Jugendlichen mit akuter lymphoblastischer T-Zell Leukämie (T-ALL) durchgeführt, da T-LBL und 
T-ALL als biologisch eng verwandte Erkrankungen gelten. Beide Patientengruppen waren 
einheitlich nach der ALL-BFM Strategie behandelt worden. Die Evaluation von Chromosom 6q 
Deletionen wurde mittels Loss-of-heterozygosity Analysen (LOH) durchgeführt, wobei ein Set 
von 25 Mikrosatellitenmarkern in den chromosomalen Banden 6q14-q24 untersucht wurde. 
Bei 108 T-LBL-Patienten wurden in Summe 1.671 Marker erfolgreich untersucht. LOH von 
Mikrosetellitenmarkern wurde bei 21 Patienten nachgewiesen. Die Marker D6S1682 und 
D6S468 flankieren eine Region, die bei 13 der 21 Patienten von der Deletion betroffen war. Die 
kumulative Inzidenz für ein Rezidiv war 9±3% bei LOH-negativen Patienten versus 63±12% bei 
LOH-positiven Patienten (P < 0.001). 
Im Vergleich dazu wurden bei insgesamt 127 T-ALL Patienten in Summe 3.109 Marker 
erfolgreich analysiert. Bei 16 Patienten wurde ein LOH von Mikrosetellitenmarkern 
nachgewiesen. 15 der 16 Fälle wiesen eine gemeinsame Verlustregion von 4,3 Mb im 
proximalen Anteil von Chromosom 6q flankiert von den Markern D6S1627 und D6S1644 auf. 
LOH im Chromosom 6q war bei T-ALL Patienten nicht mit dem Rezidiv-Risiko assoziiert.  
Zusammenfassend konnte bei T-LBL Patienten die Assoziation von 6q Deletion mit einer hohen 
Rezidiv-Wahrscheinlichkeit gezeigt werden. Im Vergleich zwischen T-ALL und T-LBL konnten 
sowohl bezüglich der prognostischen Bedeutung als auch bei den Mustern der 6q Deletionen 
Unterschiede gezeigt werden, die möglicherweise auf biologische Unterschiede zwischen  
T-LBL und T-ALL hindeuten. 
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2 Introduction 
In children and adolescents precursor T lymphoblastic neoplasms are classified into two 
diseases: acute lymphoblastic T-cell leukemia (T-ALL) and lymphoblastic T-cell lymphoma  
(T-LBL).  
Several study groups including the BFM-group (Berlin-Frankfurt-Münster) distinguish between 
leukemia and lymphoma based on the primary site of involvement. Patients with less than 25% 
lymphoblasts in the bone marrow and no peripheral blasts are diagnosed with lymphoblastic 
lymphoma; in case of 25% or more blasts in the bone marrow patients are diagnosed with 
leukemia.1;2  
Both, T-ALL and T-LBL are neoplasms of lymphoblasts committed to the T-cell lineage. The 
postulated cell of origin is the precursor T lymphoblast which differentiation is arrested at 
discrete stages of maturation.3-5 Thus, the malignant clones in patients with T-ALL or T-LBL are 
thought to originate from normal lymphoid progenitor cells arrested at early stages of T-cell 
maturation.  
 
2.1 T-cell maturation  
Lymphocytes are characterized by their potential to express highly diverse antigen receptors. 
This diversity is achieved during the process of lymphocyte maturation from bone marrow 
derived progenitors to mature lymphocytes in the peripheral lymphoid tissue. The process 
during lymphocyte maturation that generates this diversity is unique for all cell-types in the 
human organism. The so called somatic recombination is based on enzymatic deletion of 
deoxyribonucleic acid (DNA) sections which allows that initially separated germline DNA 
sequences are brought together. Different combinations of gene segments result in the diversity 
of the lymphocyte repertoire.  
The steps of T-cell development include 1) lineage commitment and proliferation, 2) expression 
of antigen receptor genes, and 3) selection of T-cells expressing useful antigen receptors.  
1) Lineage commitment: Pluripotent hematological stem cells in the bone marrow give rise to all 
lineages of hematological cells. Early precursors of T lymphocytes leave the bone marrow and 
circulate to the thymus, where further maturation takes place. The process of early T-cell 
maturation is associated with progressive restriction of the developmental potential of the cells. 
The earliest recognizable thymic precursor lost the capacity for megakaryocytic or erythroid 
differentiation, but retain T-cell, natural killer cell (NK), and dendritic cell and possibly B-cell and 
myeloid potential.6 Beside lineage commitment early T-cell maturation is characterized by 
interleukin-7 (IL-7) driven high mitotic activity of the progenitor cells.  
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2) Expression of antigen receptor genes: Next step of differentiation is the rearrangement of the 
T-cell receptor (TCR) gene loci. The recombination of the receptor gene sequences and the 
expression of the antigen receptor genes is the key event in the T-cell maturation process. The 
mature TCR is a heterodimer, either of an α chain and a covalently linked β chain (TCRαβ) or in 
the minority of T-cells a heterodimer composed of a γ chain and a δ chain (TCRγδ).  
The genes encoding the TCRα chain are located at chromosome 14q11, the genes encoding 
the TCRβ chain are at chromosome 7q34 and for TCRγ chain at chromosome 7p15. The TCRδ 
chain locus is contained within the TCRα chain locus. Each germline TCR locus includes 
variable (V) segments, joining (J) segments and constant (C) gene segments. The TCRβ and 
the TCRδ also have diversity (D) segments. The segments are separated by intervening DNA. 
The numbers of gene segments per TCR locus are listed in Table 1 and the germline 
organization of a TCR locus is shown exemplarily for the TCRβ chain locus in Figure I. 
Table 1. Number of gene segments of TCR loci 
 TCRα TCRβ TCRγ TCRδ 
Localized at chromosome 14q11 7q34 7p15 14q11 
Variable (V) segments 45 50 5 2 
Diversity (D) segments 0 2 0 3 
Joining (J) segments 55 12 5 4 
Constant (C) segments 1 2 2 1 
 
 
Figure I. Germline organization of human TCRβ chain locus. V: variable segments, J: 
joining segments, C: constant segments, D: diversity segments (mod. from Abbas and 
Lichtman, 20037)  
 
Prior to transcription and translation of TCR loci, the somatic recombination of the loci is 
necessary. In the process of somatic recombination the functional genes encoding for the 
variable region of the TCR are formed. The segments of the germline loci that are initially 
separated from another are brought together by enzymatic introduction of double-stranded 
breaks into the germline DNA, deletion of intervening sequences and re-ligation of DNA as 
shown schematically in Figure II. The somatic recombination is mediated by the so-called V(D)J 
recombinases, which recognize specific recombination signal sequences (RSS) flanking the 
5‘ 3‘
Vß1 Vßn Dß1 Dß2Jß1 Jß2Cß1 Cß2
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rearranging segment. The segments are combined randomly and the different combinations 
produce different antigen receptors.8  
 
 
Figure II. V(D)J recombination. The V(D)J recombinases recognize the recombination 
signal sequences and bring noncontiguous exons together by deletion of intervening DNA 
in most cases. The DNA in the rearranged T-cell is therefore fundamentally different from 
the DNA in cells with germline DNA and the process is irreversible. V: variable segments, 
D: diversity segments, J: joining segments, C: constant segments, En: Enhancer 
elements, solid and open triangles: recognition sequences for the recombinase enzyme 
complex (mod. from Kirsch et al., 19979)  
 
The somatic recombination of TCR loci starts with the TCRδ chain, followed by TCRγ and 
TCRβ. Successful TCRβ rearrangement in the presence of pre-Tα chain, which is an invariant 
transmembrane protein that associates with the TCRβ chain, allows the expression of a pre-
TCR on the cell surface. The cells at this state of maturation are double positive for CD4 and 
CD8, express cytoplasmic CD3 (cyCD3) and undergo massive proliferation. This process is 
known as β-selection. Beta-selection is followed by the rearrangement of TCRα gene locus and 
the replacement of the pre-TCR expression by TCRαβ expression on the cell surface.  
 
3) Selection of T-cells expressing useful antigen receptors: In the third phase of T-cell 
maturation the immature lymphocytes are selected based on the expressed antigen receptor 
with preservation of T-cells with useful receptors and elimination of potentially harmful self-
En En
En En
Germline locus
Intermediate
V1 V2 V3
D D
J1 J2 J3 J4 J5 C
V1 V2
J2
J3 J4 J5 C
En En
Rearranged locus
V1 V2 J2 J3 J4 J5 C
J1
V3
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antigen reactive T-cells. Positive selection of T-cells ensures the development of T-cells whose 
receptors bind with low affinity to the self major histocompatibility complex (MHC) which 
identifies the particular organism. In parallel these selected T-cells are able to recognize foreign 
peptides displayed by the same MHC molecules on the antigen-presenting cells in the 
periphery. The following functional maturation of positively selected T-cells includes the 
expression of several intracellular and surface molecules which are involved in the lymphocyte 
activation and effector functions. The steps of T-cell maturation and the TCR loci recombination 
are summarized in Figure III. 
 
Figure III. Stages of T-cell maturation (mod. from Abbas and Lichtman, 20037). TCR: T-cell 
receptor, BM: bone marrow 
 
The maturation of the T-cells including the rearrangement of the TCR loci is required for the 
generation of the immune response of the organism. However, the somatic recombination of 
TCR loci is catalyzed by a complex of enzymes including RAG1, RAG2 and DNA breakage and 
joining enzymes. The activity of these DNA-destabilizing enzymes in combination with the 
modification of the chromatin makes the DNA highly amenable to DNA breakage and rejoining 
events. This lymphocyte specific genetic instability is an important factor in consideration of the 
process of malignant transformation of the cells. The malignant transformation can occur at any 
stage of T-cell maturation. The subsequent clonal and uncontrolled proliferation of T-cells 
arrested at immature stages of development results in the clinical manifestation and diagnosis 
of precursor T-cell lymphoblastic lymphoma or leukemia. 
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2.2 Lymphoblastic lymphoma 
 
Definition of lymphoblastic lymphoma 
The designation of precursor T-cell lymphoblastic lymphoma (T-LBL) is used to describe 
precursor T-cell neoplasia with predominantly lymph node-based or thymic disease most 
commonly affecting the anterior mediastinum. The entity of lymphoblastic lymphoma has been 
recognized by most classifications of lymphoid neoplasms, including the Kiel classification10 and 
Working Formulation systems11. The WHO (World Health Organization) classification has 
unified precursor T-cell lymphoblastic leukemia (T-ALL) and T-LBL as precursor T-cell 
lymphoblastic leukemia/lymphoma.4 
 
Epidemiology of lymphoblastic lymphoma 
Lymphoblastic lymphoma (LBL) is a rare disease that accounts for approximately 2% of all Non-
Hodgkin lymphoma.12 LBL can be subdivided in LBL of T-lineage (T-LBL) and precursor B-cell 
lineage (pB-LBL) comprising 80% and 10% of cases. In about 10% of cases, the 
immunophenotype can not be defiend.4;12;13;13-23 The median age of pediatric T-LBL at diagnosis 
is 8.8 years and the male to female ratio is 2.5:1.18 
There is no clear evidence for a change in the incidence of lymphoblastic lymphoma in the 
recent years.24;25 
 
Diagnosis of lymphoblastic lymphoma 
T-LBL is distinguished from T-ALL based on amount of lymphoblasts in the bone marrow at the 
time of initial diagnosis. Patients with less than 25% lymphoblasts in the bone marrow and no 
blasts in the peripheral blood are diagnosed with lymphoblastic lymphoma. 
The histopathological and immunophenotypic features of lymphoblastic lymphoma are 
distinctive, so that diagnosis if properly approached, should be rarely a problem. The diagnosis 
can be established in two ways: In case of malignant effusions and/or significant bone marrow 
infiltration the diagnosis can be established by means of cytomorphology on cytospin 
preparations and immunophenotyping of cell suspensions, or in case of missing fluid specimen, 
diagnosis can be established by tissue examination coupled with immunophenotypic analysis 
after tumor biopsy.  
Differential diagnoses are the pB-LBL and the Burkitt Lymphoma. Both can be distinguished by 
immunophenotypic analysis of the cells. Further differential diagnostic considerations include 
other small round-cell tumors. CD99, which is characteristically present on Ewing’s Sarcoma 
and peripheral neuroectodermal tumor, is also expressed in lymphoblastic malignancies.26 
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Distinction from thymoma is complicated by the fact that both tumors have a thymic T-cell 
phenotype, but the morphology of the cells is generally different, and the characteristic epithelial 
distribution of thymoma is not present in lymphoma. In addition, cases of thymoma are rare in 
childhood and adolescence.  
 
Morphology of lymphoblastic lymphoma 
Morphologically, LBL show diffuse pattern of tissue involvement by a uniform population of 
small to medium-sized blastic cells. The lymph node shows complete effacement, with 
involvement of the capsule. The size of the lymphoblasts ranges from small cells with very 
condensed nuclear chromatin and no evident nucleoli to larger blasts with finely dispersed 
chromatin and relatively prominent nucleoli. The nuclear cytoplasmic ratio is high. Mitotic cells 
are invariably present and there are often apoptotic bodies in T-LBL. The classically described 
morphologic findings of T-LBL correspond to L1 (or L2) acute lymphoblastic leukemia in the 
French-American-British Classification of acute lymphoblastic leukemia.27 
 
Immunophenotype of lymphoblastic lymphoma 
The immunophenotype of the T-LBL cells corresponds with defined stages of intrathymic T-cell 
differentiation.28;29 Precursor-T-cell lymphoblastic lymphoma most commonly express CD7, 
CD5, and CD2, whereas CD3 is present cytoplasmatically (cyCD3) or on the surface (sCD3).30 
LBL are usually TdT positive, a marker that distinguishes them from all other types of 
lymphoma.15;31-35 In addition to TdT, CD34, and CD99 (MIC2)26 are also expressed by the 
majority of T-LBL and proved useful in distinguishing this malignancy from other NHL.  
CD4 and CD8 can be expressed in any combination: alone, neither, or both together. The 
expression of antigens corresponds to different stages of T-cell maturation with pro/pre-T-cells 
expressing cyCD3, CD7, CD2, CD5 or CD8, intermediate T-cell with positivity of CD1a, CD4, 
CD8 and CD3 and mature T-cells expressing membrane-bound CD3, and either CD4 or CD8, 
while CD1a is negative. In the NHL-BFM series most of the T-LBL were diagnosed with 
intermediate immunophenotype.36 
T-cell lymphoblasts may demonstrate clonal rearrangement of the T-cell receptor genes, but 
this does not have to be lineage-specific.37;38 Only CD3 is considered as a lineage specific 
marker.4 Examination of histological section of T-cell lymphoblastic lymphoma/leukemia could 
identify several cases with expression of CD79a, which is considered to be a marker for B-
lineage.39;40 Also CD10 expression is variable in T-LBL.41 Aberrant expression of myeloid-
associated antigen, a feature of some T-ALL, can occur in T-LBL.41-43 Interestingly, a small 
number of T-LBL may undergo a phenotypic switch to acute myeloid leukemia (AML).44;45 
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Although some of these lineage switches may occur secondary to treatment, examples of T-cell 
lymphoblastic malignancies that contain a very small blast population with committed myeloid 
maturation features have been reported.20  
 
Genetic alterations and pathogenesis of lymphoblastic lymphoma 
Due to the scarcity of adequate tumor tissue, reported cytogenetic or molecular genetic studies 
of T-LBL are rare and include small numbers of patients.46-50 Additionally, many reports 
describing molecular and cytogenetic findings of T-LBL include cases of ALL and vice-versa. 
Thus, an accurate summary of cytogenetic abnormalities in T-LBL devoid of the influence of 
ALL is still lacking. Cytogenetic data of a small series of six children with T-LBL showed that 
clonal aberrations are common and most frequently involve the T-cell receptor gene regions. 
The aberrations were similar to aberrations in T-ALL51, which is in line with earlier reports.47;50;52  
It was reported, that the t(9;17) translocation might appear more commonly in T-lymphoblastic 
lymphoma than in T-cell acute lymphoblastic leukemia. Patients with this translocation often 
present with a mediastinal mass and have an aggressive disease course.50;53 
The t(8;13)(p11;q11-14) has been described in rare cases of T-LBL that present with myeloid 
hyperplasia and eosinophilia.54;55 
The t(10;11)(p13-14;q14-q21) was described in T-ALL, AML and T-LBL.56-58  
The lack of cytogenetic and molecular genetic data on T-LBL hampers the understanding of the 
pathogenesis and molecular basis of T-LBL. The principal mechanisms are thought to be 
analogue to the pathogenic mechanisms in T-ALL.59 However, currently this hypothesis is not 
proven with experimental data. In the WHO classification it is stated, that the etiology of T-LBL 
and T-ALL is largely unknown.4 
 
Clinical features of lymphoblastic lymphoma 
Common presentation sites of T-LBL are the mediastinum and pleural effusions causing 
respiratory impairment. Pericardial effusion with resulting cardiac tamponade may also occur in 
individual cases. In addition, symptoms and signs of superior vena cava obstruction may be 
present. Further manifestation sites are lymph nodes, liver, spleen, skin, bone, testis and soft 
tissue. T-LBL cells have the potential for dissemination to the central nervous system (CNS), 
but this is rare in T-LBL with a frequency of about 3% in the NHL-BFM group.18 Bone marrow 
(BM) infiltration occurs in almost 20% of the cases, however, the amount of infiltration 
lymphoblasts in the bone marrow must be less than 25% per definition. 
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Prognostic factors in lymphoblastic lymphoma 
Reliable and accurate methods for predicting prognosis are required to achieve adequate 
treatment with the least invasive regimens. Identification of clinical and/or biological prognostic 
factors is essential for individual risk adapted treatment of the patients. Specific chromosomal 
aberrations in hematological malignancies have been well known for years and in some entities 
even serve as diagnostic criteria or criteria for risk stratification.60;61 However, in T-LBL the 
available genetic data are to few to prove prognostic impact of a specific genetic alteration and 
until now no genetic alteration or immunophenotypic marker with stable prognostic impact has 
been identified. 
Concerning clinical parameters, few small retrospective series of adult patients with 
lymphoblastic lymphoma identified adverse clinical prognostic factors such as advanced age, 
Ann Arbor stage of disease, bone marrow or CNS involvement, lactate dehydrogenase (LDH) 
level, B symptoms, time to attainment of complete response or International Prognostic Index 
Group.19;37;47;62-65 Only few parameters have been consistent across different series, most have 
varied in the different studies. 
In pediatric LBL Riopel and colleagues showed adverse prognostic effect of advanced Ann 
Arbor stage of disease, bone marrow involvement, CNS involvement, elevated LDH level and B 
symptoms.26 However, in the series of the BFM-group including 290 uniformly treated pediatric 
T-LBL patients, the only parameters with prognostic impact were B symptoms and critically ill 
condition at diagnosis.66  
In conclusion, there are no consistent data for T-LBL on prognostic parameters. Hence no clear 
rationale exists for the stratification of T-LBL patients into different risk groups with differences 
in the treatment intensity. The only stratification criterion in use for the ongoing clinical trial of 
the NHL-BFM group is the stage of disease with reduced treatment intensity for patients with 
stage I or II disease. However, in T-LBL less than 5% of patients are diagnosed with limited 
stage I or II disease. Therefore, in practical terms more than 95% of patients receive the 
identical chemotherapy without any individual risk adaptation of treatment intensity. 
 
Treatment and outcome of lymphoblastic lymphoma 
Combination chemotherapy with or without local radiotherapy resulted in event-free survival 
rates of 64-90% for children suffering from lymphoblastic lymphoma.36;67-74 In early studies the 
outcome of patients with lymphoblastic lymphoma was fatal for the majority of the patients. The 
introduction of intensive chemotherapy and radiation therapy protocols produced marked 
improvements in outcome. Protocols such as the LSA2-L2 regimen combined intensive 
chemotherapy with central nervous system irradiation.75 For children with LBL various strategies 
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have been implemented to further improve the treatment outcome achieved with  
LSA2-L2.36;67;69;70;76 The French Society of Pediatric Oncology incorporated courses of high-dose 
methotrexate into an LSA2-L2 backbone with excellent results.67 In the NHL-BFM-group 5-year 
event-free survival of 85-90% has been achieved with a regimen whose consolidation phase 
includes four courses of high-dose methotrexate (5g/m² given every 2 weeks).36;77 This 
improvement in outcome may be the result of higher intracellular levels of methotrexate 
polyglutamates achieved with the higher dose of methotrexate.78 In addition to an improved 
outcome, the BFM-strategy contains reduced cumulative doses of cytostatic agents with a high 
risk for late effects compared with the LSA2-L2 backbone. Other refinements in therapy that are 
thought to contribute to improved treatment outcome include the incorporation of a re-induction 
phase, as well as the incorporation of L-asparaginase.36;70;76  
 
Relapse of lymphoblastic lymphoma 
Relapses of T-LBL occur early (within the first year after diagnosis) and involve the local site of 
initial manifestation in most of the cases. With currently available rescue-treatment strategies a 
significant number of patients fail to achieve a stable second remission. Therefore the outcome 
after failure of frontline treatment is very poor with 5-years survival rates below 20%. Almost all 
patients who were successfully rescued received high-dose chemotherapy followed by allogenic 
stem-cell transplantation.79-82 
 
2.3 Acute lymphoblastic leukemia  
 
Epidemiology of lymphoblastic leukemia 
Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children.25;83 The 
majority of pediatric ALL account for precursor B-cell immunophenotype (pB-ALL), while about 
15% of cases express T-lineage associated antigens.4;28;84;85 The median age at diagnosis is 8.1 
years and the male to female ratio in childhood and adolescent T-ALL is 3:1.84 
 
Diagnosis of lymphoblastic leukemia 
Diagnosis of ALL is established by cytomorphological examination and flow cytometry analysis 
of bone marrow or peripheral blood. Differential diagnostic considerations for T-ALL include ALL 
of B-lineage, T-LBL, minimally differentiated AML and reactive bone marrow. T-ALL, pB-ALL 
and AML can be distinguished from each other by immunophenotypic analysis of the malignant 
cells. The differentiation of T-ALL and T-LBL is based on the blast count in the bone marrow. 
The diagnosis of T-ALL requires 25% or more lymphoblast infiltration in the bone marrow.  
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Morphology of lymphoblastic leukemia 
The morphologic features of the cells are indistinguishable from the morphology of T-LBL cells 
with small to medium sized blast cells with scant cytoplasm, condensed to dispersed chromatin 
and high nuclear to cytoplasmic ratio.  
 
Immunophenotype of lymphoblastic leukemia 
T-ALL and T-LBL cells are similar in basic immunophenotyping. The lymphoblasts express TdT 
and variable CD1a, CD2, CD3, CD4, CD5, CD7 and CD886-88. CD10 might be positive and 
CD79a positivity has been reported in some cases.39;40;89 Co-expression of myeloid associated 
antigens CD13, CD33 and CD117 were detectable in considerable numbers of patients.41;90 
 
Genetic alterations and pathogenesis of lymphoblastic leukemia 
How many different mutations are required for leukemic transformation still remains to be 
elucidated. As leukemic cells are thought to derive from normal lymphoblasts arrested at 
defined stages of early maturation, every cell function or pathway that ensures homeostasis of 
the T-cell maturation system is a potential target for disruption. Some nonrandom cytogenetic 
alterations were described for T-ALL cells e.g. deletions of chromosome 9p or 6q, trisomy 8, 
14q11 breakpoints, 11q23 breakpoints, 14q32 translocations, and 7q32-q36 breakpoints.91-95 
Translocations involving the T-cell receptor (TCR) loci either TCRαδ at chromosome 14q11 or 
TCRβ locus at chromosome 7q34 have been detected in 15% to one third of the patients.96;97 
The translocations lead to a deregulated expression of the partner gene by juxtaposition with 
the regulatory region of one of the T-cell receptor loci. Translocation partner genes include 
several genes with oncogenic properties such as MYC(at chromosome 8q24), TAL-1(1p32), 
RBTN/LMO1(11p15), RBTN/LMO2(11p13), HOX11(10q24) and LCK(1p34).93;98 The TCR 
breakpoints in many cases resemble TCR recombination signals, implying that the genetic 
alteration occurred during TCR rearrangement.99-103  
NOTCH1 was discovered as partner gene of the TCR locus in the translocation t(7;9) which was 
described in rare cases of T-ALL.104 Subsequently the essential role of NOTCH1 for T-cell 
maturation was shown.105;106 Interestingly, recent functional screenings of T-ALL samples 
revealed, that gain-of-function mutations of NOTCH1 can frequently be detected in T-ALL.107 
Currently, lots of efforts are undertaken to further elucidate the role of NOTCH1 activation in the 
pathogenesis of T-ALL. NOTCH1 is suggested to act as a master transcriptional regulator that 
contributes to T-cell transformation by regulating cell growth.108 Weng and colleagues could 
identified c-Myc as direct target of NOTCH1 in T-ALL cells109 and Chiang and colleagues 
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identified a regulatory sequence of NOTCH1 whose function influences the leukemogenic 
activity of NOTCH1110.  
Alteration of TAL-1 on chromosome 1p32 is considered to be one of the most common 
nonrandom genetic aberrations in T-ALL. In about 10-25% of cases TAL-1 locus is deregulated 
by a small interstitial deletion resulting in the SIL-TAL-1 fusion gene with aberrant expression of 
TAL-1.111-115 Translocations involving the TAL-1 locus were estimated to occur in 1-3% of  
T-ALL.92;116 TAL-1 (or stem cell leukemia gene SCL) encodes a basic helix-loop-helix 
transcription factor which is expressed in erythroid, myeloid, megakaryocytic, and hematopoetic 
stem cells117;118 and is required for normal hematopoesis.119;120 However, this gene is not 
expressed in normal T-lineage cells.121 Recent data indicate, that in T-lineage progenitor cells 
transcriptional effects downstream of the aberrant expression of TAL-1 are amplified in a 
complex transcriptional network that results in the disruption of critical mechanisms that control 
cell homeostasis during T-cell development.108 
The deletion of chromosome 9p occurs more frequently in T-ALL than in other immunologic 
subsets. It is observed in about 30% of cases by cytogenetic analysis and a higher percentage 
by molecular testing with even 70% or higher deletion-rate in T-ALL.122-126 This deletion results 
in the loss of CDKN2A and CDKN2B. These gene loci code for p14 and p15  which have been 
implicated for a role in the biology of T-ALL.127-132 Also inactivation of the transcripts at 
transcriptional and post-transcriptional level have been reported.132;133 The transcripts of the 
locus are involved in the upstream regulation of retinoblastoma (Rb) protein thus blocking the 
cell cycle at the G1 phase134 and in the regulation of p53 protein, which ensures cell cycle arrest 
and attempt to repair genotoxic damage before replicating DNA.135;136 
The ATM gene product (Ataxia teleangiectasia mutated gene) is another protein which plays a 
central role in mediating cellular signaling in response to DNA damage. Hereditary mutations of 
the ATM gene cause ataxia teleangiectasia, a degenerative neurological disorder, which is 
characterized by immunodeficiency and increased risk of developing hematological 
malignancies, especially of T-cell origin.137;138 In addition, acquired ATM alterations were 
described in children with lymphoid malignancies implicating ATM in leukemogenesis.139;140 A 
recent report identified five polymorphisms of the coding part of ATM in children with T-ALL, 
which were associated with higher white blood cell count and unfavorable outcome.141 
The review of the wide range of genetic alterations in T-ALL led to the understanding, that these 
chromosomal rearrangements are a hallmark of the biological diversity of T-ALL cells and are 
likely the result from defects in underlying cellular control mechanisms. Defective cell cycle 
surveillance mechanisms are likely to be the major factors leading to both, deregulated 
proliferation and chromosomal abnormalities that are associated with leukemic cells.29;142;143  
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Clinical features of lymphoblastic leukemia 
By definition all T-ALL patients have at least 25% lymphoblast count in the bone marrow and/or 
detectable lymphoblasts in the peripheral blood at initial diagnosis. T-lineage ALL is often 
associated with high leukocyte count in the peripheral blood and a mediastinal mass.144-147 
Other sites are peripheral lymph nodes, skin, liver, spleen, Waldeyer’s ring, CNS and gonads.  
 
Prognostic factors in lymphoblastic leukemia 
A number of risk factors were described in different clinical trials. Differences in risk stratification 
and treatment as well as the improvement of outcome in recent trials complicate the 
identification of stable and valid prognostic factors. 
Concerning clinical characteristics, a recent review stated that the prognostic impact of age and 
leukocyte count have little clinical significance in T-ALL.148 In an analysis of the ALL-BFM trials 
the relapse rate was slightly lower in T-ALL patients under 10 years of age.84 However, the 
association between different factors such as T-lineage immunophenotype, elevated age and 
hyperleukocytosis hamper the assessment of the direct and independent impact of age on the 
prognosis. Male gender has been reported to be associated with poor prognosis.149 However 
the adverse effect of male gender has been abolished in clinical trials in which the overall 5-year 
event-free survival rate is about 80% or more.150;151 
Regarding biological features of the leukemic cells, the prognostic impact of immunophenotypic 
characteristics of ALL were analyzed in several studies. However, the lack of standardized 
criteria for the classification of subgroups, the different treatment strategies applied and the 
association of immunophenotypic parameters with certain cytogenetic aberrations complicated 
the assessment of the independent prognostic impact of immunophenotypes. In the past, ALL 
with T-cell immunophenotype was generally considered to be at high risk148, mainly due to the 
association of T-lineage immunophenotype with numerous unfavorable clinical features. 
Therefore children with T-ALL were reported to have a worse prognosis than non-T-ALL.85;152;153 
Investigations of the prognostic impact of the maturation stage of T-ALL lymphoblasts indicate a 
favorable outcome of CD1a-positive intermediate phenotype and inferior outcome of patients 
with pro-T-cell immunophenotype.29;154-158 Some studies could show associations between the 
expression of particular immunophenotypic markers and the outcome of patients e.g. a worse 
outcome for CD10 negative T-ALL.85;146;159 A larger Children's Cancer Group series reported a 
statistically significant positive correlation between the CD2 expression level and event free 
survival.160 And it was reported that CD3 positivity combined with an abnormal karyotype was a 
significant adverse risk factor161, in contrast another study found no prognostic significance of 
CD3 expression85. In the same way the co-expression of myeloid-associated antigens remains a 
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controversial prognostic factor with similar outcome for patients with and without myeloid-
antigen co-expression in some studies29;90;154, but inferior results in others162;163. 
 
Cytogenetic abnormalities have been described in pediatric ALL and were used for risk-
stratification in clinical trials e.g. in cases with hyperdiploidy or specific translocations, such as 
t(4;11) and t(9;22). However, the majority of these specific aberrations occur in pB-ALL rather 
than in T-ALL.164 In T-ALL aberrant karyotypes particularly involving the T-cell receptor genes 
were described, but none of these cytogenetic abnormalities have been shown to have 
prognostic significance.92;93;95 The data on the prognostic impact of molecular genetic detection 
of homozygous deletion of the CDKN2A locus in childhood T-ALL are inconsistent but there 
might be an unfavorable impact.128 
Recently Breit et al. showed that activating NOTCH1 mutations in pediatric T-ALL patients 
predict a more rapid early treatment response and favorable long term outcome in the context of 
the treatment strategy ALL-BFM 2000.165 In contrast, Zhu et al. showed statistically significant 
inferior relapse-free survival for adult patients with T-ALL positive for NOTCH1 mutation 
compared with NOTCH1 mutation negative T-ALL patients. In the pediatric age-group NOTCH1 
mutation positive patients tended to an inferior outcome, but this trend was no longer 
significant.166 
Gene expression profile studies showed that most cases of T-ALL can be grouped on the basis 
of involvement of one or more specific oncogenes such as HOX11, HOX11L2, TAL-1 plus either 
LMO1 or LMO2, LYL1 plus LMO2, and MLL-ENL.167 Over-expression of these specific 
oncogenes has been reported to confer favorable or unfavorable prognosis168-172, however the 
numbers were small and the data partly inconsistent. Therefore no solid prognostic genetic 
marker has been identified and reached general acceptance so far.  
The ALL-BFM group implemented the vivo response to prednisone as an important prognostic 
parameter. In trial ALL-BFM 83 a 7-day prednisone prephase was introduced for the reduction 
of morbidity derived from tumor lysis. The reduction of lymphoblasts in peripheral blood was 
evaluated. The in vivo response to the 7-day prednisone prephase was shown to be of strong 
prognostic significance and the a leukemic blast cell count in peripheral blood of 1,000 per µl or 
more at day 8 defined a subgroup of ALL patients with a very high risk of relapse.173 Therefore 
the early prednisone response was introduced as additional risk stratification criterion in trial 
ALL-BFM 86 and remained the most important prognostic factor for the subsequent ALL-BFM 
trials.2;152;174 
In the ongoing clinical trial ALL-BFM 2000 patients are stratified into three risk groups based on 
the in vivo prednisone response, the presence or absence of the translocations t(9;22) or 
t(4;11), and the cytomorphological response in the bone marrow at day 33. Patients are further 
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stratified according to minimal residual disease (MRD) kinetics. MRD kinetic is assessed at two 
different time points, at day 33 and week 12 of treatment. Allele-specific polymerase chain 
reaction (PCR) protocols are used for quantitative detection of leukemic clone-specific T-cell 
receptor gene rearrangements.175  
 
Treatment and outcome of lymphoblastic leukemia 
Previous studies showed poorer outcomes for patients with T-lineage ALL compared to  
B-lineage.145;153;161;176;177 The criteria used for risk classification were different, complicating the 
comparisons between groups. Nevertheless T-ALL patients were assigned to more intensive 
treatment elements compared to patients with pB-ALL.173;178-181 Recent studies have reported 
improved outcomes in pediatric T-ALL150;151;182-185, which suggest that for T-ALL patients when 
treated by intensive therapeutic regimens the risk might be almost similar to that of B-lineage 
ALL.  
In the BFM-strategy based protocols, the outcome of T-ALL patients improved clearly in trial 
ALL-BFM 86 compared with previous trial ALL-BFM 83; most likely due to the introduction of 
high-dose methotrexate in trial ALL-BFM 86.153 
 
Relapse of lymphoblastic leukemia 
The outcome of patients who suffered a relapse of T-ALL is dismal because only a small 
number of patients (about 20%) can be saved with intensive chemotherapy followed by bone 
marrow transplantation (BMT).186;187  
 
26 
 
 
Distinction between T-cell lymphoblastic lymphoma and leukemia 
Both diseases share common characteristics as immunophenotypic features, the morphology of 
the lymphoblasts but also clinical characteristics as the median age at diagnosis and the 
favorable outcome after ALL-type chemotherapy. Besides the similarities there are obvious 
differences between the two diseases. In lymphoma patients an anterior mediastinal mass 
represents the primary site of disease while in leukemia patients bone marrow involvement is 
the predominant site of disease. Interestingly the typical sites of relapse differ also, with 
predominantly local relapse in lymphoma patients36;80 and systemic relapse in T-ALL186. These 
differences in the distribution of the disease might indicate differences in the homing of 
lymphoblasts between lymphoma cells and leukemia cells. This raises the question whether  
T-LBL and T-ALL represent one disease with two different presentations or whether the cells of 
the two diseases carry different biologic potentials. 
Because of the overlapping morphologic and immunophenotypic features, the distinction 
between acute lymphoblastic leukemia and lymphoblastic lymphoma is considered by some to 
be largely arbitrary.188-190 The International Lymphoma Study Group and the WHO have 
designated these malignancies precursor T lymphoblastic leukemia/lymphoma in the updated 
REAL and WHO classification.4;191;192  
However, subtle immunophenotypic, molecular, and cytogenetic differences suggest that acute 
lymphoblastic leukemia and lymphoblastic lymphoma might be biologically different in certain 
aspects.14;15;20;28;193-195  
 
Immunophenotype 
T-ALL and T-LBL show overlapping immunophenotypic features4, but some studies stated that 
lymphoblastic lymphomas in general have antigen expression profiles consistent with a more 
mature stage of intrathymic T-cell development than does T-cell acute lymphoblastic 
leukemia.14;15;20;22;193-196 However, attempts at separating lymphoblastic lymphoma from acute 
lymphoblastic leukemia by immunophenotypic features have been largely unsuccessful. 
Interestingly, it was reported on a small series, that T-ALL express more frequent the TCRγδ 
than it can be detected in T-LBL.197 However, larger comparative series analyzed with current 
immunophenotypic techniques and classified according to agreed classification systems are 
lacking. 
 
Genetics 
Compared with T-ALL, there is relatively little literature on cytogenetic studies or molecular 
analyses in T-LBL.59 The elucidation of genetic alteration in T-LBL is hampered by the scarcity 
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of specimen for detailed genetic characterization. It is stated in the literature and current text 
books that the typical chromosomal aberrations reported in T-ALL can also be found in  
T-LBL.4;20 However, larger series of cytogenetic and molecular genetic data in T-LBL are 
missing. 
Concerning molecular genetic analyses, Raetz and colleagues compared gene expression 
profiles of nine T-LBL and ten T-ALL samples. Though the number of samples was limited, the 
authors reported significant and clear distinctions in the expression profiles between T-LBL and 
T-ALL using both unsupervised and supervised methods of data analysis.198  
Baleydier and colleagues performed paraffin tissue microarray immunophenotyping, T-cell 
receptor rearrangement genotyping by Southern blot and PCR and RQ-PCR quantification of 
pTa, RAG1, HOXA5/A9, HOX11/HOX11L2, LMO1/2, LYL1, TAL-1, SIL-TAL, CALM-AF10 and 
NUP214-ABL (fusion-) transcripts in a retrospective series of 44 T-LBL (12 patients < 16 years). 
The authors concluded that pediatric T-LBL show different oncogenic profiles compared to 
those of T-ALL arrested at the same stage of maturation.199  
In addition, the incidence of NOTCH1 mutations were examined comparatively for T-ALL and T-
LBL samples and analyzed with respect to possible differences regarding clinical features or 
stage of maturation arrest of the T-lymphoblasts. 46 T-ALL samples and 44 T-LBL samples 
obtained from adult and pediatric patients were analyzed by direct sequencing for mutations in 
exons 6, 27 and 34. The authors reported NOTCH1 mutations in 48% of T-ALL samples and 
41% of T-LBL samples. The type of mutations differed insofar, as combined mutations of the 
HD (heterodimerisation) domain and the PEST domain were seen in 6/22 T-ALL and 6/18  
T-LBL, HD-mutations-only were seen in 16/22 T-ALL and 7/18 T-LBL, while PEST-mutations-
only were seen in none of the T-ALL samples but 5/18 T-LBL samples.200 
 
Clinical characteristics 
The best known difference between T-ALL and T-LBL is the primary site of involvement. T-ALL 
patients present with bone marrow involvement and lymphoblasts in the peripheral blood often 
accompanied by thrombocytopenia. In T-LBL patients the primary manifestation of the 
lymphoma is the anterior mediastinum with pleural and/or pericardial effusions.  
Splenomegaly and adenopathy was reported to be more frequent in T-ALL than in T-LBL.188 
The frequency of CNS involvement in T-ALL is more than twice of the frequency of CNS 
involvement in T-LBL.18;84 However, in general the clinical characteristics show a larger overlap 
between pediatric T-LBL and T-ALL, e.g. a high portion of T-ALL patients are diagnosed with 
mediastinal mass. 
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Treatment 
In the past the prognosis for T-ALL patients was inferior compared with the outcome of T-LBL 
patients despite treatment with comparable intensive chemotherapy protocols.23;36;153 However, 
these differences were equalized due to the improvement in outcome for T-ALL patients. 
 
 
2.4 Deletions of chromosome 6q 
 
The NHL-BFM study center in Giessen and the Oncogenetic Laboratory in the department of 
Pediatric Hematology and Oncology of the Justus Liebig University Giessen serve as national 
reference laboratories for cytomorphology, molecular genetics and cytogenetics in childhood 
and adolescent NHL. These laboratories receive tumor, blood and bone marrow samples from 
patients in Germany for central reference analysis. In addition, the Institute of Human Genetics, 
University Hospital Schleswig-Holstein, Campus Kiel, head Prof. Dr. R. Siebert (former Prof. Dr. 
W. Grote) served as national reference laboratory for cytogenetics in the trial NHL-BFM 95. 
 
During the last years a considerable number of samples for cytogenetic analysis could be 
examined to allow a retrospective analysis of the available data. This analysis of the cytogenetic 
data of T-LBL patients revealed four patients with a deletion of chromosome 6q. The full 
karyotype of these four patients is depicted in Table 2. Interestingly, all four patients exhibited a 
common deleted region at chromosomal band 6q15-q16 as illustrated in Figure IV (common 
deleted region highlighted with light grey color) and all four patients had suffered a relapse.  
 
Table 2. Karyotypes of the four index patients with cytogenetic detectable deletion 
of chromosome 6q. All four patients suffered a relapse. 
index patient I 46,XX,del(6)(q1?2q1?6),t(9;17)(q34;q22) 
index patient II 46,XY,del(6)(q12q24) 
index patient III 46,XY,t(1;5)(q32;q35), del(6)(q15q25) 
index patient IV at relapse: 45~47,XY,del(6)(q1?4q2?1),t(9;14)(q34;q11),+?20,+mar 
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Figure IV. Deleted region of chromosome 6q in the four index patients (pt.) detected by 
cytogenetic analyses. The black bars indicate the deleted region in each of the four cases.  
 
A review of the literature revealed that deletions of chromosome 6q have been reported in a 
variety of hematological malignancies such as lymphoid malignancies201-212, B-cell Non Hodgkin 
Lymphoma213-218, follicular lymphoma219;220, chronic lymphocytic leukemia (CLL)221-223, 
Waldenstrom macroglobulinemia224;225, or (pediatric) acute lymphoblastic leukemia93-95;226-241. 
Chromosome 6q deletions have also been described in a variety of solid tumors such as cystic 
carcinoma242, pancreatic cancer243, hepatocellular carcinoma244, melanoma245, prostate 
cancer246;247, breast cancer248, gastric carcinoma249, and lung cancer250. 
These data led to the suggestion, that a tumor suppressor gene is localized on chromosome 6q. 
A number of studies on hematological malignancies narrowed down different minimal regions of 
deletion202;205;206;213;216;221;237;251, and two studies identified candidate tumor suppressor genes 
localized in the minimal deleted region of the study samples, but their tumor suppressor role has 
not yet been confirmed. 201;226 
 
Concerning the prognostic value of 6q deletions in hematological malignancies, some studies 
claim deletions of chromosome 6q to be of no prognostic impact93;228;240;252, while other studies 
associate them with inferior treatment response and an increased risk for 
relapse.207;215;216;220;222;225;236;241;253;254  
 
Focused on T-LBL, there were no data about 6q deletions available in the literature. In pediatric 
acute lymphoblastic leukemia the frequency of 6q deletions was reported between 8% to 18% in 
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cytogenetic analyses92;93;95;227;228 and 15-32% with molecular genetic analyses204;240;255. 
Differentiated according to immunophenotype, 6q deletions were more frequent in T-ALL 
compared with precursor B-cell ALL.233;234;236;252 
Eight published studies of ALL samples and in some studies ALL and NHL samples which were 
based on fluorescence in situ hybridization or loss of heterozygosity analyses identified a 
common deleted region in the respective sample series.204-206;226;229;231;240;254 The relative 
positions of the common deleted regions are summarized in Figure V. 
 
Figure V. Regions of minimal deletion in ALL (and NHL) identified in published studies 
mapping 6q deletion with fluorescence in situ hybridization or loss of heterozygosity 
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The prognostic impact of 6q deletions in T-ALL has not been determined yet. It was reported 
that the early response to treatment was inferior in ALL patients with 6q deletions compared to 
patients without 6q deletions.252 Four studies indicated an association of 6q deletions with poor 
outcome. In two cytogenetic analyses of adult ALL patients deletions of 6q were associated with 
reduced event free survival and higher relapse rates.236;241 Focused on T-ALL, a karyotype 
analyses of 354 pediatric T-ALL cases reported 6q deletions in 38 patients (11%). Twenty-
seven of these 38 patients suffered a relapse.92 In addition, Foroni et al. reported inferior 
outcome in T-ALL patients with del(6)(q16q21) compared to patients without this aberration.254 
However, in some studies there was no prognostic value of 6q deletions in ALL patients.240;252;255  
 
In conclusion neither the frequency nor the prognostic impact of chromosome 6q deletions was 
analyzed in pediatric T-LBL so far. Four index patients of the NHL-BFM studies might indicate a 
possible association of 6q deletions with increased risk of relapse in T-LBL. 
T-ALL is considered to be a biologically closely related disease or according to some, simply the 
different clinical manifestation of the same disease. The available data on the impact of 6q 
deletions in T-ALL are inconsistent. Therefore, the impact of chromosome 6q deletions and the 
relationship of pediatric T-LBL and T-ALL remain to be elucidated. 
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2.5 Study objectives 
 
In T-LBL patients, the clinical impact of chromosome 6 deletions is still unclear, due to the lack 
of genetic data. In T-ALL the impact of 6q deletions is complicated due to the inconsistent 
reports in the literature. The published studies on 6q deletions in hematological malignancies 
imply, that 6q deletions might have different effects in different biological entities. In addition, the 
prognostic value might depend on the treatment applied. Therefore, this retrospective study was 
focused on a systematic comparison of chromosome 6q deletions in pediatric T-LBL compared 
with pediatric T-ALL. To allow detailed outcome analyses the current retrospective study was 
restricted to patients uniformly treated according to ALL-BFM type treatment strategies.77;153;256 
 
The first phase of the project was focused on T-LBL samples. The following study objectives 
were defined:  
• Analysis of the frequency of chromosome 6q deletions in T-LBL 
• Identification of the common deleted region in T-LBL 
• Evaluation of the prognostic impact of 6q deletions in T-LBL 
 
In the second phase of the project the study objectives were extended and transferred on  
T-ALL, a biologically closely related disease. The following study objectives were defined: 
• Analysis of the frequency of chromosome 6q deletions in T-ALL 
• Identification of the common deleted region in T-ALL 
• Evaluation of the prognostic impact of 6q deletions in T-ALL 
• Comparison of T-LBL and T-ALL concerning the frequency of chromosome 6q deletions, the 
common deleted regions of 6q deletions and the prognostic impact 
• Discussion whether the molecular genetic pattern of 6q deletions add data on the question 
concerning biologic similarities and differences between T-LBL and T-ALL 
 
Based on the limitations concerning the availability of tumor samples, especially in the T-LBL 
cases, it was intended to perform fluorescence in situ hybridization (FISH) to examine the above 
mentioned study objectives. The FISH technique allows the investigation of interphase nuclei 
and does not necessarily require metaphase nuclei as cytogenetic analysis does. Therefore, the 
spectrum of evaluable sample types is larger in FISH technique and includes also tumor touch 
imprints and cytospin preparations of malignant effusions. 
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3 Material and methods  
3.1 Materials 
3.1.1 Reagents for Fluorescence in situ hybridization (FISH) 
Table 3. Reagents for FISH reaction 
 Lysogeny Broth (LB) Medium containing Chloramphenicol* 
 Agarose, PeqGOLD Universal Agarose, Peqlab, Erlangen, Germany 
 I2-Propanol, Sigma, Steinheim, Germany 
 H2O 
 10x NT-buffer* 
 0.1 M ß-Mercaptoethanol* 
 dNTP, Roche, Mannheim, Germany* 
 Spectrum Green-dUTP, Vysis, Downers Grove, USA 
 Spectrum Orange-dUTP, Vysis, Downers Grove, USA 
 Cy3-2'-deoxy-uridine-5'-triphosphate, Amersham Biosciences, 
Buckinghamshire, UK 
 Biotin-16-2'-deoxy-uridine-5'-triphosphate, Roche, Mannheim, 
Germany 
 Digoxigenin-11-2'-deoxy-uridine-5'-triphosphate, Roche, Mannheim, 
Germany 
 DNA Polymerase I, 5 U/µl, Roche, Mannheim, Germany 
 Deoxyribonuclease I, Invitrogen, Karlsruhe, Germany 
 DNA ladder III and VI, Roche, Mannheim, Germany 
 1% Ethidium-bromide, Roth, Karlsruhe, Germany 
 0.5 M EDTA, Invitrogen, Karlsruhe, Germany 
 Human cot DNA (1 mg/ml), Invitrogen, Karlsruhe, Germany 
 Salmon sperm DNA (10 mg/ml), Sigma, Steinheim, Germany 
 3 M sodium acetate* 
 30%, 50%, 70%, 90%, 100% Ethanol, Riedel de Haen, Sigma, 
Seelze, Germany* 
 CEP Hybridization mix, Vysis, Downers Grove, USA 
 Fixative (methanol:acetic acid)* 
 0.1x SSC* 
 2x SSC* 
 0.01 M HCl* 
 Pepsin solution* 
 1x PBS* 
 Formamide solution*  
 Rubber cement Fixogum, Marabu, Tamm, Germany 
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Continue Table 3 
 1x SSC* 
 2x SSC+Tween 0.1%* 
 4x SSC+Tween 0.05%* 
 Avidin-FITC, Roche, Mannheim, Germany 
 Antidigoxigenin-Rhodamin, Roche, Mannheim, Germany 
 1% BSA, Promega, Madison, USA 
 Vectashield, Mounting Medium with DAPI, Burlingame, USA 
 5% BSA, Promega, Madison, USA 
 
* Solutions are described in detail in appendix 8.2 Solutions, buffers and media. 
 
3.1.2 Reagents for DNA preparation 
Table 4. Reagents for DNA preparation 
100% Ethanol 100% Ethanol, Riedel de Haen, Sigma, Seelze, Germany* 
Chloroform Trichlormethan Chloroform > 99%, Roth, Karlsruhe, Germany 
Sodium citrate Sodiumcitrate-Dihydrate, Merck, Darmstadt, Germany 
Sodium hydroxide Sodium hydroxide, Roth, Karlsruhe, Germany 
 
3.1.3 Reagents for PCR 
Table 5. Reagents for PCR reaction 
dNTP ROTI®-Mix PCR3 (10nM), Roth, Karlsruhe, Germany 
Polymerase AmpliTaq Gold, Applied Biosystems, Weiterstadt, Germany 
MgCl2  MgCl2 Solution 50 mM, Invitrogen, Karlsruhe, Germany 
Buffer GeneAmp 10x PCR Buffer (contains 15 mM MgCl2),  
Applied Biosystems, Weiterstadt, Germany 
H20 LiChrosolv, Merck, Darmstadt, Germany 
 
3.1.4 Reagents for fragment length analysis 
Table 6. Reagents for fragment length analysis 
Polymer Performance Opti. Polymer6 3100 (POP-6),  
Applied Biosystems, Weiterstadt, Germany 
Buffer Buffer (10x) with EDTA, Applied Biosystems, Part. No. 402824 
HI-DI Hi-DiTM Formamide, pH 7.1, Applied Biosystems 
Size standard GenescanTM 400 HD [ROXTM] Standard, Applied Biosystems 
single-stranded labeled fragments: 50, 60, 90, 100, 120, 150, 160, 
180, 190, 200, 220, 240, 260, 280, 290, 300, 320, 340, 360, 380, 400
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3.1.5 Patients’ samples 
In T-LBL cases, the samples were collected in the reference laboratories of the study NHL-BFM 
between April 1995 and May 2004. The study center and reference laboratory for 
cytomorphology and genetics at the Justus Liebig University Giessen, head Prof. Dr. A. Reiter 
provided bone marrow and blood smears, tumor touch imprints, cytospin preparation of 
malignant effusions, frozen tumor cells and frozen cells from malignant effusions. The reference 
laboratory for pathology at the Lymph Node Registry at the University in Kiel, head Prof. Dr. H. 
Wacker (former Prof. Dr. R. Parwaresch) provided DNA extracted from paraffin embedded 
tumor biopsies. The reference laboratory for immunophenotyping at the Robert-Rössle-Klinik at 
the HELIOS Klinikum Berlin-Buch, Charité Medical School, Berlin, head Prof. Dr. W.-D. Ludwig 
and the Institute of Human Genetics, University Hospital Schleswig-Holstein, Campus Kiel, 
head Prof. Dr. R. Siebert (former Prof. Dr. W. Grote) provided tumor cells of malignant effusions 
or tumor cells frozen in DMSO.  
 
In T-ALL the samples were collected between August 1999 and July 2002. The DNA of the 
initial tumor samples and blast-free follow-up samples were provided by the ALL-BFM study 
center and reference laboratory for cytomorphology and MRD monitoring, head Prof. Dr. M. 
Schrappe.  
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3.2 Molecular genetic methods 
3.2.1 Fluorescence in situ hybridization (FISH) 
In situ hybridization is a technique for the analysis of structural and numerical chromosome 
aberrations, as it allows the visualization of defined sequences of nucleic acids at the cellular 
and subcellular level. The method is based on site-specific annealing (hybridization) of single-
stranded DNA (probe) to denatured complementary sequences on cytological preparations 
(target). 
The protocol used in the current study was adapted from the early work of Gall and Pardune, 
who described the technique of in situ hybridization.257 This early technique of isotopic in situ 
hybridization was later modified using non-isotopic, in particular fluorescence in situ 
hybridization (FISH) protocols. FISH is a technique used for the detection of target DNA by 
hybridization of the samples with a complementary probe which is coupled with fluorochromes. 
The probes are synthesized with incorporated fluorescence molecules or reporter molecules 
which can be recognized with fluorochromes-labeled reporter binding molecules. Figure VI 
illustrates schematically the technique of FISH analysis. A major advantage of the FISH-
technique is, that it does not require metaphase nuclei, but also works with interphase nuclei. 
This is of great significance in cases where metaphase chromosome spreads cannot be 
prepared. 
 
Figure VI. Schematic illustration of fluorescence in situ hybridization (FISH) 
Probe
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3.2.1.1 Selection of bacterial clones, culture of bacteria and DNA preparation 
Commercial FISH probes are available for different chromosomal loci in the human genome. 
These commercial probes are already labeled with fluorescent dyes and can be used for 
hybridization without further modifications. However, the number and localization of the 
commercially available FISH probes for human chromosome 6q were not sufficient for the study 
objective to narrow down the common deleted region in the proximal part of chromosome 6q.  
Therefore bacterial artificial chromosome (BAC) clones were used in the current study. These 
clones of Escherichia coli bacteria contain a plasmid with specific human DNA sequences. The 
size of these plasmids varies, depending on the particular human DNA locus sequence. Typical 
BAC clones used for FISH analyses contain plasmids of 100 to 200 kb. After expansion of the 
bacteria, the DNA can be prepared, labeled and used as specific FISH probes. The available 
BAC clones for genetic markers in the human genome are depicted in current genome data 
bases (Internet references I, II, III). In the current study the selection of the BAC clones for the 
preparation of FISH probes was based on the analysis of the reported common deleted regions 
of 6q in the literature and the common deleted region of the four relapsed T-LBL index patients. 
The genetic markers D6S1601, D6S283 and D6S246 were affected by the relevant reports of 
common deleted regions in the literature and the markers were within or close to the common 
deleted region in the four index patients. The chromosomal localization of the marker is 
schematically depicted in Figure VII. 
 
Figure VII. Schema of the localization of the genetic markers D6S1601, D6S283 and 
D6S246 on human chromosome 6q. Light grey infill: common deleted region of the four 
relapsed index patients of the NHL-BFM series 
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Via data base research BAC clones with plasmid of complementary DNA sequences were 
identified (I, II, III). BAC clones were obtained from BACPAC Resources Online (IV). Table 7 
summarizes the name of the clones and the chromosomal localization of the clones that were 
tested in the current project. 
Table 7. BAC clones tested in the study  
Clone Chromosomal locus Marker 
RP3-435K13  6q14.3 D6S1601 
RP1-33L1 6q14.3 D6S1601 
RP11-602G22 6q14.3 D6S1601 
RP11-133H4 6q16.3 D6S283 
RP11-259I14 6q16.3 D6S283 
RP11-487F5 6q16.3 D6S283 
RP11-423D17 6q16.3 D6S283 
RP11-951B10 6q16.3 D6S283 
RP 1-111B22 6q21 D6S246 
RP3-429G5 6q21 D6S246 
RP11-815N24 6q21 D6S246 
RP11-15H7 6q24.1  
 
The aliquots of the BAC clone stocks were cultured in a preparatory culture in 5 ml Lysogeny 
Broth (LB) medium with Chloramphenicol at 37°C overnight on a vibraxer. Aliquots of the 
preparatory culture were again cultured in 50 ml LB medium with Chloramphenicol at 37°C 
overnight. DNA was prepared using JETSTAR Midi Prep, GENOMED, Loehne, Germany. The 
DNA preparation with this kit was based on a modified alkaline/sodium dodecyl sulfate (SDS) 
procedure. After neutralization the lysates were applied onto a column and the plasmid DNA 
was bound to the anion exchange resin. After washing the bound plasmid DNA was eluted from 
the column. According to the manufacturer the kit was preferentially designed to extract and 
purify high copy plasmid DNA from E.coli cultures. The components of the kit and the protocol 
for DNA extraction are summarized in Table 8. 
Table 8. DNA preparation with JETSTAR Midi Prep, GENOMED, Loehne, Germany 
Components 
Solution E1 (Cell Re-suspending) 
Solution E2 (Cell Lysis) 
Solution E3 (Neutralization) 
Solution E5 (Column Washing) 
Solution E6 (DNA Elution) 
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Continue Table 8 
Protocol 
1.  Equilibration of the columns with 10 ml solution E4 under gravity flow. 
2.  For harvesting of the cells, the E. coli cells were pelleted by centrifugation at 
6 000 rpm at 4°C for 15 min and the medium was removed. 
3.  Re-suspension of the cells with 4 ml solution E1. 
4.  Cell lysis with 4 ml solution E2 and incubation at room temperature for 5 min. 
5.  For neutralization 4 ml E3 solution were added and immediately mixed by inverting 
the tube 5 times, incubation for 10 min. 
6.  The equilibrated column was loaded with the lysate from step 5. 
7.  The column was washed with 10 ml E5 solution by gravity flow. This step was 
repeated once. 
8.  For elution 5 ml E6 solution were added and the eluate was collected 
9.  For the precipitation of the DNA 3.5 ml isopropanol were added. Centrifugation at 
15 000 rpm at 30°C for 5 min. The plasmid DNA was washed with 70% ethanol 
and re-centrifuged at 15 000 rpm for 5 min. Air dry of the pellet. Pellet was 
re-dissolved in 10-15 µl H2O. 
 
 
3.2.1.2 Nick translation 
For the detection procedure of the DNA probes, the plasmid DNA was labeled enzymatically 
according to a Nick translation protocol. Two techniques were used for labeling of the BAC 
probes: 1) probe labeling with either biotin or digoxigenin as reporter molecules and indirect 
detection of hybridized probe via avidin or antibodies or 2) direct labeling with nucleotides 
conjugated directly with fluorescent dyes. Table 9 summarizes the different labeling dyes tested 
in this study. Labeling with Cy3-dUTP for red signals and labeling with Biotin/Avidin-FITC for 
green signals revealed highest quality of the fluorescence signals.  
 
Table 9. Labeling of DNA probes 
Indirect detection  
Biotin Biotin-16-dUTP/Avidin-FITC (Roche) 
Digoxigenin Digoxigenein-11-dUTP/Antidigoxigenin-Rhodamin (Roche) 
  
Direct detection  
Cy3 Cy3-dUTP (Amersham) 
Spectrum Green Spectrum Green-dUTP (Vysis) 
Spectrum Orange Spectrum Orange-dUTP (Vysis) 
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The following protocol was used for the nick translation (Table 10). Because fluorescent dyes 
are subject to photobleaching (fading), the preparations were not permanent. During the whole 
procedure the dyes were kept away from light. 
Table 10. Reaction and protocol of nick translation 
Components  
H20 x µl 
10 x NT buffer 5 µl 
ß-Mercaptoethanol 5 µl 
dNTP 5 µl 
Biotin-16-/Cy3-dUTP 1 µl 
DNA (2 µg) x µl 
Polymerase I 2 µl 
DNAse I (1:6 000) 1 µl 
 50 µl 
Protocol  
1. 1The reaction was incubated in a 15°C water bath for 2 h. 
2.  The reaction was bedded on ice, until the actual size of the probe molecules was 
determined. 
3.  An aliquot of 6 µl was taken, gel loading buffer and 1 µl 0.5 M EDTA were added 
and the reaction was loaded on a 1.5% agarose gel (100 V, 30 min). 
4.  DNA was visualized in the gel by ethidium bromide and photographs were taken 
during UV illumination. 
5.  Fragments should be smaller than 600 bp but larger than 200 bp. 
6.  For enzyme inactivation 1 µl 0.5 M EDTA was added and the reaction was 
incubated at 65°C for 10 min. 
7.  For precipitation: careful mixture of  
 - 44 µl DNA probe (ca. 1 800 ng) 
 - 90 µl (90 µg) human cot-1-DNA (1 mg/ml) 
 - 2 µl (20 µg) salmon sperm-DNA (10 mg/ml) 
 - 1/10 volume (= 14 µl) 3 M sodium acetate (pH 5,2)  
 - 2.5-3 volumes abs. ethanol (400 µl; -20°C)  
Incubation at –20°C over night. 
8.  Centrifugation at 14 000 rpm and 4°C for 30 min. 
9.  The supernatant was removed and the pellet was washed with 2-3 volumes (400 µl) 
70% ethanol (-20°C). 
10.  Centrifugation at 14 000 rpm and 4°C for 12 min. 
11.  The supernatant was removed and the pellet was air dried at room temperature for 
20-30 min. 
12.  Elution of the pellet in 6 µl H2O. 
13.  After optimal elution of the pellet, 14 µl hybridization mix (pH 7-7,5) was added, final 
concentration of the probe: 90 ng DNA/µl. 
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3.2.1.3 Hybridization of probes 
To increase probe accessibility and to reduce fluorescence background staining, the 
microscopic slides with the target samples were pre-treated as described in Table 11.  
Table 11. Pre-treatment of microscopic slides 
1.  Fixation of the microscopic slides in fixative for 20 min. 
2.  For rehydration slides were put through a series of 70%, 50% and 30% ethanol and 
0.1x SSC at room temperature for 1 minute each. 
3.  To increase the permeability of the membranes, the slides were incubated in  
2x SSC (85°C) for 20 min. 
4.  Slides were cooled down to 37°C. 
5.  Equilibration of slides in HCl solution (37°C) for 3 min. 
6.  Addition of 300 µl Pepsin solution and incubation at 37°C. 
The period of incubation was adjusted to the thickness of the cells on the 
microscopic slide and the duration of storage of the slide prior to FISH analysis. In 
general, incubation period was increased with increasing thickness of the cells and 
longer storage period. The incubation time according to thickness of the cells and 
storage period was as follows: 
 Type of sample and thickness stored > 1 year stored > 2 years stored > 4 years
 Tumor touch imprint thin 25 min 30 min 40 min 
 Tumor touch imprint middle 30 min 35 min 45 min 
 Tumor touch imprint thick 35 min 40 min 50 min 
 Cytospin preparation normal 25 min 30 min 40 min 
 Cytospin preparation thick 30 min 35 min 45 min 
7.  Washing in 1x PBS for 3 min. 
8.  Slides were put through a series of 70%, 90% and 100% ethanol at room 
temperature for 2 minutes each. 
9.  Air dry (10 min to 1 day). 
 
Denaturation of the target samples on the microscopic slides was performed as described in 
Table 12. 
Table 12. Denaturation of target samples 
1.  150 µl 70%/2x SSC Formamide denaturation solution were applied on the slide and 
covered with a coverslip 24x60 mm. 
2.  The target samples were denatured thermally with incubation on a heater at 85°C 
for 25 min. 
3.  The coverslips were removed carefully and the slides were put through a series of 
70% ethanol for 2 min and 90% and 100% ethanol for 1 minute each at room 
temperature for dehydration. 
4.  Air dry for 10 min. 
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The denaturation of the probes, the hybridization of probes and target samples and the 
subsequent washing procedure for probes labeled for direct detection with Cy3-dUTP are 
described in Table 13. 
Table 13. Denaturation of probes, hybridization and post-hybridization washing for 
probes with Cy3-dUTP labeling for direct detection 
1.  The DNA probes were denatured thermally with incubation at 75°C for 5 min. 
2.  5 µl DNA probe was applied on the slide, covered with a coverslip 18x18 mm and 
sealed with rubber cement. 
3.  The hybridization reaction was carried out at 37°C overnight in a moist chamber. 
4.  The rubber cement was removed carefully and microscopic slides were collected in 
2x SSC (37°C) for 2 min. 
5.  Incubation in 2x SSC (37°C) for 3-5 min on a vibraxer for the removal of the 
coverslip. 
6.  Washing in 1x SSC (72°) for 8 min. 
7.  Washing in 2x SSC + Tween for 5 min. 
8.  Washing in 1x PBS at room temperature for 3 min. 
9.  Slides were put through a series of 70%, 90% and 100% ethanol at room 
temperature for 2 minutes each. 
10.  Air dry for 10 min. 
11.  20 µl Vectashield were applied on the slide, a coverslip 24x50 mm was added and 
sealed with rubber cement (Fixogum). 
12.  Storage at 4°C. 
 
 
For the probes labeled with biotin-16-dUTP for indirect detection, the protocol was modified as 
specified in Table 14. 
Table 14. Denaturation of probes, hybridization and post-hybridization washing for 
probes with indirect detection 
 Steps 1-6 as described in Table 13. 
7.  Incubation of the slides in 4x SSC + Tween at room temperature for 5 min. 
8.  For blocking 60 µl 5% BSA were applied on the slide, coverage with a coverslip 
24x60 mm. 
9a. Incubation in a moist chamber at 37°C for 15 minutes. 
9b. In parallel: preparation of the fluorochrome-conjugated reporter binding molecules:  
Dilution of the Avidin-FITC 1 : 400 in 1% BSA  
Centrifugation at 12 000 rpm for 3 min. 
10.  Careful removal of the coverslip; collection of the slides in 4x SSC + Tween. 
11.  For detection, 60 µl of the solution with Avidin-FITC were applied on the microscopic 
slide and covered with a coverslip. 
12.  Incubation in a moist chamber at 37°C for 20 min. 
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continue Table 14 
13.  Careful removal of the coverslip. 
14.  Washing in 4x SCC + Tween (43°C) on a vibraxer for 3 min, repeated once. 
15.  Washing in 1x PBS at room temperature for 3 min. 
16.  For dehydration slides were put through a series of 70%, 90% and 100% ethanol at 
room temperature for 2 min each. 
17.  Air dry for 10 min. 
18.  20 µl Vectashield were applied on the slide and a coverslip was added. 
19.  Storage at 4°C. 
 
Repetitive elements in genomic DNA are known to cause unspecific fluorescent signals due to 
unspecific hybridization of the repetitive sequences in the labeled DNA probe and the target 
DNA samples. To reduce unspecific hybridization of repetitive elements in the labeled probe 
with complementary sequences in the samples, human cot DNA and salmon sperm DNA were 
used. The reagents were added to the plasmid DNA probe in step 8 of the nick translation 
(Table 10). In principal, the labeled probe fragments are denatured together with an excess of 
unlabeled competitor DNA. The repetitive sequences in the excess of competitor DNA hybridize 
rapidly with the single-stranded repetitive elements of the target sample, while the less frequent 
specific sequences remain single-stranded. These sequences hybridize with the specific 
sequences of the labeled plasmid DNA. 
 
3.2.1.4 Fluorescence microscopy 
The signals of the locus specific DNA probes were visualized using an Axiophot fluorescence 
microscope with Pan-Neofluor objectives and a 100 Watt mercury lamp (Zeiss, Göttingen, 
Germany). The microscope was equipped with a high performance charge coupled device 
(CCD) camera (COHU, San Diego, USA).  
Analyses of interphase nuclei included the examination of 200 nuclei per slide. Two 
fluorescence signals of a probe per nucleus indicated germline status for the particular locus. 
Detection of only one fluorescence signal per nucleus indicated the deletion of the second loci. 
The analyses were performed on 400x magnification. The cut-off for significant findings in a 
sample was defined by at least 5% aberrant findings in 200 analyzed nuclei. 
The nick translation, preparation of samples, denaturation of probe and target DNA, 
hybridization, washing and fluorescence microscopy were performed in the Oncogenetic 
Laboratory, head Prof. Dr. J. Harbott in the Department of Pediatric Hematology and Oncology, 
Justus-Liebig University, Giessen. 
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3.2.2 Loss of Heterozygosity analysis (LOH) 
Loss of heterozygosity (LOH) in a cell represents the loss of a single parent's contribution to 
part of the cell's genome. In a heterozygote, loss of heterozygosity can arise by two methods. In 
the first, a region of a chromosome is deleted, resulting in only one copy remaining. In the 
second, genetic recombination leaves the cell with two copies of the chromosomal region, but 
both come from the same parent. The first method is thought to be the by far more frequent 
event that results in LOH. Under the assumption, that the finding of LOH of a chromosomal 
locus corresponds to deletion of one copy of the respective locus, LOH analyses represent one 
technique to analyze deletions in the genome.  
 
LOH can be identified in tumor cells by noting the presence of heterozygosity at a genetic locus 
in an organism's germline DNA. Then comparing the tumor DNA can reveal the absence of 
heterozygosity at that locus. LOH analysis is often done using polymorphic markers, such as 
microsatellites or single nucleotide polymorphisms, for which the two parents contributed 
different alleles. After polymerase chain reaction (PCR) amplification the polymorphic alleles 
can be detected e.g. using fluorescence detection. 
 
In the current study LOH analysis was based on microsatellite marker analysis. These 
microsatellite markers are spread over the whole genome and characteristically contain repeats 
of di-, tri,- or tetra-nucleotide sequences (short tandem repeats STR). In certain markers, the 
number of these repeats is highly polymorphic, as exemplarily shown in the upper part of Figure 
VIII for the tri-nucleotide repeat with one to ten copies of the TAA-tri-nucleotide sequence in 
marker D6S2407. This results in the variable fragment length of microsatellite markers which 
can be detected by fragment length analysis (FLA).  
 
In heterozygotes the analysis of germline DNA provides two alleles which differ in the size of the 
two fragments (middle part of Figure VIII). Comparative analysis of the respective marker in the 
tumor DNA of the same individual can reveal either retained heterozygosity or loss of 
heterozygosity, when only one fragment is detectable and the second fragment is lost (lower 
part of Figure VIII). The principal of LOH analysis based on fragment lengths polymorphism of 
microsatellite marker is illustrated in Figure VIII by one characteristic finding of LOH in a study 
patient. For the LOH analysis in this patient DNA was prepared from samples with germline 
DNA and separately from tumor samples of the same patient. The two template DNAs were 
then amplified separately by PCR using marker specific primer pairs (underlined sequences in 
Figure VIII). The PCR products were the subjected to electrophoresis on a genetic analyzer 
(ABI PRISM 3100, Applied Biosystems, Weiterstadt, Germany).  
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Figure VIII. Example of LOH detected in a study patient. The upper part shows the DNA 
sequence of marker D6S2407 in the human genome. The microsatellite marker contains a 
tri-nucleotide repeat sequence TAA, which can be present in the DNA in one to ten 
copies. The middle part of the figure shows the results of fragment length analysis of 
germline DNA in patient No. 66. The two peaks represent the two different sized alleles of 
the microsatellite marker indicating heterozygosity in the germline DNA of the patient with 
fragment length of 148 bp and 154 bp. The lower part of the figure shows the results of 
the fragment length analysis of the same marker in the corresponding tumor DNA of the 
identical patient. The allele with 154 bp is no longer detectable, representing a loss of 
heterozygosity. Underlined sequences: primer sequences. 
 
3.2.2.1 Preparation of DNA in T-LBL samples 
Prior to LOH analyses, DNA was prepared from the available samples. In T-LBL high-molecular-
weight germline DNA was extracted from peripheral blood (PB) and bone marrow (BM) smears, 
or from frozen peripheral blood and bone marrow cells. No significant infiltration by lymphoma 
cells in the PB and BM smears was demonstrated by morphological analyses and additionally, 
in about half of the cases, no infiltration by lymphoma cells in the PB and BM was demonstrated 
by flow cytometry analysis. Morphological review was performed by Prof. Dr. A. Reiter, 
Hannover/Gießen. The central flow cytometry analysis was performed by Prof. Dr. W.-D. 
Ludwig, Berlin. 
Initial tumor DNA from the time of diagnosis was prepared from tumor touch imprints, cytospin 
preparations of malignant effusions, frozen tumor cells from tumor biopsies or malignant 
effusions or from paraffin embedded tumor biopsies. Patients whose material was available only 
from the time of relapse and not from the initial diagnosis were not included in this analysis. As 
reported by others, representative sections from T-LBL samples showed minimal percentage of 
background stromal cells.198  
Marker D6S2407
TTC CAA GGA TCT GGC ATT TGT ATT TTT AAG AAT CTA AAA CTT 
AAA GTA TAA TAA TAA TAA TAA TAA TAA TAA TAA TAA TCT 
CAA AAA AAA ATC TAA AGC AGA ATT AAA TAT TTT CAT TGA TTT 
GTG TTT TCT CTG ACT TGG CAT ATA GGT TGG CAC AGT TAA TTA
germline control DNA
patient 66 
marker D6S2407
tumor DNA
patient 66 
marker D6S2407
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Depending on the type of specimen, different DNA purification kits were used. DNA preparation 
from smears, cytospins or tumor touch imprints were performed with peqGOLD Forensic DNA 
Kit (PeqLab) or ChargeSwitch® Forensic DNA Purification Kit (Invitrogen). DNA preparation 
from frozen cells was performed using either E.Z.N.A. blood DNA kit (PeqLab) or peqGOLD 
TriFast kit (PeqLab). The DNA preparation is described in detail in the following paragraphs. 
 
PeqGOLD Forensic DNA Kit, PeqLab, Erlangen, Germany 
This DNA preparation kit was designed to recover small amounts of DNA quantitatively from 
different specimens, including blood stains. The components of the kit and the protocol used for 
DNA preparation are described in Table 15. 
Table 15. DNA preparation with PeqGOLD Forensic DNA Kit 
Components 
Carrier suspension 
Lysis Buffer D 
Bone Lysis Enhancer  
Elution Buffer D 
Wash Buffer 
Protocol 
1.  Samples were scratched from the slides using a sterile scalpel. 
2.  1 ml Lysis Buffer D was added and incubated for at least one hour at room 
temperature. 
3.  30 sec full speed centrifugation and transfer of the supernatant into a new reaction 
tube. 
4.  The carrier suspension was vortexed thoroughly and 15 µl were added to the 
reaction tube and then vortexed. 
5.  Incubation for 5 minutes at room temperature. 
6.  Centrifugation for 1 sec at 10 000 rpm to pellet down the carrier. The supernatant 
was discarded. 
7.  1 ml wash buffer was added and the briefly vortexed to completely re-suspend the 
pellet. Centrifugation for 1 sec at 10 000 rpm. The supernatant was discarded. 
8.  2 repeats of step 7, the residual fluid was spined down and the wash buffer was 
removed. 
9.  The pellet was dried by replacing the open tube on a heater at 60°C. 
10.  The pellet was re-suspended in 50 µl H2O and incubated for 5 min at 60°C. 
11.  Centrifugation for 2 min at full speed. The DNA-containing supernatant was 
transferred into a fresh tube. This step was repeated once. Elution volume 100 µl. 
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ChargeSwitch® Forensic DNA Purification Kit, Invitrogen, Karslruhe, Germany 
According to the manufacturer, the ChargeSwitch® kit was specifically designed to allow efficient 
purification of genomic DNA from forensic samples. The kit uses magnetic bead-based 
technology to isolate genomic DNA. The surface charge of the magnetic beads depends on the 
pH of the surrounding buffer with a positive charge in low pH conditions that binds negatively 
charged DNA backbone. Contaminants and proteins are not bound and washed away in an 
aqueous wash buffer. For the elution of DNA, the charge on surface of the bed is neutralized by 
raising the pH to 8.5. 
Table 16. DNA preparation with ChargeSwitch® Forensic DNA Purification Kit 
Components 
ChargeSwitch® Lysis Buffer (L13) 
ChargeSwitch® Magnetic Beads 
Proteinase K 20 mg/ml in 50 mM Tris-HCl, pH 8.5, 5 mM CaCl2, 50% glycerol 
ChargeSwitch® Purification Buffer (N5) 
ChargeSwitch® Wash Buffer (W12) 
ChargeSwitch® Elution Buffer (E5) 10 mM Tris-HCl, pH 8.5 
MagnaRack®, Invitrogen 
Protocol 
1.  Samples were scratched from the slides using a sterile scalpel and transferred into 
a microcentrifuge tube. 
2.  1 ml Lysis buffer and 10 µl Proteinase K were mixed. 
3.  Lysis Mix was added to the sample tube. 
4.  Incubation at 55°C for 30-60 min. 
5.  The supernatant was transferred to a fresh tube. 
6.  200 µl purification buffer was added to the tube. 
7.  After vortexing, 20 µl magnetic beads were added to the sample. 
8.  Incubation at room temperature for 1-5 min; then the tube was placed in the 
MagnaRack® for 1 min. 
9.  Supernatant was removed and discarded; the tube was removed from the rack. 
10.  500 µl wash buffer was added and mixed gently and the tube was placed in the 
MagnaRack® for 1 minute. 
11.  Supernatant was removed and discarded; the tube was removed from the rack. 
12.  The wash step was repeated once. 
13.  For eluting the DNA 100 µl E5 elution buffer were added to the tube and gently 
mixed until the beads were completely re-suspended. 
14.  Incubation at room temperature for 1-5 min, gently mixed again. 
15.  The tube was placed in the MagnaRack® for 1 min until beads form a tight pellet. 
16.  The elute containing the purified DNA was transferred to a new tube. Elution 
volume 100 µl. 
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E.Z.N.A. Blood DNA Kit, PeqLab, Erlangen, Germany 
The E.Z.N.A. Blood kits use a reversible DNA-binding property of the HiBind® matrix for DNA 
purification. After lysis under denaturing conditions, samples were applied to the HiBind® spin 
columns, which bind DNA, while cellular debris, hemoglobin, and other proteins were washed 
away. DNA was finally eluted with water. The components of the kit and the protocol used for 
DNA preparation are specified in Table 17. 
Table 17. DNA preparation with E.Z.N.A. Blood DNA Kit 
Components 
Buffer BL 
DNA Wash Buffer Concentrate 
HB Buffer 
Elution Buffer 
OB-Protease 
RNase A 
TE buffer 10 mM 
HiBind® DNA Columns 
Collection tubes 2 ml (other materials) 
100% Ethanol (supplied by user) 
Protocol 
1.  250 µl sample were mixed with 25 µl protease and 250 µl BL Buffer. 
2.  5 µl RNase A were added and sample was incubated at 70°C and once during 
incubation briefly vortexed. 
3.  260 µl 100% Ethanol was added to the sample. 
4.  Half of the solution was transferred into a column which was assembled in a 2 ml 
collection tube; centrifugation at 8 000 rpm for 1 min. 
5.  Step 4 was repeated with the 2nd half of the solution. 
6.  The collection tube and the flow-through liquid were discharged and the column 
was placed into new 2 ml collection tube. 
7.  500 µl HB Buffer were added on the column; centrifugation at 8 000 rpm for 30 sec. 
The flow-through was discarded. 
8.   The column was placed into a new collection tube and 600 µl wash buffer were 
added; centrifugation at 8 000 rpm for 1 min. The flow-through was discarded. 
9.  Step 8 was repeated once. 
10.  The column was placed into a new collection tube and centrifuged with full speed 
for 2 min. 
11.  The column was placed into a sterile 1.5 ml microfuge tube and 60 µl of pre-heated 
(70°C) H2O were added. Incubation for 2 min. 
12.  Centrifugation with 8 000 rpm for 1 min to elute DNA from the column. 
13.  Step 11 and 12 were repeated once. Elution volume 100 µl. 
49 
 
peqGOLD TriFast, PeqLab, Erlangen, Germany 
The TriFast kit was used for DNA preparation of tumor frozen cells. The advantage of this 
preparation is that it allows parallel preparation of DNA, RNA and proteins. The protocol used 
for DNA preparation is described in Table 18. 
Table 18. DNA preparation with peqGOLD TriFast Kit 
Components 
TriFast 
Supplied by user: Chloroform, Sodium citrate, Sodium hydroxide 
1.  Phase separation: 700 µl TriFast were added to the sample; incubation at room 
temperature for 5 min. 
 a. After addition of 200 µl chloroform sample was shaken by hand for 15 sec. 
and then incubated at room temperature for 3-10 min. 
 b. Centrifugation at 12 000 rpm and 4°C for 5 min which separated the mixture 
in 3 phases. 
 c. 3 phases: lower chloroform phase (red) with DNA and proteins, interphase 
with DNA and proteins and a colorless upper phase with RNA. 
1.  DNA precipitation 
 a. The aqueous phase was removed and 300 µl of 100% ethanol were added. 
Incubation at room temperature for 2-3 min. 
 b. Centrifugation at 2 000 rpm at 4°C for 5 min. 
2.  DNA wash 
 a. The supernatant was removed. 
 b. The DNA pellet was washed with 1 ml 0.1 M sodium citrate/10% ethanol for 
30 minutes. Centrifugation at 2 000 rpm at 4°C for 5 min. 
 c. Step b was repeated once. 
 d. The DNA pellet was suspended in 2 ml of 75% ethanol and incubated at 
room temperature for 15 min. 
 e. Centrifugation at 2 000 rpm at 4°C. 
3.  DNA solubilization  
 a. DNA pellet was dried at room temperature or on the heater at 37°C. 
 b. Suspension in 8 mM NaOH by slowly passing the pellet through a wide bore 
pipette; amount of NaOH was adjusted to the pellet with final DNA 
concentration to 0.2-0.3 µg/µl. 
 
Parts of the patients were included in an earlier study, in which the genotype of MTHFR and 
TNFα was examined.258;259 For this analysis germline DNA preparation from PB or BM smears 
was performed by Dr. K. Seidemann, Medical School Hannover, Germany using Roche High 
Pure PCR Template Preparation kit.  
Preparation of DNA from paraffin embedded tumor biopsies was performed by Dr. Wolfram 
Klapper, Institute of Pathology and Lymph node registry, University Hospital Schleswig-Holstein, 
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Campus Kiel, Germany. Paraffin embedded tumor specimens were cut with a microtome using 
a clean blade. Two to five sections of 5 µm thickness were transferred into a reaction tube for 
removal of paraffin by xylol treatment. After a proteinase K digestion at 42°C over night in Tris-
Buffer, the DNA was purified in parts of the samples (see appendix 8.3), using the QIAamp DNA 
mini kit (Qiagen, Hilden, Germany) according to the manufacturer's manual. 
After preparation, the DNA was stored at -20°C until usage. The available specimen, the DNA 
purification kit and the amount of prepared DNA for each case are specified in appendix 8.3 
DNA preparation in T-LBL samples.  
 
3.2.2.2 Preparation of DNA in T-ALL samples 
In T-ALL mononuclear cells were isolated from BM or PB samples. Genomic DNA was prepared 
using the QIAamp DNA blood midi kit (Qiagen GmbH, Hilden, Germany). The isolation of the 
mononuclear cells and the DNA preparations using the QIAamp DNA blood midi kit were 
performed at the ALL-BFM Study center in Hannover/Kiel.  
40 µl aliquots containing 50 ng DNA/µl were provided by the ALL-BFM study center. Tumor 
DNA was prepared from initial BM or PB samples with a blast percentage > 70%. Germ line 
DNA was prepared from follow-up samples of BM or PB without blast infiltration.  
In a small number of cases no mononuclear cells were available for the preparation of DNA. In 
these cases either cells from malignant effusions or BM smears were used for DNA preparation. 
The DNA preparation was performed according to the protocols specified above. The available 
specimen, the DNA purification kit and the amount of prepared DNA for all cases are depicted in 
detail in the appendix 8.4 DNA preparation in T-ALL samples. 
 
3.2.2.3 UV spectrometry 
After all DNA preparations the quality and concentration of DNA was examined by UV 
spectrometry. DNA shows characteristic maximal absorption spectrum at wavelength of 260 nm. 
Therefore UV spectrometry at this wavelength allows the calculation of DNA concentration. For 
the calculation the following assumptions were made: An OD (optical density) of one unit 
corresponds to a concentration of ~50 µg/ml of doubled-stranded DNA.260 
The typical contamination of DNA elutes are proteins which show characteristic absorption 
spectrum with maximum at 280 nm. The ratio between the readings at 260 nm and 280 nm 
provided an estimate of the purity of the DNA elutes. OD260 : OD280 of 1.8 to 2.0 were 
considered as pure DNA elutes.  
The UV spectrophotometry was performed on a Ultraspec 1000, Pharmacia Biotech, 
Cambridge, UK, using 5 µl aliquots of elutes + 95 µl H20 (1:20). All newly prepared DNA elutes 
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were checked for sufficient DNA quality and DNA concentration. If necessary, the elutes were 
diluted to DNA concentrations of ~ 5-10 ng/µl, depending on the type of sample and the kit used 
for DNA preparation. 
 
3.2.2.4 Polymerase chain reaction 
The polymerase chain reaction (PCR) provides a powerful technique for direct amplification of 
short segments of the genome. 
The reaction contains the two primers, the template DNA, thermo stable DNA-polymerase (taq 
DNA-polymerase), all four 2`-deoxynucleoside 5`-triphosphates (dNTPs) dATP, dCTP, dGTP, 
dTTP, a buffer and magnesium chloride ions.  
The PCR protocol starts with denaturation of the DNA preparation at 94°C. The double-stranded 
DNA is separated by heat into single-stranded DNA serving as a template for amplification. 
Amplification of the DNA is achieved by DNA polymerase producing a complementary DNA-
strand. DNA polymerase needs a double-stranded sequence of DNA as a starting point. To 
provide this double-stranded DNA the single-stranded DNA is annealed with one forward and 
one reverse primer sequences of ~20 bases. Each primer is complementary to a site on the 
opposite strand determining the target microsatellite marker. After denaturation the temperature 
is lowered in an annealing step to 45°-53°C so both primers can ideally anneal to their 
complementary regions on the template DNA. The annealing temperature is modified according 
to the melting temperature of the specific primer pair. In a third step (extension) the temperature 
is raised to 72°, the temperature optimum for the taq DNA-polymerase. In the extension step 
new DNA-strands are synthesized complementary to the template DNA. The entire cycle is 
repeated 35 times resulting in copies of non-determined length (with only one primer at one 
end) but also copies with a length defined by the two primers. Throughout amplification the 
number of copies of non-determined length grows linearly whereas the number of copies of 
determined length grows exponentially. Therefore the predominant majority of products of 
determined length exist after 25-32 cycles.  
The PCR was accomplished in programmable thermo-cyclers which guarantee quick and 
precise temperature changes.  
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3.2.2.5 Microsatellite markers 
The microsatellite markers used in the present study were polymorphic short tandem repeat 
markers (STR). The samples were analyzed with a set of 25 microsatellite markers spanning a 
64 Mb region on chromosome 6q14-q24.  
Markers were chosen based on two criteria: The first selection criterion was that the markers 
had to cover chromosomal bands 6q15-q16, which represented the common deleted region in 
cytogenetic analysis of the four relapsed T-LBL index patients in the trial NHL-BFM 95, and the 
markers should cover the minimal deleted regions of reported deletions of proximal 
chromosome 6q in hematological malignancies.204;205;226;229;231;240;251  
The second selection criterion was a preferred rate of >75% heterozygosity, as reported in the 
Genome Database (II).  
The following microsatellite markers were analyzed: D6S1589, D6S2407, D6S251, D6S1609, 
D6S1627, D6S1004, D6S1644, D6S1043, D6S1274, D6S300, D6S1682, D6S1284, D6S1716, 
D6S1717, D6S468, D6S283, D6S1580, D6S1021, D6S447, D6S278, D6S261, D6S1657, 
D6S1639, D6S435, and D6S310. The localization of these markers is depicted in Figure IX 
schematically. 
Figure IX. Schema of the localization of the 25 microsatellite markers used for LOH 
analysis in the present study  
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3.2.2.6 Primers for polymerase chain reaction 
Primer sequences for amplifying the microsatellite marker sequences were retrieved from GDB 
and the ensembl data base (I, II). PCR primers were synthesized by MWG Biotech (Ebersberg, 
Germany) with the forward primer labeled at the 5' end with the fluorescent dye 6-FAM. 
 
3.2.2.7 Polymerase chain reaction conditions  
Paired normal and tumor DNA samples from each patient were amplified with AmpliTaq Gold 
enzyme (Applied Biosystems, Weiterstadt, Germany) in PCR reactions using 0.5-100 ng of 
genomic DNA as a template (as specified in appendix 8.3 and 8.4). PCR was performed in a  
25 µl reaction volume containing 1 µl of 10 pmol/µl primer solution and 2.5 µl 10x standard PCR 
buffer. Thirty-five cycles were carried out in a thermal cycler under conditions specified in table 
19-22. 
Table 19. PCR reaction   
genomic DNA  0.5-100 ng 
Primer solution 10 pmol/µl 1 µl  
10x standard PCR buffer 2.5 µl  
Taq Gold (5 U/µl) 0.5 µl  
dNTP (10 mM each) 1 µl  
Mg2Cl (50 mM) 0-2 µl  
H2O x  
 Σ 25 µl  
 
The concentration of MgCl2 in the PCR reaction was optimized for each primer pair. The amount 
of additional MgCl2 added to the PCR reaction according to the primer pairs is summarized in 
Table 20.  
Table 20. MgCl2 concentration according to markers  
Primer pair for marker MgCl2 (50 mM) 
D6S435 0 µl 
D6S1274, D6S1717, D6S283, D6S1021 2 µl 
D6S1589, D6S2407, D6S251, D6S1609, D6S1627, D6S1004, 
D6S1644, D6S1043, D6S300, D6S1682, D6S1284, D6S1716, 
D6S468, D6S1580, D6S447, D6S278, D6S261, D6S1657, D6S1639, 
D6S310 
1 µl 
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The PCR program was retrieved from the PCR conditions as specified in GDB database (II).  
Table 21. PCR program 
1x 10 min 94°C   
 
35x 
denaturation  
45 sec 94°C 
annealing  
45 sec 45°C  
elongation  
45 sec 72°C 
1x 30 min 72°C   
then continuous 4°C   
 
The annealing temperature of the PCR program was modified according to the melting 
temperature of the primer sequences. The rest of the protocol was identical for all markers. The 
modified PCR program annealing temperatures are listed in the following table 22. 
 
Table 22. Modifications of the annealing temperature for the different primer pairs 
Primer pair for marker Annealing 
temperature 
D6S1682 45°C 
D6S251 48°C 
D6S1609, D6S1644, D6S1043, D6S1274, D6S300, D6S1284, 
D6S1717, D6S468, D6S283, D6S1021, D6S278, D6S1657, D6S435, 
D6S310, D6S261 
50°C 
D6S1716 52°C 
D6S1589, D6S2407, D6S1627, D6S1004, D6S1580, D6S447, 
D6S1639 
53°C 
 
PCR was performed using the following types of thermocyclers: GeneAmp PCR system 9600, 
Perkin-Elmer, Rodgau-Juegesheim, Germany or Tgradient 96, Biometra, Goettingen, or 
Tpersonal 48, Biometra, Goettingen, Germany. 
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3.2.2.8 Fragment length analysis 
Aliquots of 1.5 µl of the PCR products were mixed with 18.5 µl HiDi-formamide and 0.5 µl size 
standard, denatured, and subjected to electrophoresis on a genetic analyzer (ABI PRISM 3100 
Genetic Analyzer, Applied Biosystems, Weiterstadt, Germany). The automatically collected data 
from fragment-length analysis were analyzed with GeneScan software as described in the 
manufacturer’s manual. The conditions of fragment length analysis are summarized in Table 23. 
 
Table 23. Conditions of fragment lengths analysis with ABI Prism 3100 
Capillary 16 silicar capillaries 
 length to detector 50 cm 
Polymer Performance Opti. Polymer6 3100 (POP-6), Applied Biosystems 
Buffer Buffer (10x) with EDTA, Applied Biosystems, Part. No. 402824 
Electrophoresis 15 kV, 60°C 
Size standard GenescanTM 400 HD [ROXTM] Standard, Applied Biosystems 
single-stranded labeled fragments:  
50, 60, 90, 100, 120, 150, 160, 180, 190, 200, 220, 240, 260, 280, 
290, 300, 320, 340, 360, 380, 400 
Laser Argon-ion laser 
Emission wave lengths 488 nm and 541.5 nm 
Detection CCD-camera (charge-coupled-device) 
Collected emission spectrum from 500 nm to 700 nm 
Software ABI-Prism 3100 Data collection software, Version 1.1,  
GeneScan 3.7 
 
 
56 
 
3.2.2.9 Data analysis of LOH results 
Markers were regarded as informative when two different-sized fragments of the microsatellite 
marker were detected in germline DNA, and tumor DNA showed either a heterozygous pattern 
or LOH. To define LOH, ratios for the heights of peak levels of the two alleles in tumor material 
and in germline DNA were compared. A tumor material ratio below 50% or above 150% of the 
germline peak height ratio was considered indicative of LOH. An example of the definition of 
LOH is shown in Figure X.  
 
 
Figure X. Example of LOH  
In germline DNA peak height of first allele was 3932, peak height of second allele was 
2222 resulting in a ratio of 1.77 (1.77±50% range: 0.89-2.66). In tumor DNA the ratio of 
first allele height to second allele height was 687/4522 resulting in a ratio of 0.15, which is 
clearly outside the acceptable variation range for retained heterozygosity of 0.89-2.66. 
Therefore the present case was regarded as a finding of LOH. 
 
A homozygous pattern in the germline control DNA or microsatellite instability rendered the 
microsatellite marker not informative for LOH analysis. A microsatellite marker was considered 
unstable if the PCR product from tumor DNA had an altered fragment length compared to 
alleles in the corresponding germline DNA.261  
The most centromeric and telomeric markers with LOH defined the putative deleted region in 
each patient. This definition of the putative deleted region was based on the assumption that in 
the majority of cases with 6q aberration, there is only one deletion at 6q and only in exceptional 
cases two different deleted regions at chromosome 6q will have to be expected. 
In contrast to the un-interpreted LOH results, the putative deleted region covers chromosomal 
regions with no informative markers. The putative deleted region has the advantage of not being 
influenced by the rate of heterozygosity or the feasibility of LOH analysis of the markers. 
height 2222
height 3932
ratio 3932/2222 = 1.77 
ratio + 50% = 0.89-2.66
height 4522
height 687 ratio 687/4522 = 0.15
germline DNA
tumor DNA
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3.3 Diagnostics and treatment of patients 
3.3.1 Diagnostics and treatment of T-LBL patients 
The diagnosis was established by histopathology of the lymph node or tumor biopsy and/or by 
cytological27 and immunophenotypic examination262 of cells from malignant effusions (pleural 
effusion, ascites, pericardial effusion). Cases were classified according to the updated Kiel 
classification10 and the WHO Classification of Hematological Malignancies.192 Sub-classification 
of immunophenotypic subgroups was performed according to EGIL criteria.263  
In more than 90% of cases, the diagnosis was centrally reviewed by one of the reference 
laboratories for pathology, cytomorphology and/or immunophenotyping.  
Staging included PB and BM aspiration smears, cerebrospinal fluid (CSF), serum lactate 
dehydrogenase analysis, ultrasound, X-ray, computed tomography (CT) or magnetic resonance 
imaging (MRI), and skeletal scintigraphy. St. Jude staging system was used.264  
Patients were treated according to the subsequent treatment protocols NHL-BFM 95 and 
EURO-LB 02. These protocols were based on the ALL-BFM treatment strategy. Patients with 
LBL stage III/IV received an induction protocol I followed by the extra-compartment 
consolidation protocol M, re-induction protocol II and maintenance up to total therapy duration of 
24 months. Patients with stage I/II disease received the induction protocol I and the extra-
compartment consolidation protocol M followed by maintenance up to a total therapy duration of 
24 months.77 The simplified treatment strategy is outlined in Figure XI. 
 
Figure XI. Overview of the treatment plan for T-LBL patients 
 
CNS-positive patients received two additional doses of intrathecal MTX at days 18 and 27 of 
induction and received cranial radiotherapy (CRT) after re-induction. The dosage was 12 Gy in 
the second year of life and 18 Gy in older children (children <1 year of age were not irradiated). 
The details of the treatment are described in appendix 8.1. 
LBL stage I/II
Induction Consolidation Maintenance
months 2,5 6 248
Induction Consolidation Re-Induction Maintenance
months 2,5 6 248
LBL stage III/IV
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Treatment was identical in the trial EURO-LB 02 with the exception for the dose of the E.coli  
L-Asparaginase in induction protocol I. In trial NHL-BFM 95 patients received E.coli  
L-Asparaginase 5,000 U/m2 in the induction protocol I while in trial EURO-LB 02 patients received 
E.coli L-Asparaginase 10,000 U/m2 in the induction protocol I.  
Response to treatment was evaluated at day 33 of induction. Sufficient response was defined 
as at least 70% tumor-regression, less than 5% BM-blasts, no CNS-disease. For patients with 
insufficient response at day 33 treatment was to be intensified according to the high-risk branch 
of trial ALL-BFM 95.265 Non-response was defined as persistence of a residual mass ≥ 30% of 
initial tumor volume, or persistence of ≥ 5% lymphoblasts in the bone marrow or persistence of 
lymphoblasts in the CSF (with ≥ 5 cells/µl) evaluated after the third course of high-risk 
treatment. Relapse was defined as the re-occurrence of lymphoma manifestations during or 
after the end of frontline treatment 
 
3.3.2 Diagnostics and treatment of T-ALL patients 
For T-ALL patients the diagnosis was established by cytomorphology of bone marrow (BM) 
and/or peripheral blood (PB) smears and flow cytometry analysis. Immunophenotyping was 
conducted as previously described266 and the criteria for subclassification of T-ALL were 
adopted from EGIL criteria263. In more than 95% of the patients the diagnosis was centrally 
reviewed by the reference cytomorphological laboratory at the ALL-BFM study center in Kiel 
and/or the central reference laboratory for immunophenotyping at the Robert-Rössle Clinic in 
Berlin-Buch (head Prof. Dr. W.-D. Ludwig). 
Patients were treated according to protocol ALL-BFM 2000, which is based on the ALL-BFM 
treatment strategy.153;256 The treatment was comparable to the treatment of patients with T-LBL 
with stage III/IV disease as described above.  
In T-ALL treatment was stratified according to the early in vivo response to a 7-day prednisone 
treatment and one intrathecal dose of methotrexate, defined by the number of peripheral blood 
blasts per microliter on day 8.2;152 Based on the prednisone response, patients were classified 
into prednisone good responders (< 1000 blasts/µl) (PGR) and poor responders (≥ 1000 
blasts/µl) (PPR). The patients were further stratified according to minimal residual disease 
(MRD) kinetics.175  
Complete remission (CR) was defined as the absence of leukemia blasts in the peripheral blood 
and cerebrospinal fluid, less than 5% lymphoblasts in bone marrow aspiration smears, and no 
evidence of localized disease. Relapse was defined as recurrence of lymphoblasts or localized 
leukemic infiltrates at any site. 
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3.4 Statistical analysis 
The probability of event-free survival (pEFS) was calculated according to Kaplan and Meier267 
with differences compared by the log-rank test.268 pEFS was calculated from the date of 
diagnosis to the first event (death from any cause, non-response, relapse, or second 
malignancy) or to the date of the last follow-up. Patients lost to follow-up (LFU) were censored 
at the time of their last follow-up examination. Cumulative incidence functions for relapse were 
constructed by the method of Kalbfleisch and Prentice.269 Functions were calculated from the 
date of initial diagnosis to the date of diagnosis of non-response or relapse and compared with 
Gray's test.270 Differences in the distribution of individual parameters among patient subsets 
were analyzed using the χ² test or Fisher's exact test. Odds ratios were calculated using 
standard methods.271  
For the calculation of the risk ratios for relapse, patients with less than two years follow-up due 
to death from initial complications or treatment related mortality (TRM) were excluded. For the 
group of 217 T-LBL patients, corrected estimates for the probabilities of relapse in patients with 
and without LOH and the resulting risk ratio were calculated according to Bayes’ formula. This 
estimation was based on the relapse rate of 27/209 patients with sufficient follow-up. For the 
group of 186 T-ALL patients, corrected estimates for the probabilities of relapse in patients with 
and without LOH and the resulting risk ratio were calculated according to Bayes’ formula based 
on a relapse rate of 27/177, excluding 9 patients who died from treatment-related toxicity.  
Statistical analyses were conducted using the SAS statistical program (SAS-PC, Version 9.1, 
Cary, NC: SAS Institute Inc.). Follow-up data were updated as of December 2005 for T-LBL 
patients and March 2006 for T-ALL patients. 
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4 Results 
4.1 Results of fluorescence in situ hybridization examinations 
The design of useful FISH probes was complicated by the problem that several probes 
prepared from bacterial artificial chromosome clones turned out to hybridize with chromosomal 
sequences other than the target sequence at chromosome 6q. Hybridization and fluorescence 
microscopy of these particular probes revealed multiple fluorescence signals (4-10 signals) per 
nucleus. Experiments showing multiple signals per nucleus were retested. In case of repeated 
findings of multiple signals per nucleus, the clone was excluded from further examinations. The 
multiple fluorescence signals were interpreted as an indicator of unspecific hybridization of the 
probe to chromosomal regions with a high amount of homologous sequences compared with 
target sequence on chromosome 6q.  
Testing of several clones for each of the three target sequences led to the identification of 
useful probes for each of the loci. After multiple testing three locus specific probes could be 
identified with clone RP11-602G22 (~157 kb) hybridizing to the locus specific DNA sequence 
flanking genetic marker D6S1601 at chromosome 6q14, clone RP11-951B10 (~190 kb) 
complementary to marker D6S283 and clone RP11-815N24 (~207 kb) complementary to 
marker D6S246. These probes showed only two fluorescence signals per nucleus; one for each 
chromosome 6q. The localization of the probe at the target sequence was controlled by the 
examination of hybridization results in metaphase nuclei in which the chromosome 6 were 
identifiable. The results for all clones tested are depicted in the following table 24. 
 
Table 24. Hybridization results of the different BAC probes 
Clone Locus Marker Hybridization results 
RP3-435K13  6q14.3 D6S1601 multiple fluorescence signals/nucleus 
RP1-33L1 6q14.3 D6S1601 multiple fluorescence signals/nucleus 
RP11-602G22 6q14.3 D6S1601 2 fluorescence signals/nucleus 
RP11-133H4 6q16.3 D6S283 multiple fluorescence signals/nucleus 
RP11-259I14 6q16.3 D6S283 multiple fluorescence signals/nucleus 
RP11-487F5 6q16.3 D6S283 multiple fluorescence signals/nucleus 
RP11-423D17 6q16.3 D6S283 multiple fluorescence signals/nucleus 
RP11-951B10 6q16.3 D6S283 2 fluorescence signals/nucleus 
RP 1-111B22 6q21 D6S246 multiple fluorescence signals/nucleus 
RP3-429G5 6q21 D6S246 multiple fluorescence signals/nucleus 
RP11-815N24 6q21 D6S246 2 fluorescence signals/nucleus 
RP11-15H7 6q24.1   multiple fluorescence signals/nucleus 
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In early phase of testing, newly prepared microscope slides with fixated cells of bone marrow of 
blood were used for hybridization. Exemplary hybridization results in this type of target samples 
are shown in Figure XII. 
 
 
Figure XII. Results of fluorescence hybridization of nucleated blood cells after fixation. 
Hybridization of an interphase nucleus and a metaphase nucleus with Cy3-labeled probes 
from RP11-602G22 and Biotin-labeled probes from RP11-815N24 
 
After successful and stable hybridization results in newly prepared samples of fixated cells, 
further optimization of the FISH technique was necessary due to the characteristics of the 
available tumor samples that were intended to be analyzed by FISH. These samples were 
mainly cytospin preparations or tumor touch imprints which were prepared at the time of 
diagnosis of the patients and then stored for several years at room temperature. For the 
necessary adaptation of the hybridization protocol according to the duration of storage, the 
following steps of optimization were undertaken: 
1) Increase of pepsin concentration and duration of pepsin treatment to improve 
permeability of cell membrane 
2) Modification of the temperature for the denaturation of the target DNA 
3) Optimization of the amount of sample probe to allow specific hybridization signals with 
minimum background staining 
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These measures improved the hybridization results. However, several hybridization series 
proved, that the hybridization results were insufficient for microscopic slides that were stored for 
a longer time period. The quality of the results remained highly variable and critical, especially 
for samples after storage for two years or longer. 
 
In conclusion, three specific BAC clones could be identified and establish for FISH analysis to 
detect deletions of the proximal part of chromosome 6q. This technique was applicable in 
samples with high or optimal sample quality. However, in the current study the available 
samples are of low quality due to long storage of the cytospin preparations or smears at room 
temperature for several years.  
Therefore, the attempt to narrow down a minimal deleted region in pediatric T-LBL by FISH 
analysis turned out to be not feasible with the available sample series. In consequence, the 
implementation of a different methodological approach was considered. This new approach was 
supposed to allow analysis of the available samples with reduced amount and quality of DNA. 
For this purpose, the technique of loss of heterozygosity (LOH) analysis was implemented.  
 
 
4.2 Characterization of the available samples for LOH analysis 
LOH is an alternative method to detect deletions of chromosomal material, which allows 
analyzing specimens that do not fulfill the prerequisites in terms of quantity and quality 
necessary for other methods, e.g. FISH or cytogenetics. The samples which were available for 
LOH analysis are characterized in the following section. 
 
T-LBL samples 
From April 1995 to May 2004, 217 patients were diagnosed with T-LBL and registered in the 
NHL-BFM study center after informed consent. From this cohort, cases with available tumor and 
germline control DNA were chosen for the current analysis. One hundred eight of the 217 T-LBL 
patients had available samples for the preparation of tumor and germline DNA. The available 
samples in these 108 patients are summarized in Table 25. For details see appendix 8.3. 
 
Table 25. Available tumor samples in the 108 evaluable T-LBL patients 
T-LBL samples for preparation of tumor DNA  No. of pts
Cytospin(s) of malignant effusion 27 
Tumor touch imprint(s) 21 
Paraffin embedded tumor biopsy 20 
Tumor touch imprints + paraffin embedded tumor biopsy 15 
Cytospin of malignant effusion + frozen cells of malignant effusion 12 
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continue Table 25  
Frozen cells of malignant effusion 4 
Tumor touch imprints + paraffin embedded tumor biopsy + frozen tumor cells 2 
Frozen tumor cells 1 
Tumor touch imprints + frozen tumor cells 1 
Tumor touch imprints + cytospin of malignant effusion 1 
Tumor touch imprints + frozen cells of malignant effusion 1 
Cytospin of malignant effusion + tumor touch imprints + frozen cells of 
malignant effusion 1 
Cytospin of malignant effusion + frozen cells of malignant effusion + paraffin 
embedded tumor biopsy 1 
Cytospin of malignant effusion + paraffin embedded tumor biopsy 1 
 
Table 26. Available samples for the preparation of control DNA in the 108 evaluable 
T-LBL patients 
T-LBL samples for preparation of germline control DNA  No. of pts
Blood and/or bone marrow smears 90 
Blood and/or bone marrow smears + frozen cells of blood and/or bone 
marrow 10 
Frozen cells of blood and/or bone marrow 8 
 
 
T-ALL samples 
From August 1999 to July 2002, 186 pediatric T-ALL patients were consecutively enrolled in the 
multicenter trial ALL-BFM 2000 after informed consent. One hundred twenty-seven of the 186 
T-ALL patients had available tumor DNA and germline DNA. Blast count of the initial blood or 
bone marrow smears was examined by central cytomorphological review in the ALL-BFM study 
center (Kiel, former Hannover). The initial blast count of the bone marrow or blood smears was 
>70% in 113 of the 127 analyzed samples. In the remaining 14 samples, the blast count in the 
smear preparations was 16% (additional examination of pleural effusion), 34%, 38%, 40%, 
43%, 49%, 50%, 50%, 53%, 55%, 58%, and 3x 60%, respectively. However, the 
cytomorphologic blast count did not represent the blast count in the analyzed samples. Due to 
the preparation of mononuclear cells from the fluid bone marrow or blood samples, 
lymphoblasts were enriched in the analyzed sample probes and the blast count was certainly 
higher than the blast count in the smear preparations for cytomorphology. The resources for the 
analyzed samples are summarized in the following Tables 27 and 28. The control DNA was 
extracted from follow-up samples cytomorphologically proven to be free of remaining 
lymphoblast infiltration. 
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Table 27. Resource of tumor DNA in T-ALL patients   
T-ALL samples for preparation of tumor DNA No. of pts
Bone marrow 106 
Peripheral blood 18 
Bone marrow smear 1 
Pleural effusion 2 
 
Table 28. Resource of control DNA in T-ALL patients  
T-ALL samples for preparation of germline control DNA  No. of pts
Follow-up samples of blood or bone marrow 127 
 
 
4.3 Validation of data - quality and results control 
The following aspects contribute to the validity and significance of the data obtained in the LOH 
analyses: 
 
1. Regarding the number of results per patients, a median of 17 markers (9 informative 
markers) per patient was available in T-LBL cases. Three patients were included with three 
informative markers, 11 patients with four or five informative markers, 42 patients with six to 
nine informative markers, and 52 patients with 10 or more informative markers. In T-ALL 
cases a median of 25 markers (19 informative markers) was available per patient. All T-ALL 
cases had more than 10 informative markers. In both entities, cases with less than three 
informative results in LOH analyses were excluded prior to the start of the study due to 
insufficient DNA quality and/or quantity.  
 
2. To rule out PCR errors, LOH findings were retested and confirmed in an independent 
second experiment for 69% of all LOH findings in T-LBL (at least one per LOH positive 
case), and for 98% of all LOH findings in T-ALL. Findings of isolated LOH of a single marker 
were retested and confirmed in a third experiment (cases 19, 63, 65, O, and P).  
 
3. To test the impact of less-than-100% blast counts in tumor samples, exemplary dilution 
experiments were performed in two cases of LOH positive T-ALL with almost 100% blasts in 
initial cytomorphological differentiation of initial bone marrow smears. LOH analysis of 
undiluted DNA and 1:1 diluted DNA from initial BM with control germline DNA from the same 
patient revealed identical findings of LOH in undiluted and diluted initial BM DNA. 
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4. To test a possible impact of different types of samples used for the preparation of the tumor 
DNA in T-LBL cases, a systematic comparison of results was performed. In two 
representative patients with detectable LOH at chromosome 6q tumor DNA was extracted 
from tumor touch imprints and in parallel DNA was extracted from paraffin embedded tumor 
biopsies. A total of 39 informative markers were examined and the comparative analysis of 
the results revealed no difference for any of the markers between the two different sources 
of tumor DNA. Therefore it could be shown that different types of samples lead to 
reproducible results in the LOH analysis. In the following, the availability of different sources 
of tumor DNA in about one third of patients was used to increase the total number results of 
in these cases.  
 
5. The following criteria for the quality of the results were used: minimal peak height 200 and 
optimal peak height 1000. With respect to the quality of the available samples in the current 
series, the criteria were more stringent than the criteria used by an European Consortium 
focused on quantitative analysis chimerism after allogeneic stem cell transplantation, which 
defined a minimal peak height of 50 and an optimal peak height of 5000 (Sandra Preuner 
personal communication272). 
 
 
4.4 Deletions of chromosome 6q in T-LBL 
4.4.1 Patients' characteristics in T-LBL 
For the entire group of 217 T-LBL patients the probability of event-free survival (pEFS) at  
5 years was 80±3%. pEFS was 77±4% for the 108 evaluable T-LBL patients. The median 
follow-up of was 4.4 (1.2-10.1) years for the entire group. In line with the NHL-BFM protocol, 5 
of the 108 analyzed patients received intensified therapy with high-risk courses of the ALL-BFM 
protocol because of insufficient tumor reduction after 5 weeks of treatment.  
Table 29 depicts the clinical characteristics of the 108 patients evaluable for LOH analysis 
compared with the 109 patients in whom no DNA specimens were available. The 108 patients 
evaluable for LOH analysis and the 109 non-evaluable patients were similar with respect to age, 
sex ratio, stage of disease, BM involvement, CNS involvement and lactate dehydrogenase 
(LDH) level. The group of patients not evaluable for LOH analysis was less frequently 
diagnosed with a mediastinal mass and the immunophenotype was more frequently not further 
classified. The evaluable group of 108 T-LBL patients included 21 of 27 patients in the total 
cohort who suffered from relapse. 
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Table 29. Patients' characteristics of 109 not evaluable and 108 evaluable patients 
with T-LBL 
Characteristics Patients not evaluable 
for LOH analysis 
(N=109) 
Patients evaluable 
for LOH analysis 
(N=108) 
P value 
(Fisher) 
Gender   female 32 29% 36 33%  
     male 77 71% 72 67% 0.56 
Age    < 10 y 54 50% 65 60%  
     10–14 y 38 35% 33 31%  
     > 14 y 17 16% 10 9% 0.20 
Stage of disease 
     stage I 
 
1 
 
1% 
 
0 
 
0% 
     stage II 3 3% 2 2% 
     stage III 84 79% 82 76% 
     stage IV 19 18% 24 22% 
 
 
 
 
0.61 
BM involvement 18 17% 21 19% 0.60 
Mediastinal tumor 93 85% 102 94% 0.04 
CNS involvement  2 2% 6 6% 0.17 
LDH         < 500 U/l 53 58% 45 50%  
    > 500 U/l 38 42% 45 50% 0.28 
Immunophenotype      
pro/pre-T-cell 13 12% 10 9%  
intermediate T-cell 39 36% 66 61%  
mature T-cell 12 11% 8 8%  
T-cell nfc 45 41% 24 22% 0.01 
Events  early death 2 2% 1 1%  
toxic death 4 4% 1 1%  
relapse/progress 6 6% 21 19%  
2nd malignancy 6 6% 1 1%  
LFU  7 7% 2 2%  
CCR 84 77% 82 76%  
Outcome     pEFS (5y) 83±4%  77±4%  0.30 (LR) 
incidence of relapse 5.5±2.3%  20.2±4.1%  0.002 (Gray)
Data refer to patients with successful investigation of the respective criteria. LOH: Loss of 
heterozygosity, y: years, BM: bone marrow; CNS: central nervous system, LDH: lactate 
dehydrogenase, nfc: not further classified, LFU: Lost to follow-up, CCR: continuous 
complete remission, pEFS (5y): probability of event-free survival at 5 years; LR: log rank 
test 
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4.4.2 Frequency of LOH in T-LBL 
Fragment-length analysis of germline and tumor DNA from the 108 patients was successful for 
a total of 1,671 marker analyses, with LOH in 104 markers, retention of heterozygous status in 
991 markers, homozygous patterns in 426 markers, and microsatellite instability in 150 markers. 
LOH of one or more markers was detected in 21 of the 108 T-LBL patients (19%). The detailed 
results of all 108 patients evaluable for this analysis are illustrated in appendix 8.5. 
 
4.4.3 Common deleted region in T-LBL 
The informative results and the putative deleted regions for the 21 patients with detectable LOH 
are depicted in Figure XIII.  
Four cases showed LOH of all informative markers (cases 1, 2, 3, and 4).  
In 15 cases, interstitial deletions of chromosome 6q were detected.  
Two cases showed two regions of deletion (cases 5 and 17).  
 
In 13 of the 21 cases, the putative deleted region (grey infill) spanned marker D6S1284 and/or 
adjacent marker D6S1716 and/or adjacent marker D6S1717, which therefore represents the 
chromosomal region most frequently deleted in this analysis of pediatric T-LBL samples. 
 
 
68 
 
 
 
Figure XIII. Informative markers and putative deleted regions in 21 patients with T-LBL and detectable loss of heterozygosity at chromosome 6q
Case No.
Marker 4* 1* 3* 66 62* 2* 16 17 7* 8* 10* 13* 6* 18 65 12* 9* 64 5* 19 63
D6S1589
D6S2407
D6S251
D6S1609
D6S1627
D6S1004
D6S1644
D6S1043
D6S1274
D6S300
D6S1682
D6S1284
D6S1716
D6S1717
D6S468
D6S283
D6S1580
D6S1021
D6S447
D6S278
D6S261
D6S1657
D6S1639
D6S435
D6S310
* relapsed patients
loss of heterozygosity
retained heterozygosity
putative deleted region
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4.4.4 Correlation of LOH results with clinical characteristics in T-LBL 
The clinical features of the 21 LOH positive T-LBL patients were not significantly different from 
those of the 87 T-LBL patients with no detectable LOH with respect to sex ratio, age, stage of 
disease, BM involvement, mediastinal involvement, CNS involvement and LDH level (Table 30). 
 
Table 30. Clinical features of 87 patients without detectable LOH at chromosome 6q 
compared to 21 T-LBL patients with LOH 
Characteristics Patients without LOH
(n=87) 
Patients with LOH 
(n=21) 
P value 
(Fisher) 
Gender   female 29 33% 7 33%  
     male 58 67% 14 67% 1.00 
Age    < 10 y 54 62% 11 52%  
     10–14 y 24 28% 9 43%  
     > 14 y 9 10% 1 5% 0.34 
Stage of disease     
     stage II 1 1% 1 5% 
     stage III 67 77% 15 71% 
     stage IV 19 22% 5 24% 
 
 
 
0.52 
BM involvement 16 18% 5 24% 0.55 
Mediastinal tumor 83 95% 19 91% 0.33 
CNS involvement  6 7% 0 0% 0.59 
LDH        < 500 U/l 37 53% 8 40%  
    > 500 U/l 33 47% 12 60% 0.45 
Immunophenotype      
pro/pre-T-cell 9 10% 1 5%  
intermediate T-cell 57 66% 9 43%  
mature T-cell 5 6% 3 14%  
T-cell nfc 16 18% 8 38% 0.15 
Data refer to patients with successful investigation of the respective criteria. LOH: Loss of 
heterozygosity, y: years, BM: bone marrow, CNS: central nervous system, nfc: not further 
classified 
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4.4.5 Prognostic impact of 6q-LOH in T-LBL 
In the outcome analysis, detectable LOH at 6q was associated with a significantly higher 
relapse rate in LOH positive patients compared to LOH negative patients as depicted in Table 
31.  
Table 31. Outcome of 87 T-LBL patients without detectable LOH at chromosome 6q 
compared to 21 T-LBL patients with LOH  
Characteristics Patients without LOH
(n=87) 
Patients with LOH 
(n=21) 
P value 
Events    early death 1 1% 0 0%  
toxic death 0 0% 1 5%  
relapse/progress 8 9% 13 61%  
2nd malignancy 1 1% 0 0%  
LFU  2 2% 0 0%  
CCR 75 86% 7 33%  
Outcome     pEFS (5y) 88±3%  33±10%  <0.0001 (LR) 
LOH: Loss of heterozygosity, LFU: Lost to follow-up, CCR: continuous complete 
remission, pEFS (5y): probability of event-free survival at 5 years, LR: log rank test 
 
In the group of patients with sufficient follow-up, LOH was detected in 13 of the 21 analyzed 
patients with relapse compared to 7 of the 85 patients without relapse (odds ratio 16.3, 95% 
confidence interval 5.2-50.1).The 5-year cumulative incidence of relapse was 9±3% for LOH 
negative T-LBL patients compared with a cumulative incidence of relapse of 63±12% for LOH 
positive T-LBL patients (Gray P < 0.001) as shown in Figure XIV. 
 
Figure XIV. Cumulative incidence of relapse in 21 patients with T-LBL and detectable LOH 
at chromosome 6q compared with LOH negative T-LBL cases  
LOH neg. 
LOH pos. 
years
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 1 2 3 4 5
P
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Because of the over-representation of relapsed patients in the analyzed group, this group was 
not representative of the total group of 209 T-LBL patients with sufficient follow-up. Using 
Bayes' formula, this selection bias for relapsed patients was corrected to allow estimation of the 
probability of relapse in patients with and without LOH and the resulting risk ratio. Given the 
relapse rate of 27/209 for the total cohort of T-LBL patients, the corrected probability of relapse 
in patients without detectable LOH was 6%, while the probability of relapse in patients with 
detectable LOH was 50%. The corrected risk ratio for relapse in patients with detectable LOH 
was 8.6. 
 
4.4.6 Correlation of LOH results with available cytogenetic data 
Cytogenetic data from diagnostic tumor samples were available in 16 of the 108 evaluable T-
LBL patients (Table 32). In one case (case 3) cytogenetic data were available from the time of 
initial diagnosis and from the time of relapse. 
In 13 cases, neither cytogenetics nor LOH analysis revealed structural abnormalities in 
chromosome 6q (cases 1041, 1015, 1029, 1026, 26, 45, 34, 55, 43, 54, 1055, 11, and 15).  
In case 2, a cytogenetically described deletion del(6)(q1?2q1?6) was confirmed by LOH 
analysis; however, LOH was also detected for markers D6S278 and D6S310, which were 
allocated to chromosomal bands 6q21 and 6q24.  
For two cases (cases 6 and 3), normal karyotypes were reported in diagnostic tumor samples. 
LOH analysis, however, detected deletions of chromosome 6q in both cases: in case 6, there 
was an interstitial deletion of markers assigned to bands 6q16-q21, with LOH at markers 
D6S1716, D6S1717 and D6S278. The distance between markers D6S1716 and D6S278 is 
about 10 Mb. An interstitial deletion of that small size might be undetectable with standard 
cytogenetic methods.  
LOH neg. 
LOH pos. 
years
0.0
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0.4
0.5
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0.9
1.0
0 1 2 3 4 5
P
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In case 3, LOH analyses of the initial tumor sample identified LOH for all informative markers, 
while the cytogenetic report stated normal karyotype. Interestingly, at the time of relapse 
cytogenetic analysis revealed a deletion of chromosome 6q. In this case, the metaphases 
analyzed at initial karyotyping might not have been representative for the lymphoma cells. 
 
Table 32. Correlation of available cytogenetic data and LOH data in 16 of the 108 
patients evaluable for LOH analysis 
case LOH at 6q karyotype 
case 1041 - 47,XY,+mar 
case 1015 - 46,XY  
case 1029 - 46,XY  
case 1026 - 46,XY 
case 26 - 46,XY  
case 45 - 46,XY  
case 34 - 46,XX  
case 55 - 45,XY,t(1;14)(p33;q11),dic(9;13)(p1?3;p13),t(10;12)(q21;p12) 
case 43 - 46,XX,t(7;10)(q35;q24) 
case 54 - 47,XX,t(9;17)(q34;q22),+20 
case 1055 - 46,XY,del(21)(q22) 
case 11 - 46,XX,t(6;17)(q24;q12),del(11)(q23) 
case 15 - 47,XY,+8,i(9)(q10),t(10;11)(p13;q14) 
case 6 + (3 markers) 46,XX 
case 2 + (8 markers) 46,XX,del(6)(q1?2q1?6),t(9;17)(q34;q22) 
case 3 + (6 markers 
in diagnostic 
sample) 
at diagnosis: 46,XY 
subsequent analysis at time of relapse: 
45~47,XY,del(6)(q1?4q2?1),t(9;14)(q34;q11),+?20,+mar 
 
 
4.5 Deletion of chromosome 6q in T-ALL 
One hundred twenty-seven of the 186 T-ALL patients had available tumor DNA and germline 
DNA. Except for the distribution of the immunophenotypes, this subgroup of patients did not 
differ from the non-evaluable group in terms of basic clinical characteristics such as age, sex 
ratio, mediastinal involvement, CNS involvement, LDH level, and white blood cell count at 
diagnosis (WBC) (Table 33).  
The evaluable group of 127 T-ALL patients included 22 of the 27 patients in the total cohort who 
suffered from relapse.  
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Table 33. Patients' characteristics of 59 not evaluable and 127 evaluable patients 
with T-ALL 
Characteristics Patients not 
evaluable for LOH 
analysis (N=59) 
Patients evaluable 
for LOH analysis 
(N=127) 
P value 
(Fisher) 
Gender     female 17 29% 31 24%  
       male 42 71% 96 76% 0.59 
Age      < 10 y 35 59% 68 54%  
       10–14 y 18 31% 36 28%  
       > 14 y 6 10% 23 18% 0.38 
Mediastinal tumor 34 59% 79 64% 0.57 
CNS involvement  8 16% 9 8% 0.17 
LDH         < 500 U/l 13 26% 21 18%  
      > 500 U/l 37 74% 94 82% 0.30 
Phenotype   pro/pre-T-cell 21 36% 25 20%  
intermediate T-cell 23 39% 81 64%  
mature T-cell 9 15% 19 15%  
T-cell, nfc 6 10% 2 2% 0.001 
WBC      <10 000 16 28% 14 11%  
10 000 <20 000 5 9% 14 11%  
20 000<100 000 16 28% 53 42%  
100 000<200 000 11 19% 23 18%  
>=200 000 10 17% 23 18% 0.06 
Prednisone response PGR 41 72% 78 62% 
        PPR 16 28% 47 38% 
 
0.24 
Events       early death 0 0% 0 0%  
toxic death 2 3% 7 6%  
relapse/progress 5 9% 22 17%  
2nd malignancy 0 0% 0 0%  
LFU 1 2% 0 0%  
CCR 51 86% 98 77%  
Outcome     pEFS (5y) 88±4%  77±4%  0.09 (LR) 
incidence of relapse 8.7±3.8%  17.4±3.5%  0.12 (Gray)
Data refer to patients with successful investigation of the respective criteria. LOH: Loss of 
heterozygosity, y: years, CNS: central nervous system, LDH: lactate dehydrogenase, 
WBC: white blood cell count per microliter, PGR: prednisone good response (day 8), PPR: 
prednisone poor response (day 8), LFU: Lost to follow-up, CCR: continuous complete 
remission, pEFS (5y): probability of event-free survival at 5 years; LR: log rank test 
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4.5.1 Frequency of LOH in T-ALL 
Fragment-length analysis of germline DNA and corresponding tumor DNA was successful for a 
total of 3,109 marker analyses, with LOH of 168 markers, retention of heterozygous status in 
2,132 markers, homozygous patterns in 786 markers, and microsatellite instability in 23 
markers. LOH of one or more markers was detected in 16 patients (13%). The detailed results 
of all 127 T-ALL patients evaluable for this analysis are illustrated in appendix 8.6. 
 
4.5.2 Common deleted region in T-ALL 
The informative results and putative deleted regions for the 16 patients with detectable LOH are 
depicted in Figure XV.  
None of the cases showed LOH of all informative markers at chromosome 6q.  
In 15 cases interstitial deletions were detected. 
One case showed two regions of deletion (case J). 
In 15 of the 16 cases, the putative deleted region spanned marker D6S1004. Thus, the 
chromosomal region between adjacent markers D6S1627 and D6S1644 represents the 
common deleted region in the T-ALL samples of this analysis. 
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Figure XV. Informative markers and putative deleted regions in 16 patients with T-ALL and detectable loss of heterozygosity at chromosome 6q 
Case No.
Marker A B C D E F G H* I J K L M N O P
D6S1589
D6S2407
D6S251
D6S1609
D6S1627
D6S1004
D6S1644
D6S1043
D6S1274
D6S300
D6S1682
D6S1284
D6S1716
D6S1717
D6S468
D6S283
D6S1580
D6S1021
D6S447
D6S278
D6S261
D6S1657
D6S1639
D6S435
D6S310
H* LOH+ patient with relapse
loss of heterozygosity
retained heterozygosity
putative deleted region
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4.5.3 Additional markers to delineate the centromeric breakpoint 
In the marker set used, marker D6S1589 at chromosomal band 6q14 was the most centromeric 
marker analyzed. Interestingly, this marker showed findings of LOH in 11 cases of T-ALL (cases 
A-K) and in additionally three cases the most centromeric marker with informative results 
showed LOH (cases L, M, and N). This indicates that in these cases the proximal break point of 
the interstitial deletion was located proximal to the analyzed region. To narrow down the 
proximal break point in theses cases, additional microsatellite markers were introduced. The 
localization of the additional markers D6S1638, D6S294, D6S1557 and D6S1596 are depicted 
in Figure XVI. 
 
Figure XVI. Localization of the additional markers at chromosome 6 (red color) 
 
The results of the LOH analysis of the additional markers are depicted in Figure XVII. In two 
cases the analysis of the additional markers did not reveal additional information as the markers 
were not informative (cases M and N). In the remaining 12 cases, six cases showed LOH of the 
centromeric markers at chromosome 6q but retained heterozygosity at chromosome 6p (cases 
E, L, I, K, G, and D). Six cases showed retained heterozygosity of the centromeric markers at 
chromosome 6q (cases F, B, A, C, H, and J).  
Figure XVII. Informative results of additional markers in T-ALL cases with proximal LOH 
D6S2407
D6S1589
chromosome 6
q14
D6S1596
D6S1557
D6S294
D6S1638
q13
q12
p12
marker
D6S251
centromere
marker E L I K G D F B A C H J M N
6p D6S402 ab ab ab bb bb ab ab bb
D6S294 bb ab ab ab ab ab ab ab bb
centromere
6q D6S1557 x x x x bb bb ab ab bb
D6S1596 x x x x bb bb ab ab ab ab
D6S1589 x x x x x x x x x x x bb bb
D6S2407 x x x x x x x x x
D6S251 x x x x x x x x x x x x x x
loss of heterozygosity retained heterozygosity putative deleted region
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These findings indicate, that in 14 of the 16 T-ALL patients with detectable LOH at chromosome 
6q the proximal break point of the interstitial deletion was localized close to the centromere. 
However, in none of the informative cases the putative deleted region spanned chromosome 
6p. In four cases the localization of the break point could be narrowed down to be localized 
between the adjacent marker D6S1596 and D6S1557 (cases A, C, H, J). In two cases the 
localization of the break point was between the 6q markers D6S1589 and D6S1557. In four 
cases the breakpoint was proximal to the most centromeric 6q marker D6S1557 (cases E, L, I, 
K). And in two cases the available informative results indicate the break point between marker 
D6S1596 at 6q and marker D6S294 at chromosome 6p. 
Therefore, in the majority of the cases the proximal break point was localized within the 
chromosomal region flanked by markers D6S402 and D6S1589. However, the present LOH 
analysis did not allow identifying a common break point localization in pediatric T-ALL. 
 
4.5.4 Correlation of LOH results with clinical characteristics in T-ALL 
The clinical features of the 16 LOH positive T-ALL patients were not significantly different from 
those of the 111 LOH negative patients with respect to sex ratio, white blood cell count, 
mediastinal involvement, CNS involvement, and immunophenotype. There was a trend to 
younger age and differences in the distribution of immunophenotypes in LOH positive patients 
compared with LOH negative patients (Table 34). 
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Table 34. Clinical features of 111 T-ALL patients without detectable LOH at 6q 
compared to 16 T-ALL patients with LOH  
Characteristics Patients without 
LOH (n=111) 
Patients with LOH 
(n=16) 
P value 
(Fisher) 
Gender      female 26 23% 5 31%  
        male 85 77% 11 69% 0.54 
Age       < 10 y 55 50% 13 81%  
        10–14 y 34 31% 2 13%  
        > 14 y 22 20% 1 6% 0.06 
Mediastinal tumor 69 65% 10 63% 0.91 
CNS involvement  6 6% 3 20% 0.10 
LDH         < 500 U/l 21 21% 0 0%  
       > 500 U/l 79 79% 15 100% 0.07 
Phenotype   pro/pre-T-cell 25 23% 0 0%  
intermediate T-cell 70 63% 11 69%  
mature T-cell 15 14% 4 25%  
T-cell nfc 1 1% 1 6% 0.06 
WBC       <10 000 13 12% 1 6%  
10 000<20 000 13 12% 1 6%  
20 000<100 000 44 40% 9 56%  
100 000<200 000 22 20% 1 6%  
>=200 000 19 17% 4 25% 0.47 
Data refer to patients with successful investigation of the respective criteria. LOH: Loss of 
heterozygosity, y: years, CNS: central nervous system, LDH: Lactate dehydrogenase, nfc: 
not further classified, WBC: white blood cell count per microliter 
 
 
4.5.5 Correlation of LOH results and early treatment response  
Early treatment response (evaluated by prednisone response at day 8 in PB) and the 
stratification of patients into risk arms showed no differences between LOH positive T-ALL 
patients and LOH negative T-ALL patients. In the LOH negative group 48 of the 111 patients 
were stratified to receive intensified high risk treatment compared with 5 patients in the group of 
16 LOH positive patients. The allocation of the patients in prednisone good responder and 
prednisone poor responder according to LOH status is depicted in Table 35. 
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Table 35. Early treatment response of 111 T-ALL patients without detectable LOH 
at chromosome 6q compared to 16 T-ALL patients with LOH  
Characteristics Patients without 
LOH (n=111) 
Patients with LOH 
(n=16) 
P value 
(Fisher) 
Prednisone good response 67 60% 11 69% 
Prednisone poor response 42 38% 5 31% 
Prednisone response not 
evaluated 
2 2% - - 
 
 
0.78 
LOH: Loss of heterozygosity 
 
 
4.5.6 Prognostic impact of 6q-LOH results in T-ALL 
In the outcome analysis of T-ALL patients, there was no significant difference between 16 LOH 
positive and the 111 LOH negative T-ALL patients. (Table 36).  
 
Table 36. Outcome of 111 T-ALL patients without detectable LOH at 
chromosome 6q compared to 16 T-ALL patients with LOH  
Characteristics Patients without 
LOH (n=111) 
Patients with LOH 
(n=16) 
P value 
(Fisher) 
Events   toxic death  7 6% 0 0%  
relapse/progress 21 19% 1 6%  
CCR 83 75% 15 94%  
Outcome  pEFS (5y) 75±4%  94±6%  0.10 (LR) 
LOH: Loss of heterozygosity, CCR: continuous complete remission, pEFS (5y): probability 
of event-free survival at 5 years, LR: log rank test 
 
 
Comparing patients with sufficient follow-up, LOH was detected in 1 of the 22 analyzed patients 
with relapse compared to 15 of the 98 patients without relapse (odds ratio 0.29, 95% confidence 
interval 0.04-2.3) The cumulative incidence of relapse at 5 years was 6±6% for LOH positive T-
ALL patients and 19±4% for LOH negative T-ALL patients. The difference was statistically not 
significant different (Gray P = 0.21) (Figure XVIII).  
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Figure XVIII. Cumulative incidence of relapse in 16 patients with T-ALL and detectable 
LOH at chromosome 6q compared with LOH negative T-ALL cases  
 
With a relapse rate of 27 relapses in 177 patients for the total cohort of T-ALL patients and after 
correction for over-representation of relapse patients in the analyzed group using Bayes' 
formula, the corrected probability of relapse in patients with no detectable LOH was 17%, while 
the probability of relapse in patients with detectable LOH was 6%. The corrected risk ratio for 
relapse in patients with LOH was 0.3. 
 
4.6 Delineation of a critical region of deletion 
To determine the prognostic impact of LOH at the different markers, the LOH rate and the 
deletion rate were analyzed for each marker. The LOH rate was defined as the number of 
findings of LOH in all informative results per marker. The deletion rate of a marker was defined 
as the percentage of cases with putative deleted regions spanning the particular marker. The 
putative deleted region in the particular patient was defined by the most centromeric and 
telomeric markers with LOH. The estimates for the LOH rate and the deletion rate are illustrated 
exemplarily for 7 markers in the T-ALL series in Figure XIX.  
Figure XIX. Definition of the putative deleted region comparing the LOH rate and the 
deletion rate 
LOH neg. 
LOH pos. 
years
0.0
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P
Case No.
Marker A B C D E F G H* I J K L M N O P LOH rate deletion rate
D6S1716 9 / 15 = 60% 10 / 16 = 63%
D6S1717 8 / 14 = 57% 9 / 16  = 56%
D6S468 4 / 10 = 40% 7 / 16 = 44%
D6S283 6 / 12 = 50% 8 / 16 = 50%
D6S1580 6 / 14 = 43% 8 / 16 = 50%
D6S1021 4 / 11 = 36% 8 / 16 = 50%
D6S447 6 / 11 = 55% 9 / 16 = 56%
loss of heterozygosity retained heterozygosity putative deleted region
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The definition of the putative deleted region was based on the assumption that in the majority of 
cases with 6q aberration, there is only one detectable deletion. In contrast to the LOH rate, the 
putative deleted region covers chromosomal regions with no informative markers. The putative 
deleted region has the advantage of not being influenced by the rate of heterozygosity or the 
feasibility of LOH analysis of the markers. Therefore the deletion rate might be advantageous 
for the analysis of markers with only a limited number of informative results.  
For the determination of the prognostic impact of LOH at the different markers, both, the LOH 
rate and the deletion rate were analyzed. The estimated rates were compared for 
1) T-ALL versus T-LBL 
2) T-LBL patients with and without relapse  
3) T-ALL patients with and without relapse. 
For the comparison of T-ALL and T-LBL, the deletion rates are illustrated in Figure XX. Due to 
the higher number of markers without results in T-LBL compared with T-ALL, the illustrative 
comparison of the deletion rates must be analyzed with certain caution. Therefore the 
comparison of the LOH rates are depicted in Table 37.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure XX. Deletion rates of particular markers in chromosome 6q of T-ALL (black bars) 
and T-LBL patients (light grey bars). For the markers telomeric to marker D6S1682, the 
deletion rate differed between T-LBL and T-ALL patients with statistically significant 
differences for markers D6S1657 and D6S1639. *: statistically significant differences 
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Table 37. LOH rates per marker in patients with T-ALL and T-LBL 
 T-ALL patients (n=127) T-LBL patients (n=108) 
Marker No. of 
results 
No. of 
informative 
results 
No. of 
LOH 
LOH 
rate (%)
No. of 
result
s 
No. of 
informative 
results 
No. of 
LOH 
LOH 
rate (%)
D6S1589 123 96 11 11% 84 53 6 11% 
D6S2407 123 81 9 11% 81 51 6 12% 
D6S251 126 101 14 14% 39 31 2 6% 
D6S1609 123 84 11 13% 39 27 4 15% 
D6S1627 116 96 12 13% 76 59 3 5% 
D6S1004 126 84 8 10% 74 45 4 9% 
D6S1644 125 110 11 10% 65 53 4 8% 
D6S1043 125 104 11 11% 94 74 6 8% 
D6S1274 127 86 7 8% 54 32 5 16% 
D6S300 121 101 7 7% 54 39 8 21% 
D6S1682 126 78 8 10% 48 19 1 5% 
D6S1284 126 48 4 8% 57 38 7 18% 
D6S1716 127 96 9 9% 64 41 2 5% 
D6S1717 124 98 8 8% 81 50 7 14% 
D6S468 127 88 4 5% 92 50 4 8% 
D6S283 119 98 6 6% 34 25 1 4% 
D6S1580 126 97 6 6% 92 55 5 9% 
D6S1021 123 93 4 4% 69 48 5 10% 
D6S447 126 88 6 7% 84 48 3 6% 
D6S278 123 85 6 7% 48 32 5 16% 
D6S261 127 100 4 4% 78 53 2 4% 
D6S1657 126 104 1 1% 77 49 4 8% 
D6S1639 125 111 0 0% 59 45 4 9% 
D6S435 122 75 0 0% 48 19 2 11% 
D6S310 127 98 1 1% 80 59 4 7% 
 
The deletion rates according to outcome of the patients were analyzed separately for T-ALL and 
T-LBL patients and illustrated in Figures XXI and XXII. For this analysis only patients with 
relapse or patients with follow-up of at least two years were included. Of the 108 T-LBL patients, 
two patients could not be included in this analysis because of toxic death (case 58) or death 
after initial complications (case 19; LOH positive for marker D6S1004). Of the 127 T-ALL 
patients, seven cases (all LOH negative) were excluded due to toxic death.  
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Figure XXI. Deletion rates of particular markers in relapsed T-ALL patients (black bars) 
and in T-ALL patients without relapse (light grey bars). All P values not signficant 
Figure XXII. Deletion rates of particular markers in relapsed T-LBL patients (black bars) 
and in T-LBL patients without relapse (light grey bars). *: statistically significant 
differences of the deletion rates in patients with and without relapse (P value ≤ 0.05) 
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In T-ALL, statistical analysis using Fisher's exact test comparing the deletion rates according to 
outcome of the patients did not reveal significant differences for any of the markers. In contrast, 
in T-LBL patients, the deletion rates were significantly different for all markers with higher rates 
in relapsed patients compared with clearly lower deletion rates in patients without relapse.  
 
Combining the findings described above, led to the identification of markers, the deletion of 
which was associated with high risk of relapse in T-LBL patients. The adjacent markers 
D6S1284, D6S1716, D6S1717, D6S468, D6S283 and D6S1580 showed a deletion rate of 43% 
in the 21 relapsed T-LBL patients. In contrast, the deletion rate for each of these markers was 
less than 5% for T-LBL patients without relapse and less than 15% for T-ALL cases with or 
without relapse. 
Therefore, the centromeric marker D6S1682 and the telomeric marker D6S1021 flank a 
chromosomal region, that was frequently deleted in relapsed T-LBL patients, but not in T-LBL 
patients without relapse or in T-ALL patients. Thus, the results of the current study might be a 
first step for the identification of a chromosomal region which might be a "critical region" for 
determining the risk of relapse in T-LBL patients.  
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5 Discussion 
Knowledge about genetic alterations in T-cell lymphoblastic lymphoma (T-LBL) is very limited. 
The main reason for this is the scarcity of adequate tumor material for cytogenetic or molecular 
genetic analysis. Almost all T-LBL patients are diagnosed with a large mediastinal mass and a 
significant number of patients suffer from severe respiratory impairment at the time of their 
admission to the hospital. In these critically ill patients invasive procedures to obtain diagnostic 
samples are limited to the absolute minimum, in order to not aggravate the clinical condition of 
the patients. Under these circumstances, the available samples are usually sufficient for 
obligatory examinations to assure the diagnosis but usually do not allow additional research 
experiments. In addition, the remaining samples are often processed and stored in a way that 
limits possible techniques for molecular biological and genetic analyses.  
This is in certain contrast to pediatric acute T-cell lymphoblastic leukemia (T-ALL), where initial 
bone marrow and/or blood samples provide large amounts of leukemic cells. Although these 
samples are primarily used for diagnostic procedures, in almost all cases parts of the samples 
remain unused and can be stored. These samples have been collected and used for extensive 
research during the last decades, and the findings of this research allow certain insights into the 
genetic alterations and deregulated pathways in leukemic cells.  
Both T-LBL and T-ALL derive from malignant thymocytes corresponding to defined stages of 
intrathymic T-cell maturation. T-LBL and T-ALL are often considered to be different 
manifestations of one and the same disease.4 Several study groups, including the BFM group, 
distinguish between leukemia and lymphoma based on the primary site of involvement. Patients 
with less than 25% lymphoblasts in the bone marrow and no lymphoblasts in the peripheral 
blood are diagnosed with lymphoblastic lymphoma (T-LBL), while patients with 25% or more 
blasts in the bone marrow are diagnosed with lymphoblastic leukemia (T-ALL).  
Both diseases share common characteristics such as immunophenotypic features and 
lymphoblast morphology, as well as clinical characteristics such as median age at diagnosis 
and favorable outcome after ALL-type chemotherapy (our own data and 4;18;20;84).  
However, there are also differences between the two diseases. In lymphoma patients an 
anterior mediastinal mass represents the primary site of disease in the vast majority of cases, 
while in leukemia patients bone marrow involvement is the predominant site of manifestation, 
although mediastinal involvement is commonly seen in T-ALL. Interestingly, the typical sites of 
relapse differ, with predominantly local relapse in lymphoma patients36;80 and systemic relapse 
in T-ALL.153 In addition, involvement of the central nervous system (CNS) at the time of 
diagnosis is more frequent in T-ALL compared with T-LBL.18;84 These differences in the site of 
disease manifestation might indicate differences in the homing of lymphoblasts between 
lymphoma cells and leukemia cells.  
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This raises the question of whether T-LBL and T-ALL are really one and the same disease with 
two different manifestations, or whether the cells of the two diseases carry different biologic 
potential. The resolution of this question is hampered by the scarcity of available T-LBL 
specimens for detailed genetic and immunophenotypic characterization. It is stated in the 
literature and in current textbooks that the typical chromosomal aberrations reported in T-ALL 
can also be found in T-LBL.20;192 However, larger series of cytogenetic and molecular genetic 
data for T-LBL are lacking. Frequently the knowledge obtained in T-ALL is transferred onto  
T-LBL without any experimental prove.  
Three recent reports addressed the comparison of genetic features in T-LBL and T-ALL. Raetz 
and colleagues compared gene expression profiles of nine T-LBL and ten T-ALL samples. They 
reported significant and clear distinctions in the expression profiles of T-LBL and T-ALL using 
unsupervised and supervised methods of data analysis. Though the number of samples was 
limited.198  
In a retrospective series of 44 T-LBL cases (12 patients < 16 years), Baleydier and colleagues 
performed T-cell receptor rearrangement genotyping by Southern blot, paraffin tissue 
microarray immunophenotyping, and PCR and RQ-PCR quantification of pTa, RAG1, 
HOXA5/A9, HOX11, HOX11L2, LMO1/2, LYL1, TAL-1, SIL-TAL, CALM-AF10 and NUP214-ABL 
(fusion-) transcripts. The authors concluded that pediatric T-LBL is a disease of T-lymphoblasts 
arrested during beta-selection of T-cell maturation but with different oncogenic profiles 
compared to those of T-ALL arrested at the same stage of maturation.199 
The same group compared the incidence of NOTCH1 mutations. NOTCH1 plays a fundamental 
role in physiological T-cell maturation and has been shown to be mutated in the 
heterodimerisation (HD) and/or PEST domains in 50% of pediatric T-ALLs. Comparing T-ALL 
and T-LBL the findings differed insofar as HD and PEST mutations were seen in 6/22 T-ALL 
and 6/18 T-LBL with mutations and HD-only mutations in 16/22 and 7/18 respectively, whereas 
PEST-only mutations were not seen in T-ALL compared to 5/18 T-LBL cases.200 
These three recent reports encourage the hypothesis that T-ALL and T-LBL might be closely 
related albeit with differences in the biologic potential of the cells. These biological distinctions 
might be reflected in the differences of the clinical manifestations of the diseases.  
The present study is specifically focused on one genetic alteration: deletions in chromosome 6q. 
The rationale for this focus is two-fold: 
First, a very small series of T-LBL patients with available cytogenetic data indicated that 6q 
deletions might be associated with poor outcome. All four patients with 6q deletion suffered a 
relapse of their disease. Since the prognosis for patients with T-LBL who failed frontline 
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treatment is still very poor, parameters that allow early adaptation of frontline treatment to 
different relapse risks are urgently needed. For this reason further investigation of the impact of 
6q deletions seemed worthwhile, even though the number of index patients was very small and 
there were no published data on 6q deletion in pediatric T-LBL. 
The second rationale for the study was derived from analysis of the available published data on 
6q deletions in T-ALL, which is considered to be a closely related disease. The reports in the 
literature on 6q deletions in pediatric T-ALL patients are inconsistent. So far, neither the role in 
pathogenesis nor the impact on treatment outcome of patients has been clarified. Because of 
inconsistent findings the clinical impact of chromosome 6q deletions remains unclear and it was 
supposed that these deletions might have different effects in different biological entities. In 
addition, the prognostic value might depend on the respective treatment applied. 
 
5.1 Methods and samples 
T-LBL samples of tumor material were available in the NHL-BFM study center (Non-Hodgkin 
Lymphoma Berlin-Frankfurt-Münster group) for 108 T-LBL patients. These samples were mostly 
tumor touch imprints or cytospin preparations of malignant effusions. Given this limitation, the 
first attempt to obtain additional information on 6q deletion in T-LBL was performed with 
fluorescence in situ hybridization (FISH) analysis. In general, FISH analysis is an adequate 
technique for the analysis of cells transferred onto microscopic slides, which offers the 
opportunity to analyze tumor touch imprints and cytospin preparations. However, FISH analysis 
of the available sample series was hampered by the long period of storage of the slides, which 
led to complete and irreversible dehydration of the cells, making the slides unusable for FISH 
analysis. 
In a second attempt loss of heterozygosity (LOH) analysis was used, which is an alternative 
method for the detection of deletions of chromosomal material and allows analyzing specimens 
that do not fulfill the prerequisites in terms of quantity and quality necessary for other methods, 
e.g. FISH or cytogenetics. Therefore this technique was optimal for the examination of the 
available series of T-LBL samples. 
The samples used showed a certain variety in quality and quantity. For optimal utilization of the 
available resources different protocols were used for DNA preparation in order to allow 
maximum amount of DNA recovery according to the type of sample.  
 
5.2 Common deleted regions and prognostic impact of 6q deletions 
A total of 108 T-LBL and 127 T-ALL patients were evaluable for this study. In these groups of 
patients, LOH analysis was successfully performed for more than 4,500 microsatellite marker 
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analyses. These data represent the largest comparative analysis of T-LBL and T-ALL. In 
addition, all patients had been treated with an ALL-BFM treatment regimen, meaning that direct 
comparison and detailed analysis of outcome data of the patients was possible. 
 
5.2.1 Common deleted regions and prognostic impact of 6q deletions in T-ALL 
LOH of at least one marker was detected in 16 of 127 analyzed T-ALL cases (13%). The 
frequency of LOH at 6q observed in the present study was comparable to those reported in the 
literature.92;93;95;204;227;228;240;255  
Regarding clinical characteristics, there was a trend in LOH positive cases for younger age, 
more frequent CNS involvement and less frequent immature T-cell immunophenotype, even 
though these findings did not reach statistical significance. There were no differences with 
respect to sex ratio, the incidence of mediastinal tumor, the lactate dehydrogenase (LDH) level 
and the white blood cell count at diagnosis. Therefore, no specific association of 6q deletions 
with other clinical characteristics could be assessed. 
Regarding the identification of a common deleted region in the present T-ALL series, it was 
interesting to observe that the vast majority of LOH positive cases showed LOH of the 
microsatellite markers at the proximal part of chromosome 6q, while the more telomeric markers 
retained heterozygosity. Due to the fact that in 14 of the 16 LOH positive patients the most 
centromeric informative marker showed LOH, the proximal break points of 6q could not be 
identified with the set of 25 markers used in this analysis. To narrow down the location of the 
proximal break points, additional microsatellite markers were implemented. Twelve cases could 
be analyzed successfully with these additional markers, showing either retained heterozygosity 
at more centromeric marker on 6q or retained heterozygosity at the most centromeric marker 
localized on chromosome 6p. These results confirm the finding of interstitial deletions with 
proximal break points close to the centromere. The telomeric break points varied but were 
almost all within the chromosomal bands 6q15, 6q16 and 6q21. Only one patient with two 
regions of deletion showed LOH of the more telomeric markers. 
Regarding the minimal common deleted region of the 16 LOH positive T-ALL cases, a small 
region of 4.3 Mb at the passage of chromosomal bands 6q14 and 6q15 could be identified. This 
region was spanned by the putative deleted region in 15 of the 16 LOH positive patients (94%). 
Since the centromeric limitation of this common deleted region was defined by only one 
individual case (case O; isolated LOH of marker D6S1004; shown in three independent PCR 
and fragment length analysis reactions), further analysis will be necessary to confirm this 
finding. The telomeric limitation of the common deleted region was defined by a total of three 
cases (cases J, N, and O), which might provide certain evidence for the telomeric limitation of 
the minimal common deleted region in our series of pediatric T-ALL cases.  
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Interestingly, the common deleted region in the current sample series does not overlap with 
most of the common deleted regions described in the literature. Figure XXIII summarizes the 
relative positions of common deleted regions in ALL or in some studies ALL plus NHL samples 
identified by fluorescence in situ hybridization or LOH in eight published studies.204-
206;226;229;231;240;254 
 
Figure XXIII. Regions of minimal deletion in ALL (+NHL) identified in published studies 
mapping 6q deletion with fluorescence in situ hybridization or loss of heterozygosity.  
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Only one of the eight identified common deleted regions overlaps with the common deleted 
region detected in our T-ALL series. Interestingly, the study of Hatta et al. was the only 
published series that was restricted to leukemia samples of T-cell immunophenotype, however, 
the population were HTLV-I positive adult T-cell leukemia patients, which is biologically different 
from pediatric T-ALL. The other studies included precursor B-cell and T-cell ALL and cases of 
Non-Hodgkin lymphoma. The almost complete overlap of the common deleted regions identified 
in our T-cell-restricted study and that of Hatta et al. supports the theory that, although 6q 
deletions are observed in a variety of hematological malignancies, the pattern of 6q deletion 
might be specific for the immunophenotype of the cells. Such subtype-specific minimal regions 
of deletion were described earlier for different subtypes of B-cell non-Hodgkin lymphoma213;216 
and were reported to allow discrimination of Waldenstrom macroglobulinemia from IgM 
monoclonal gammopathy of undetermined significance273. 
 
In the outcome analysis of the T-ALL patients there was no association between clinical 
characteristics or incidence of relapse and the LOH status of the patients. Due to better options 
of response evaluation in T-ALL compared with T-LBL, in general more T-ALL patients are 
stratified into the high-risk arm of treatment. However, the initial response to treatment was not 
associated with the LOH status, and the percentage of patients stratified to receive high-risk 
treatment was similar for LOH positive and LOH negative T-ALL patients. To further rule out any 
possible effect of the intensified high-risk treatment on the prognostic impact of 6q deletions in 
T-ALL, high-risk patients were excluded in a separate analysis (data not shown). However, this 
analysis, too, did not show any prognostic impact of LOH at 6q in T-ALL patients. Therefore, the 
higher rate of patients receiving high-risk treatment in T-ALL compared with T-LBL cannot 
explain the difference between the two diseases regarding prognostic impact of 6q deletions. 
 
5.2.2 Common deleted regions and prognostic impact of 6q deletions in T-LBL 
Findings of LOH at chromosome 6q were detected in 21 of the 108 evaluable T-LBL patients 
(19%). There was no association of LOH status with clinical features such as sex, age, stage of 
disease, BM involvement, mediastinal involvement, and CNS involvement. 
Correlated with the available cytogenetic data, 6q deletions were detected more frequently with 
LOH analysis than by standard karyotyping. This can be explained by the higher resolution of 
the results obtained with the current set of microsatellite markers compared to the characteristic 
resolution of cytogenetic analysis. In the proximal part of chromosome 6q the markers were 
chosen to lie within less than 2 Mb (million base-pairs) distance from each other, while 
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cytogenetic analysis only allows a resolution of > 10 Mb, depending on the quality of the 
metaphase preparation.  
In the 21 LOH positive T-LBL cases the putative deleted regions showed only a partial overlap, 
which complicated the definition of a common deleted region. The chromosomal region most 
frequently deleted in this analysis spanned marker D6S1284 and/or adjacent marker D6S1716 
and/or adjacent marker D6S1717 in 13 of the 21 LOH positive cases. 
 
In the current sample series, the most interesting result in T-LBL was not primarily the 
description of a common deleted region but the strong association between detectable LOH at 
6q and the occurrence of relapses. Outcome analysis revealed that detectable LOH at 6q was 
associated with a significantly higher relapse rate compared to LOH-negative patients. The  
5-year cumulative incidence of relapse was 9±3% for LOH-negative patients compared with 
63±12% for LOH-positive patients (P < 0.001). A total of 21 relapsed patients were included in 
the current analysis and LOH was detected in 13 of the 21 patients. This LOH rate was 
significantly higher than in the group of 85 patients without relapse, where only 7 patients were 
LOH positive (odds ratio 16.3, 95% confidence interval 5.2-50.1).  
These results must be discussed with a certain caution, since the evaluable group of 108 
patients was not fully representative for the whole group of 217 patients. Comparison of 
patients' characteristics showed more frequent mediastinal involvement and an intermediate 
immunophenotype in the evaluable group compared to the patients from whom no samples 
were available. In addition, patients with relapse were over-represented in the analyzed group. 
Using Bayes' formula, this selection bias for relapsed patients was corrected to allow estimation 
of the probability of relapse in patients with and without LOH and the resulting risk ratio. Given 
the relapse rate of 27/209 for the total cohort of T-LBL patients with sufficient follow-up, the 
corrected probability of relapse in patients without detectable LOH was 6%, while the probability 
of relapse in patients with detectable LOH was 50%. The corrected risk ratio for relapse in 
patients with detectable LOH was 8.6. 
Yet the findings concerning the prognostic impact of 6q deletions contrast with our own data of 
the T-ALL series and some reports on lymphoid malignancies, including pediatric ALL, which 
could not detect a predictive value of 6q deletions for poor outcome.93;240;252 These 
discrepancies might be explained by our hypothesis that the deletion of a circumscribed region 
of the q-arm of chromosome 6 is associated with poor outcome, whereas 6q deletions not 
involving this critical region do not affect outcome. 
Aiming to identify this critical chromosomal region, the deletion of which confers a high risk of 
relapse on the patients, detailed case-by-case analysis was performed. This analysis revealed a 
critical region on chromosomal band 6q16, for which LOH was detected in nine out of 21 
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analyzed relapsed T-LBL patients (deletion rate 43%). This region included the markers 
D6S1284, D6S1716, D6S1717, D6S468, D6S283, and D6S1580. The deletion rate of these 
particular markers was less than 5% for T-LBL patients without relapse and less than 15% for  
T-ALL patients with or without relapse.  
Interestingly Foroni et al. reported an association of del6q16-q21 with poor outcome in 
childhood and adult T-ALL-patients.254 Unfortunately the report provided only rare data on the 
patients’ characteristics. Therefore the data could not be read separately for children and adults. 
In addition the provided data do not allow checking whether cases with T-LBL according to the 
BFM-definition were included in the study of Foroni et al. This differentiation of T-LBL cases 
would be have been relevant for further discussion, as the minimal region of deletion in the 
study of Foroni et al. (as indicated for ALL samples in Sinclair et al.226) does not overlap with the 
common deleted region of the T-ALL samples in our study. But the minimal deleted region of 
Foroni et al. partly overlaps with the critical region of deletion identified in our T-LBL patients 
(Figure XXIII). These preliminary data might support our hypothesis of a critical region in the 
chromosomal band 6q16, the deletion of which might be associated with a high risk of relapse. 
In our series this region was frequently deleted in T-LBL, while in T-ALL the markers of the 
critical region were retained in the majority of cases. Whether the deletion of the critical region 
confers high risk of relapse in although in T-ALL needs to be analyzed in a larger series of 
cases.  
The group of Foroni et al. mapped a minimal region of deletion in ALL between markers 
D6S1510 and D6S1692 at chromosomal band 6q16. Expression and mutational analyses 
identified GRIK2 as a candidate tumor suppressor gene. In patients with T-lineage ALL, 6q 
deletions were associated with a statistically significant reduction in GRIK2 expression.226 Data 
on the expression level of this postulated candidate tumor suppressor gene in ALL are currently 
lacking for lymphoblastic lymphoma samples. However, one might speculate that either GRIK2 
or another gene located in the critical 6q region identified from our T-LBL samples might 
influence the treatment response and chemosensitivity of lymphoma cells.  
The critical region within chromosome 6q has been fully sequenced.274 The genes, predicted 
genes and open reading frames allocated to the critical region between markers D6S1682 and 
D6S1021 are listed in Table 38. 
 
Table 38. Genes, predicted genes and open reading frames in the critical region 
of chromosome 6q  
KIAA0776 KIAA0776 
LOC442237  similar to 40S ribosomal protein S7 (S8) 
LOC642420 hypothetical protein LOC642420 
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continue Table 38 
KIAA1900 KIAA1900 
FHL5 four and a half LIM domains 5  
GPR63 G protein-coupled receptor 63 
C6orf66 chromosome 6 open reading frame 66 
C6orf167 chromosome 6 open reading frame 167 
POU3F2 POU domain, class 3, transcription factor 2  
DHRS6P1 dehydrogenase/reductase (SDR family) member 6 pseudogene 1 
COQ3 coenzyme Q3 homolog, methyltransferase (yeast) 
USP45 ubiquitin specific peptidase 45 
CCNC cyclin C 
GPR145 G protein-coupled receptor 145 
LOC442238  similar to hypothetical protein FLJ20619 
SIM1 single-minded homolog 1 (Drosophila) 
LOC153893  similar to RP42 homolog 
ASCC3 activating signal cointegrator 1 complex subunit 3 
LOC653171 similar to MAPK-interacting and spindle-stabilizing protein 
GRIK2 glutamate receptor, ionotropic, kainate 2 
FBXL4 F-box and leucine-rich repeat protein 4 
C6orf168 chromosome 6 open reading frame 168 
C6orf111 chromosome 6 open reading frame 111 
LOC642765  hypothetical protein LOC642765 
PRDM13 PR domain containing 13 
LOC642491  hypothetical protein LOC642491 
LOC442239 similar to Peroxiredoxin 2 (Thioredoxin peroxidase 1)  
 
Several possible candidate genes in addition to GRIK2 were allocated to that region, e.g., the 
transcription factors POU3F2 and SIM1 and the putative ubiquitin processing enzymes FBXL4 
and USP45. Candidate genes cyclin C and open reading frame 111 (C6orf111) have been 
shown to be expressed in hematopoetic cells,226;275 and cyclin C is a known negative regulator 
of cell growth.276  
An unselected prospective study with a larger series of T-LBL patients is necessary in order to 
characterize the patterns of 6q deletions in T-LBL in further detail. Also, further experimental 
studies will be necessary to clarify whether deletion of the suggested critical region of 6q leads 
to altered expression of one or more of the above mentioned genes and to identify the 
mechanism responsible for the altered chemosensitivity of lymphoma cells.  
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5.2.3 Comparison of LOH findings in T-ALL and T-LBL 
Interestingly, the results of LOH analysis were similar in T-LBL and T-ALL considering only the 
naïve data of all analyzed markers. This comparison is shown in Figure XXIV. 
 
Figure XXIV. Comparison of the sum of LOH results in the group of T-LBL patients versus 
the group of T-ALL patients 
 
The rate of LOH findings was almost identical, with 6% of LOH in T-LBL compared to 5% of 
LOH in T-ALL. Also, the number of homozygous markers was identical in both T-ALL and  
T-LBL. This confirms the validity of the results, because analysis of patients belonging to an 
identical population (Germany/Switzerland) is expected to result in identical rates of 
homozygous markers. The rate of markers with retained heterozygosity was higher in  
T-ALL, while the rate of instable markers was higher in T-LBL. It is the objective of a 
subsequent ongoing research project to rule out, whether this reflects a reproducible difference 
between the two diseases and not an artificial phenomenon e.g. caused by the differences of 
the sample types.  
 
Although the rate of markers with detectable LOH was similar, going into detail revealed clear 
differences in the patterns of LOH between T-LBL and T-ALL samples. In T-ALL, cases showed 
interstitial 6q deletions which were – except one case – restricted to the proximal part of 
chromosome 6q. The centromeric and telomeric breakpoints were not identical for the cases, 
but the breakpoint regions could be narrowed down to relatively small chromosomal regions. 
homozygous
marker instability
heterozygous
LOH
T-LBL: 108 pts, 1671 results T-ALL: 127 pts, 3109 results
25% homozygous
59%
heterozygous
9%
6%
homozygous
marker instability
heterozygous
LOH
25% homozygous
69% 
heterozygous
1%
5%
not informative not informative
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The homogenous breakpoint regions might indicate a common mechanism introducing the 
interstitial deletions of proximal chromosome 6q in T-ALL.  
Different mechanisms are discussed to cause interstitial deletions. In general, interstitial 
deletions are supposed to be caused by DNA double strand breaks (DSB) and subsequent 
illegitimate joining of DNA ends. One possible mechanism is the inappropriate activity of V(D)J 
recombinases which mediate the rearrangement of the T-cell receptor gene segments (TCR) 
during lymphoid maturation. The lymphoid-specific RAG1 and RAG2 proteins introduce double-
strand breaks at specific recognition sequences (recombination signal sequences, RSSs) in the 
process of the rearrangement of the T-cell receptor genes. It was reported, that these proteins 
were also capable of transposing RSS-ended fragments into new DNA sites.277 In addition, the 
access of RAG proteins to the DNA is strongly regulated so that particular chromosomal sites 
are available only in certain developmental stages.278 In a preliminary hypothesis, one might 
speculate, whether the common breakpoint regions of chromosome 6q in T-ALL might be 
marked by increased RAG accessibility during certain stage of T-cell maturation. Such a 
mechanism of illegitimate RAG activity has been reported to be involved e.g. in the deletions of 
chromosome 9q21 in lymphoid leukemia and in the translocations of BCL-2 and follicular 
lymphoma.279-281 Further structural analyses are necessary to elucidate the mechanism of the 
interstitial 6q deletion in T-ALL. 
 
In T-LBL, the findings of LOH were not as homogeneous as in T-ALL. Neither the size of the 
deleted regions nor the breakpoints clustered in a recognizable muster. Interestingly, the rate of 
markers with marker instability was higher in T-LBL compared with T-ALL. These alterations of 
the length of simple repetitive genomic sequences often indicate deficiency of the human 
mismatch repair genes hMSH2, hMSH6 and hMLH1.282 These mismatch repair (MMR) proteins 
are capable of recognizing and processing single base-pair mismatches and insertion-deletion 
loops that occur during DNA replication. Impairment of mismatch repair function is postulated to 
play a role in mutations of DNA double-strand breaks repair genes e.g. ATM.283 In a recent 
report it was shown, that impairment of the MMR system caused aberrant transcripts of the DSB 
repair genes ATM and MRE11 in leukemia and lymphoma cell lines. This might lead to 
decreased function of the DSB repair system, inducing the accumulation of genetic damage.284 
It was reported earlier, that germline or acquired ATM alterations are associated with lymphoid 
malignancies, especially of T-cell origin.137;138;140;285 Further efforts will be undertaken to analyze 
the possible association of microsatellite instability in T-LBL patients with defects in the MMR 
system. 
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5.2.4 Conclusions of the study 
The present study describes differences in the patterns of 6q deletion between pediatric T-cell 
lymphoblastic leukemia and T-cell lymphoblastic lymphoma patients. These differences were 
not only in the localization of the common deleted region, but also in the prognostic impact of 6q 
deletions, with a strong association with poor outcome in T-LBL but not in T-ALL patients. The 
pattern of 6q deletions in hematological malignancies might partly depend on the subtype and 
the immunophenotype of the malignant cells. Comparing uniformly treated and well-
characterized groups of patients might be an important step in clarifying the impact of 6q 
deletions in different hematological diseases. Conversely, knowledge of 6q deletion patterns 
might be helpful in the differentiation of subtypes of these diseases. The data obtained in the 
current analysis support the hypothesis that there are indeed genotypic differences between 
pediatric T-cell lymphoblastic leukemia and T-cell lymphoblastic lymphoma.  
 
The detailed analysis of 6q deletions in T-ALL revealed a common deleted region that was 
altered in 15 of the 16 LOH positive cases. It might be worthwhile to spend further efforts on the 
characterization of the genes located in this common deleted region in order to identify their 
possible contribution to the pathogenesis of pediatric T-ALL. 
 
In addition, for T-LBL patients a critical region of deletion could be suggested; a region, the 
deletion of which was associated with a higher risk of relapse. A larger prospectively evaluated 
series of patients and comprehensive biological and functional studies of the genes in this 
critical region will be necessary to confirm this result. However, the result of the current study 
might be a first step in identifying specific genetic alterations in T-LBL cells to distinguish low- 
and high-risk patients, enabling successful risk adaptation of frontline treatment. 
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7 List of abbreviations 
A  
ABL1 v-abl Abelson murine leukemia viral oncogene homolog 1 gene 
AF10 myeloid/lymphoid or mixed-lineage leukemia translocated to 10 gene (MLLT10) 
ALL Acute lymphoblastic leukemia 
AML Acute myeloid leukemia 
ATM Ataxia teleangiectasia mutated gene 
  
B  
BAC Bacterial artificial chromosome 
BCL-2 B-cell CLL/lymphoma 2 gene 
BFM Berlin-Frankfurt Münster 
BM Bone marrow 
BMT Bone marrow transplantation 
bp Base-pairs 
  
C  
°C Degree Celsius 
CCD Charge coupled device 
CRR Constant complete remission 
CD Cluster of differentiation 
CDKN2A cyclin-dependent kinase inhibitor 2A gene (ARF, INK4a, p14, p14ARF, p16, 
p16INK4a, p19) 
CDKN2B cyclin-dependent kinase inhibitor 2B gene (INK4B, p15) 
CNS Central nervous system 
CR Complete remission 
CRT Cranial radiotherapy 
C segments Constant segments 
CSF Cerebrospinal fluid 
CT Computed tomography 
  
D  
ddH2O Double distilled H2O 
dATP 2-Desoxyadenosin-5-triphosphate 
dCTP 2-Desoxycytidine-5-triphosphate 
dGTP 2-Desoxyguanosine-5-triphosphate 
dUTP 2-Deoxyuridine 5-triphosphate 
dTTP 2-Desoxythymidine-5-triphosphate 
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dNTP 2-Desoxyribonucleosid–5-triphosphate 
DNA Deoxyribonucleic acid 
DSB Double strand breaks 
D segments Diversity segments 
  
E  
E. coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
EFS Event free survival 
e.g. For example "exempli gratia" 
  
F  
6-FAM 6-Carboxyfluorescein 
FISH Fluorescence in situ hybridization 
FITC Fluorescein isothiocyanate 
FLA Fragment length analysis 
  
G  
g Gram 
G 1 phase G1 phase is a period in the cell cycle during interphase 
GRIK2 Glutamate receptor, ionotropic, kainate 2 gene 
  
H  
H Hour(s) 
H2O Water 
HD Heterodimerisation domain 
hMLH1 MutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) gene 
hMSH2 MutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) gene 
hMSH6 MutS homolog 6 (E. coli) gene 
HOX11 T-cell leukemia homeobox 1 gene (TLX1) 
HOX11L2 T-cell leukemia homeobox 3 gene (TLX3) 
HR High risk arm 
HTLV-I Human T-lymphotropic virus type I 
  
I  
IL Interleukin 
Iv Intravenously 
It intrathecally 
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J  
J segments Joining segments 
  
K  
kb Kilo base-pairs (1 000 base-pairs) 
  
L  
LBL Lymphoblastic lymphoma 
LCK Lymphocyte-specific protein tyrosine kinase gene 
LDH Lactate dehydrogenase 
LFU Lost to follow up 
LMO1 LIM domain only 1 gene (rhombotin 1) (RBNT1) 
LMO2 LIM domain only 2 gene (rhombotin-like 1) (RBNT2) 
LOH Loss of heterozygosity 
LYL1 Lymphoblastic leukemia derived sequence 1 gene 
  
M  
Mb Million base-pairs 
MHC Major histocompatibility complex 
min Minute(s) 
MMR Mismatch repair 
MML Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila) 
gene 
MRE11 MRE11 meiotic recombination 11 homolog A (S. cerevisiae) gene 
MRD Minimal residual disease 
MRI Magnetic resonance imaging 
MTX Methotrexate 
MYC v-myc myelocytomatosis viral oncogene homolog gene 
  
N  
N Number(s) 
NaCl Natriumchloride 
NHL Non-Hodgkin Lymphoma 
NK cell Natural killer cell 
NOTCH1 Notch homolog 1 gene 
NUP214 Nucleoporin 214kDa gene 
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O  
OD Optical density 
  
P  
P Probability (of statistical test) 
p14 cyclin-dependent kinase inhibitor 2A  
p15 cyclin-dependent kinase inhibitor 2B 
p16 cyclin-dependent kinase inhibitor 2A 
p53 tumor protein p53 gene 
PB Peripheral Blood 
pB-ALL Precursor B-cell acute lymphoblastic leukemia 
pB-LBL Precursor B-cell acute lymphoblastic l lymphoma 
PCR Polymerase chain reaction 
pEFS Probability of event free survival 
PGR Prednisone good responder 
PPR Prednisone good responder 
Pre-Tα Pre T-cell receptor alpha chain 
Pt Patient 
Pts Patients 
  
R  
RAG1 Recombination activating gene 1 
RAG2 Recombination activating gene 2 
Rb Retinoblastoma 1 gene (RB1) 
RBTN1 LIM domain only 1 (rhombotin 1) (LMO1) 
RBTN2 LIM domain only 2 (rhombotin-like 1) (LMO2) 
REAL Revised European American Lymphoma Classification 
rpm Revolutions per minute 
RR Risk ratio 
RSS Recombination signal sequences 
  
S  
SD Standard deviation 
SDS Sodium dodecyl sulfate 
Sec seconds 
SIL SCL/TAL-1 interrupting locus (STIL) 
STR Short tandem repeat 
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T  
Tab. Table 
TAL-1 T-cell acute lymphocytic leukemia 1 gene (SCL) 
Taq Thermus aquaticus 
T-ALL Precursor T-cell acute lymphoblastic leukemia 
TCR T-cell receptor 
TCRαβ T-cell receptor alpha beta 
TCRα T-cell receptor alpha chain 
TCRβ T-cell receptor beta chain 
TCRγδ T-cell receptor gamma delta 
TCRγ T-cell receptor gamma chain 
TCRδ T-cell receptor delta chain 
TdT Terminal deoxynucleotidyl transferase 
T-LBL Precursor T-cell lymphoblastic lymphoma 
TRM Treatment related mortality 
  
U  
U Units 
UV Ultraviolett 
  
V  
V Volt 
V segments Variable segments 
  
W  
WHO World Health Organization 
  
Y  
y Year(s) 
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8 Appendix 
8.1 Detailed treatment plan NHL-BFM 95 for lymphoblastic lymphoma 
Drug Dose Given on days 
Induction Protocol I (week 1-9) 
Prednisone (orally) 
Vincristine (iv) 
Daunorubicin (iv over 1 h) 
E. coli L-Asparaginase (iv over 1h) 
Cyclophosphamide & (iv over 1 h) 
Cytarabine (iv) 
6-Mercaptopurine (orally) 
Methotrexate (it)** 
60 mg/m2  
1.5 mg/m2 (max 2 mg) 
30 mg/m2  
5,000 IU/m2  
1000 mg/m2  
75 mg/m2  
60 mg/m2  
12 mg 
1-28, then taper over 3x3 days 
8, 15, 22, 29 
8, 15, 22, 29 
12, 15, 18, 21, 24, 27, 30, 33 
36, 64 
38-41, 45-48, 52-55, 59-62 
36-63 
1, 12, 33, 45, 59* 
Protocol M (starting two weeks after the end of protocol I) 
6-Mercaptopurine (orally) 
Methotrexate*** 
Methotrexate (it)*** 
25 mg/m2 
5 g/m2 
12 mg 
1-56 
8, 22, 36, 50 
8, 22, 36, 50 
Re-Induction Protocol II (starting two weeks after the end of protocol M) 
Dexamethasone (orally) 
Vincristine (iv) 
Doxorubicin (iv over 1 h) 
E.coli L-Asparaginase (iv over 1h) 
Cyclophosphamide (iv over 1 h) 
Cytarabine (iv) 
6-Thioguanine (orally) 
Methotrexate (it)** 
10 mg/m2 
1.5 mg/m2 (max 2mg) 
30 mg/m2  
10,000 IU/m2  
1000 mg/m2  
75 mg/m2  
60 mg/m2  
12 mg 
1-21, then taper over 3x3 days 
8, 15, 22, 29 
8, 15, 22, 29 
8, 11, 15, 18 
36 
38-41, 45-48 
36-49 
38, 45 
Maintenance 
  
6-Mercaptopurine (orally) 
Methotrexate (orally) 
50mg/m² 
20mg/m² 
daily 
weekly 
iv = intravenously; it = intrathecally 
* additional doses at days 18, 27 for CNS-positive patients 
** MTX intrathecally was given 2 hours after the start of the MTX iv infusion (6 mg for age < 1 
year; 8 mg for age 1 year to <2 years, 10 mg for age 2 years to <3 years, 12 mg for age ≥ 3 
years) 
*** 10% of the dose over 30 minutes, and 90% as a 23.5-hour continuous iv infusion. 
Leucovorin rescue: 15 mg/m2 iv at hours 42, 48 and 54. Serum levels of MTX should be 
<3 µmol/l at hour 36 after the start of the MTX infusion, <1 µmol/l at hour 42, and  
< 0.4 µmol/l at hour 48 
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8.2 Solutions, buffers, and media 
 
10x NT-buffer 1 M Tris-HCl, pH 8.8, Roth, Karlsruhe, 
Germany 
2.5 ml 
 0.5 M MgCl2, Merck, Darmstadt, Germany 0.5 ml 
 10 mg/ml Bovine Serum Albumin, 
acetylated, Promega, Madison, USA 
0.25 ml 
   
20x SSC NaCl, Roth, Karlsruhe, Germany 175.3 g 
 Tri-Na-Citratdihydrate, Roth, Karlsruhe, 
Germany 
88.2 g 
 ddH2O ad 1000 ml 
 adjustment of pH 7.0   
 autoclave  
   
4x SSC+Tween 0.05% 20x SSC 200 ml 
 ddH2O 800 ml 
 Tween 20, Merck-Schuchardt, Hohenbrunn, 
Germany 
0.5 ml 
 adjustment of pH 7.0 0.5 ml 
   
2x SSC 20x SSC (pH 7.0) 100 ml 
 ddH2O 900 ml 
 adjustment of pH 7.0   
   
2x SSC+Tween 0.1%,  20x SSC 100 ml 
 ddH2O 900 ml 
 Tween 20, Merck-Schuchardt, Hohenbrunn, 
Germany 
1 ml 
 adjustment of pH 7.0 1 ml 
   
1x SSC 20x SSC (pH 7.0) 50 ml 
 ddH2O 950 ml 
 adjustment of pH 7.0   
   
0.1x SSC 2x SSC (pH 7.0) 50 ml 
 ddH2O 950 ml 
 adjustment of pH 7.0   
   
   
10x PBS NaCl, Roth, Karlsruhe, Germany 80 g 
 KCl, Merck, Darmstadt, Germany 2 g 
 Na2HPO4, Merck, Darmstadt, Germany 14.4 g 
 KH2PO4, Merck, Darmstadt, Germany 2.4 g 
 ddH2O ad 1000 ml 
 autoclave  
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1x PBS 10x PBS 100 ml 
 ddH2O 900 ml 
   
3 M Sodium Acetate Sodium acetate, Roth, Karlsruhe, Germany 408 g 
 ddH2O ad 1000 ml 
   
Ethanol series Ethanol 30%, 50%, 70%, 90% dilutions of  
 Riedel de Haen, Sigma, Seelze, Germany  
   
Fixative  
methanol:acetic acid 
Methanol, JT Baxter, Unterschleissheim, 
Germany 
80 ml 
 Acetic acid, JT Baxter, Unterschleissheim, 
Germany 
20 ml 
   
HCl solution 1 N HCl, Merck, Darmstadt, Germany 1 ml 
 ddH2O 99 ml 
   
Formamide solution  Formaldehyde solution 99%, Sigma, 
Steinheim, Germany 
7 ml 
 20x SSC 1 ml 
 ddH2O 2 ml 
 adjustment of pH 7.0  
   
Pepsin solution (10%) Pepsin (3,200-4,500 units/mg protein, No. 
P-6887), Sigma, Steinheim, Germany,  
250 mg 
 ddH2O 2.5 ml 
   
Lysogeny Broth (LB) 
Medium 
Trypton/Pepton from Casein, Roth, 
Karlsuhe, Germany 
10 g 
 Bacto-Yeast-Extract, Becton Dickinson, 
Heidelberg, Germany 
5g 
 NaCl, Roth, Karlsruhe, Germany 10 g  
 H20 ad 1000 ml 
 adjustment of pH 7.0, autoclave  
 Chloramphenicol, 25 mg/ml 800 µl/1000 ml 
medium 
   
0.1 M ß-
Mercaptoethanol 
14.4 M ß-Mercaptoethanol, Roth, 
Karlsruhe, Germany 
35 µl 
 ddH2O 4.965 ml 
   
dNTP, Roche, Roche, 
Mannheim, Germany 
100 mM dATP, Roche, Mannheim, 
Germany 
5 µl 
 100 mM dCTP, Roche, Mannheim, 
Germany 
5 µl 
 100 mM dGTP, Roche, Mannheim, 
Germany 
5 µl 
 100 mM dTTP, Roche, Mannheim, 
Germany 
5 µl 
 ddH2O 984 µl 
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8.3 DNA preparation from T-LBL samples 
 
DNA preparation kits  
PeqLab Forensic PeqGOLD Forensic DNA Kit, PeqLab, Erlangen, Germany 
Invitrogen Forensic ChargeSwitch® Forensic DNA Purification kit, Invitrogen,  
Karlsruhe, Germany 
PeqLab E.Z.N.A. Blood E.Z.N.A. Blood DNA Kit, PeqLab, Erlangen, Germany 
TriFast PeqGOLD TriFast, PeqLab, Erlangen, Germany 
QIAamp DNA mini kit QIAamp DNA mini kit, Qiagen, Erlangen, Germany 
Roche High Pure PCR High Pure PCR Template Preparation Kit,  
Roche, Mannheim, Germany 
 
case type of sample DNA preparation kit DNA concentration 
[ng/µl] 
DNA amount 
as PCR 
template 
[ng] 
70 pleural effusion cytospin PeqLab Forensic 148 20-50 
 pleural effusion frozen 
cells in DMSO 
PeqLab E.Z.N.A. Blood 14 10 
 BM smear PeqLab Forensic 151 5-40 
 germ line DNA* Roche High Pure PCR 105 10 
71 tumor touch imprint PeqLab Forensic 159 50 
 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
397 10 
 PB smear PeqLab Forensic 90 20 
 germ line DNA* Roche High Pure PCR 26 10 
25 pleural effusion cytospin PeqLab Forensic 137 40-80 
 BM smear PeqLab Forensic 121 20 
 germ line DNA* Roche High Pure PCR 37 5 
26 pleural effusion cytospin PeqLab Forensic 132 20-40 
 pleural effusion frozen 
cells in DMSO 
PeqLab E.Z.N.A. Blood 88 5 
 BM smear PeqLab Forensic 47 5 
 BM frozen cells in 
DMSO 
PeqLab E.Z.N.A. Blood 51 5 
21 tumor touch imprint PeqLab Forensic 392 20 
 BM smear PeqLab Forensic 42 5 
69 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
1427 10 
 tumor touch imprint PeqLab Forensic 137 20-80 
 BM smear PeqLab Forensic 67 5-50 
 PB smear PeqLab Forensic 162 10-100 
 germ line DNA* Roche High Pure PCR 37 10 
5 tumor touch imprint PeqLab Forensic 212 100 
 BM smear PeqLab Forensic 185 100 
22 tumor touch imprint PeqLab Forensic 903 100 
 BM smear PeqLab Forensic 304 100 
28 pleural effusion cytospin PeqLab Forensic 200 40 
 BM smear PeqLab Forensic 247 20-40 
126 
 
case type of sample DNA preparation kit DNA concentration 
[ng/µl] 
DNA amount 
as PCR 
template 
[ng] 
72 pleural effusion cytospin PeqLab Forensic 185 20-100 
 pleural effusion frozen 
cells in DMSO 
PeqLab E.Z.N.A. Blood 62 5 
 PB smear PeqLab Forensic 165 5-50 
 germ line DNA* Roche High Pure PCR 16 10 
29 pleural effusion cytospin PeqLab Forensic 154 20 
 pleural effusion cytospin Invitrogen Forensic 25 5 
 BM smear PeqLab Forensic 47 5-100 
 germ line DNA* Roche High Pure PCR 97 10 
2 pleural effusion cytospin PeqLab Forensic 342 40 
 BM smear PeqLab Forensic 155 5-20 
 germ line DNA* Roche High Pure PCR 92 10 
30 tumor touch imprint PeqLab Forensic 259 40 
 BM smear PeqLab Forensic 103 20-80 
 germ line DNA* Roche High Pure PCR 65 5 
31 tumor touch imprint PeqLab Forensic 53 20-40 
 tumor touch imprint Invitrogen Forensic 13 1 
 BM smear PeqLab Forensic 142 5 
32 pleural effusion cytospin PeqLab Forensic 70 20-100 
 PB smear PeqLab Forensic 79 5-100 
 germ line DNA* Roche High Pure PCR 17 10 
73 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
712 10 
 PB smear Invitrogen Forensic 21 2.5 
4 tumor touch imprint PeqLab Forensic 207 20 
 BM smear PeqLab Forensic 40 5-20 
 germ line DNA* Roche High Pure PCR 21 10 
74 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
228 10 
 BM smear Invitrogen Forensic 7 5 
11 pleural effusion cytospin PeqLab Forensic 42 20-50 
 tumor touch imprint PeqLab Forensic 142 20 
 pleural effusion frozen 
cells in DMSO 
PeqLab E.Z.N.A. Blood 79 25 
 BM smear PeqLab Forensic 54 2.5 
33 tumor touch imprint PeqLab Forensic 204 80 
 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
47 10-20 
 BM smear PeqLab Forensic 152  
 PB smear PeqLab Forensic 144  
 germ line DNA* Roche High Pure PCR 6 10 
34 pleural effusion frozen 
cells in DMSO 
PeqLab E.Z.N.A. Blood 73 20 
 BM frozen cells in 
DMSO 
PeqLab E.Z.N.A. Blood 75 20 
 PB smear PeqLab Forensic 112 20-50 
 germ line DNA* Roche High Pure PCR 109 10 
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case type of sample DNA preparation kit DNA concentration 
[ng/µl] 
DNA amount 
as PCR 
template 
[ng] 
35 pleural effusion cytospin PeqLab Forensic 289 20-50 
 pleural effusion cytospin PeqLab Forensic 86 20-50 
 pleural effusion frozen 
cells in DMSO 
PeqLab E.Z.N.A. Blood 38 25-50 
 BM smear PeqLab Forensic 68 10-80 
 BM smear PeqLab Forensic 80 10-80 
75 tumor touch imprint PeqLab Forensic 61 20-40 
 tumor cells frozen  PeqLab E.Z.N.A. Blood 17 20-40 
 PB smear Invitrogen Forensic 12 2.5-20 
 PB smear PeqLab Forensic 40 2.5-20 
1 tumor touch imprint PeqLab Forensic 146 60-100 
 tumor touch imprint Invitrogen Forensic 93 60-100 
 BM smear PeqLab Forensic 24 2.5-50 
36 pleural effusion cytospin PeqLab Forensic 176 40-80 
 BM smear PeqLab Forensic 273 100 
63 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
500 10 
 BM smear PeqLab Forensic 61 10 
76 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
1936 10 
 BM froze cells PeqLab E.Z.N.A. Blood 
Kit 
43 10 
77 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
1258 10 
 BM smear Invitrogen Forensic 17 2.5 
20 pleural effusion cytospin PeqLab Forensic 731 20-60 
 PB smear PeqLab Forensic 121 5-40 
 germ line DNA* Roche High Pure PCR 35 20 
14 pleural effusion cytospin PeqLab Forensic 118 50 
 pleural effusion cytospin PeqLab Forensic 106 50 
 BM smear PeqLab Forensic 105 5 
12 pleural effusion cytospin PeqLab Forensic 151 50 
 BM smear PeqLab Forensic 71 5-30 
 germ line DNA* Roche High Pure PCR 93 20 
37 tumor touch imprint PeqLab Forensic 60 20-40 
 BM frozen cells in 
DMSO 
PeqLab E.Z.N.A. Blood 86 5 
 BM smear PeqLab Forensic 68 20-50 
3 pleural effusion cytospin PeqLab Forensic 125 20-60 
 pleural effusion cytospin PeqLab Forensic 114 40 
 BM smear PeqLab Forensic 104 5 
38 tumor cells frozen in 
DMSO 
PeqLab E.Z.N.A. Blood 
Kit 
81 5-10 
 BM smear PeqLab Forensic 121 50 
60 pleural effusion cytospin PeqLab Forensic 201 20-100 
 pleural effusion frozen 
cells in DMSO 
PeqLab DNA mini 92 10 
 PB smear PeqLab Forensic 144 5-100  
 germ line DNA* Roche High Pure PCR 171 10 
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case type of sample DNA preparation kit DNA concentration 
[ng/µl] 
DNA amount 
as PCR 
template 
[ng] 
78 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
649 10 
 BM smear Invitrogen Forensic 17 2.5 
79 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
1513 10 
 BM smear Invitrogen Forensic 34 2.5 
80 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
1598 5 
 BM frozen cells PeqLab E.Z.N.A. Blood 50 5 
64 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
368 10-20 
 germ line DNA* Roche High Pure PCR 23 10 
39 tumor touch imprint PeqLab Forensic 177 20 
 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
682 10 
 BM smear PeqLab Forensic 46 5 
 germ line DNA* Roche High Pure PCR  5 
40 pleural effusion cytospin PeqLab Forensic 40 5-40 
 pleural effusion cytospin Invitrogen Forensic 28 0.75 
 pleural effusion frozen 
cells in DMSO 
PeqLab E.Z.N.A. Blood 82 20-50 
 BM smear PeqLab Forensic 63 2.5-20 
41 pleural effusion cytospin PeqLab Forensic 107 20-40 
 BM smear PeqLab Forensic 31 20 
42 pleural effusion cytospin PeqLab Forensic 275 50 
 BM smear PeqLab Forensic 223 20 
 germ line DNA* Roche High Pure PCR 48 10 
43 pericardial effusion 
cytospin 
PeqLab Forensic 163 20-60 
 pericardial effusion 
frozen cells in DMSO 
PeqLab E.Z.N.A. Blood 101 20 
 BM smear PeqLab Forensic 73 5 
13 tumor touch imprint PeqLab Forensic 140 20-100 
 BM smear PeqLab Forensic 95 5 
10 tumor touch imprint PeqLab Forensic 229 100 
 BM smear PeqLab Forensic 293 100 
44 tumor touch imprint PeqLab Forensic 218 100 
 BM smear PeqLab Forensic 248 100 
45 tumor touch imprint PeqLab Forensic 538 40 
 BM smear PeqLab Forensic 36 10-20 
 germ line DNA* Roche High Pure PCR 34 10 
46 tumor touch imprint PeqLab Forensic 300 40-80 
 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
453 10 
 BM smear PeqLab Forensic 312 20 
 germ line DNA* Roche High Pure PCR 47 10 
47 pleural effusion cytospin PeqLab Forensic 159 70 
 BM smear PeqLab Forensic 36 5 
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case type of sample DNA preparation kit DNA concentration 
[ng/µl] 
DNA amount 
as PCR 
template 
[ng] 
65 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
1874 10 
 germ line DNA* Roche High Pure PCR 10 10 
48 tumor touch imprint PeqLab Forensic 138 20-100 
 paraffin embedded 
tumor biopsy**  
xylol treatment and 
proteinase K digestion 
104 10 
 PB smear PeqLab Forensic 67 5-50 
 germ line DNA* Roche High Pure PCR 33 10 
81 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
629 10 
 BM smear Invitrogen Forensic 21 2.5 
82 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
877 10 
 PB smear Invitrogen Forensic 9 2.5 
83 pleural effusion cytospin Invitrogen Forensic 27 10 
 germ line DNA* Roche High Pure PCR 85 10 
49 tumor touch imprint PeqLab Forensic 482 60 
 BM smear PeqLab Forensic 105 10-40 
 germ line DNA* Roche High Pure PCR 6 5 
84 pleural effusion cytospin PeqLab Forensic 189 40-60 
 pleural effusion frozen 
cells in DMSO 
PeqLab E.Z.N.A. Blood 113 5 
 BM smear PeqLab Forensic 396 20-40 
 germ line DNA* Roche High Pure PCR 40 5 
50 pleural effusion cytospin PeqLab Forensic 171 20-40 
 pleural effusion frozen 
cells in DMSO 
PeqLab E.Z.N.A. Blood 28 30 
 BM smear PeqLab Forensic 85 5 
85 tumor touch imprint PeqLab Forensic 136 20-40 
 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
544 10 
 BM smear PeqLab Forensic 38 5-20 
 germ line DNA*  Roche High Pure PCR 27 10 
51 tumor touch imprint PeqLab Forensic 143 20-50 
 tumor touch imprint PeqLab Forensic 366 20-50 
 pleural effusion frozen 
cells in DMSO 
PeqLab E.Z.N.A. Blood 68 5 
 BM smear PeqLab Forensic 58 5-10 
52 pleural effusion frozen 
cells in DMSO 
PeqLab E.Z.N.A. Blood 141 5 
 germ line DNA* Roche High Pure PCR 36 50 
86 pleural effusion cytospin PeqLab Forensic 83 20-50 
 pleural effusion frozen 
cells 
PeqLab E.Z.N.A. Blood 574 5-10 
 BM smear PeqLab Forensic 36 5-20 
 PB smear PeqLab Forensic 104 10-40 
 BM frozen cells PeqLab E.Z.N.A. Blood 111 5-10 
87 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
2227 10 
 BM smear Invitrogen Forensic 15 2.5 
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case type of sample DNA preparation kit DNA concentration 
[ng/µl] 
DNA amount 
as PCR 
template 
[ng] 
88 pleural effusion cytospin PeqLab Forensic 256 40-100 
 pleural effusion frozen 
cells in DMSO 
PeqLab E.Z.N.A. Blood 453 10 
 BM smear PeqLab Forensic 276 20-100 
 germ line DNA* Roche High Pure PCR 16 10 
66 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
1051 5-10 
 germ line DNA* Roche High Pure PCR 42 5 
89 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
983 10 
 PB smear Invitrogen Forensic 12 2.5 
90 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
1506 10 
 PB smear Invitrogen Forensic 16 2.5 
53 pleural effusion cytospin PeqLab Forensic 187 20 
 PB smear PeqLab Forensic 26 5-100 
54 pleural effusion cytospin PeqLab Forensic 152 40-100 
 pleural effusion cytospin PeqLab Forensic 207 20 
 PB smear PeqLab Forensic 90 5-50 
 PB smear PeqLab Forensic 90 5-50 
 germ line DNA* Roche High Pure PCR 135 5 
18 tumor touch imprint PeqLab Forensic 22 20-100 
 tumor touch imprint PeqLab Forensic 208 20-100 
 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
643 10 
 BM smear PeqLab Forensic 64 5-30 
 germ line DNA* Roche High Pure PCR  10 
91 paraffin embedded 
tumor biopsy**  
xylol treatment and 
proteinase K digestion 
2289 10 
 BM smear PeqLab Forensic 108 10 
55 pleural effusion cytospin PeqLab Forensic 269 20 
 BM smear PeqLab Forensic 200 5-40 
 BM smear PeqLab Forensic 135 5-40 
 germ line DNA* Roche High Pure PCR 101 10 
56 tumor touch imprint PeqLab Forensic 284 40-80 
 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
527 10 
 BM smear PeqLab Forensic 236 20-100 
 germ line DNA* Roche High Pure PCR - 5 
92 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
2550 10 
 BM smear Invitrogen Forensic 31 2.5 
93 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
622 10 
 BM frozen cells PeqLab E.Z.N.A. Blood 109 5 
23 pleural effusion frozen 
cells in DMSO 
PeqLab E.Z.N.A. Blood 59 5 
 germ line DNA* Roche High Pure PCR 41 20 
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case type of sample DNA preparation kit DNA concentration 
[ng/µl] 
DNA amount 
as PCR 
template 
[ng] 
17 pleural effusion cytospin PeqLab Forensic 305 40-100 
 pleural effusion frozen 
cells in DMSO 
PeqLab E.Z.N.A. Blood 10 40 
 BM smear PeqLab Forensic 306 100 
57 tumor touch imprint PeqLab Forensic 97 20 
 BM smear PeqLab Forensic 44 2.5-5 
19 pleural effusion cytospin PeqLab Forensic 112 20-50 
 pleural effusion cytospin Forensic Invitrogen 10 20-40 
 BM smear PeqLab Forensic 51 2.5 
7 pleural effusion cytospin PeqLab Forensic 45 20-40 
 pleural effusion cytospin Invitrogen Forensic 139 50 
 germ line DNA* Roche High Pure PCR 76 15 
 BM smear PeqLab Forensic 177 5-20 
 PB smear PeqLab Forensic 67  
8 pleural effusion cytospin PeqLab Forensic 135 60 
 PB smear PeqLab Forensic 69 5-60 
 germ line DNA* Roche High Pure PCR 28 40 
9 pleural effusion cytospin PeqLab Forensic 338 20 
 BM smear PeqLab Forensic 77 10 
24 tumor touch imprint PeqLab Forensic 471 80 
 BM smear PeqLab Forensic 287 20-40 
 germ line DNA* Roche High Pure PCR 92 5 
59 tumor touch imprint PeqLab Forensic 306 20-100 
 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
221 10 
 BM smear PeqLab Forensic 174 100 
15 tumor touch imprint PeqLab Forensic 257 20 
 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
92 no results 
 BM smear PeqLab Forensic 26 5-20 
 BM smear PeqLab Forensic 121 5-20 
 germ line DNA* Roche High Pure PCR 17 5 
58 pleural effusion frozen 
cells in DMSO 
PeqLab E.Z.N.A. Blood 27 50 
 BM frozen cells in 
DMSO 
PeqLab E.Z.N.A. Blood 73 2.5 
16 pleural effusion cytospin PeqLab Forensic 220 50 
 BM smear PeqLab Forensic 62 10-20 
61 tumor touch imprint PeqLab Forensic 147 20-50 
 tumor touch imprint Invitrogen Forensic 39 20 
 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
595 10 
 BM smear PeqLab Forensic 138 5-20 
 germ line DNA* Roche High Pure PCR  10 
94 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
325 10 
 germ line DNA* Roche High Pure PCR 16 10 
6 tumor touch imprint PeqLab Forensic 532 100 
 BM smear PeqLab Forensic 447 100 
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case type of sample DNA preparation kit DNA concentration 
[ng/µl] 
DNA amount 
as PCR 
template 
[ng] 
95 pleural effusion cytospin PeqLab Forensic 112 20-60 
 pleural effusion cytospin Invitrogen Forensic 17 2.5 
 pleural effusion frozen 
cells 
TriFast 205 10 
 paraffin embedded 
tumor biopsy** 
xylol treatment, 
proteinase K digestion, 
QIAamp DNA mini kit 
92 1 
 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
1017 20 
 BM smear PeqLab Forensic 144 5-100 
 BM smear Invitrogen Forensic 12 2  
 BM smear Invitrogen Forensic 40 2 
96 ascites cytospin PeqLab Forensic 90 20 
 ascites cytospin Invitrogen Forensic 88 2.5 
 BM smear PeqLab Forensic 17 5 
 BM frozen cells PeqLab E.Z.N.A. Blood 215 5 
97 pleural effusion cytospin PeqLab Forensic 133 20-40 
 pleural effusion cytospin Invitrogen Forensic 32 2.5-5 
 PB smear PeqLab Forensic 73 10 
 PB smear Invitrogen Forensic 34 2.5-5 
98 pleural effusion cytospin PeqLab Forensic 53 10-40 
 paraffin embedded 
tumor biopsy** 
xylol treatment, 
proteinase K digestion, 
QIAamp DNA mini kit 
160 1 
 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
1134 20 
 PB smear PeqLab Forensic 39 5-15 
 BM frozen cells PeqLab E.Z.N.A. Blood 135 1-5 
99 tumor touch imprint PeqLab Forensic 41 20-40 
 tumor touch imprint Invitrogen Forensic 53 10-20 
 tumor cells frozen TriFast 57 5-10 
 paraffin embedded 
tumor biopsy** 
QIAamp DNA mini kit 231 1 
 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
1283 20 
 BM smear PeqLab Forensic 89 5-10 
 BM smear PeqLab Forensic 180 5-10 
 BM smear Invitrogen Forensic 109 2.5 
100 tumor touch imprint PeqLab Forensic 102 20-50 
 paraffin embedded 
tumor biopsy** 
xylol treatment, 
proteinase K digestion, 
QIAamp DNA mini kit 
82 1 
 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
149 20 
 PB smear PeqLab Forensic 54 5-30 
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case type of sample DNA preparation kit DNA concentration 
[ng/µl] 
DNA amount 
as PCR 
template 
[ng] 
67 tumor touch imprint PeqLab Forensic 97 20 
 paraffin embedded 
tumor biopsy** 
xylol treatment, 
proteinase K digestion, 
QIAamp DNA mini kit 
69 1 
 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
538 20 
 isolated tumor DNA - 223 20 
 BM smear PeqLab Forensic 32 2.5-5 
 BM smear PeqLab Forensic 46 2.5-5 
 BM cells frozen PeqLab E.Z.N.A. Blood 145 2.5-5 
68 pleural effusion cytospin PeqLab Forensic 58 20-40 
 BM cells frozen PeqLab E.Z.N.A. Blood 46 2.5-20 
101 pleural effusion cytospin PeqLab Forensic 275 20 
 BM cells frozen PeqLab E.Z.N.A. Blood 84 5 
102 pleural effusion cytospin PeqLab Forensic 61 10-20 
 BM cells frozen PeqLab E.Z.N.A. Blood 34 2.5-5 
103 pleural effusion cytospin PeqLab Forensic 57 20 
 pleural effusion cytospin Invitrogen Forensic 16 20 
 BM cells frozen PeqLab E.Z.N.A. Blood 201 2.5-20 
104 tumor touch imprint PeqLab Forensic 107 20-50 
 tumor touch imprint PeqLab Forensic 150 20-50 
 PB smear PeqLab Forensic 129 5-20 
 PB smear PeqLab Forensic 126 5-20 
105 tumor touch imprint PeqLab Forensic 68 20-50 
 paraffin embedded 
tumor biopsy** 
xylol treatment, 
proteinase K digestion, 
QIAamp DNA mini kit 
37 1 
 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
198 20 
 BM smear PeqLab Forensic 14 5-10 
 BM cells frozen PeqLab E.Z.N.A. Blood 238 2.5-10 
106 tumor touch imprint PeqLab Forensic 34 10-50 
 tumor touch imprint PeqLab Forensic 53 10-50 
 tumor touch imprint Invitrogen Forensic 369 10-50 
 paraffin embedded 
tumor biopsy** 
xylol treatment, 
proteinase K digestion, 
QIAamp DNA mini kit 
98 1 
 paraffin embedded 
tumor biopsy** 
xylol treatment and 
proteinase K digestion 
652 20 
 tumor cells frozen TriFast 53 5-10 
 BM smear PeqLab Forensic 62 5-10 
 BM smear Invitrogen Forensic 63 2  
 BM cells frozen TriFast 34 5-10 
107 tumor touch imprint PeqLab Forensic 283 20 
 BM smear PeqLab Forensic 95 5-10 
62 tumor touch imprint PeqLab Forensic 87 10-50 
 tumor touch imprint PeqLab Forensic 130 10-50 
 tumor touch imprint PeqLab Forensic 197 10-50 
 BM smear PeqLab Forensic 51 5-20 
 BM smear PeqLab Forensic 28 5-20 
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case type of sample DNA preparation kit DNA concentration 
[ng/µl] 
DNA amount 
as PCR 
template 
[ng] 
108 tumor touch imprint PeqLab Forensic 54 20-40 
 tumor touch imprint Invitrogen Forensic 133 20-40 
 PB smear PeqLab Forensic 97 5-100 
 BM smear Invitrogen Forensic 29 2.5 
72 pleural effusion cytospin PeqLab Forensic 36 20-40 
 tumor touch imprint PeqLab Forensic 286 20-40 
 tumor touch imprint Invitrogen Forensic 266 20-40 
 BM smear PeqLab Forensic 6 5-100 
 BM smear PeqLab Forensic 183 5-100 
 BM smear Invitrogen Forensic 141 2.5 
 BM cells frozen  PeqLab E.Z.N.A. Blood 242 5-100 
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8.4 DNA preparation from T-ALL samples 
 
DNA preparation kits  
QIAamp DNA blood midi QIAamp DNA blood mini, Qiagen, Erlangen, Germany 
Invitrogen Forensic ChargeSwitch® Forensic DNA Purification kit, Invitrogen,  
Karlsruhe, Germany 
PeqLab E.Z.N.A. Blood E.Z.N.A. Blood DNA Kit, PeqLab, Erlangen, Germany 
 
case type of sample DNA preparation kit DNA 
concentration 
[ng/µl] 
DNA amount as 
template for 
PCR [ng 
Q BM day 0 QIAamp DNA blood midi* 50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
R BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
D PB day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior Prot. M QIAamp DNA blood midi*  50 0.5-0.75 
S BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
T BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
U BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
V BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
W BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
X BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
Y PB day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior Prot. M QIAamp DNA blood midi*  50 0.5-0.75 
DC PB day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
Z BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
AA BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior Prot. M QIAamp DNA blood midi*  50 0.5-0.75 
AB BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 52 QIAamp DNA blood midi*  50 0.5-0.75 
AC BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
AD PB smear day 0 Invitrogen Forensic 27 0.75 
 PB smear day 0 Invitrogen Forensic 25 0.75 
 BM smear prior to 
protocol III 
Invitrogen Forensic 15 0.75 
 BM smear prior to 
protocol III 
Invitrogen Forensic 57 0.75 
AE BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior Prot. M QIAamp DNA blood midi*  50 0.5-0.75 
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case type of sample DNA preparation kit DNA 
concentration 
[ng/µl] 
DNA amount as 
template for 
PCR [ng 
AF BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
AG PB day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 52 QIAamp DNA blood midi*  50 0.5-0.75 
AH BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
DD pleural effusion 
day 0  
QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior Prot. M QIAamp DNA blood midi*  50 0.5-0.75 
DE BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
AI BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior Prot. M QIAamp DNA blood midi*  50 0.5-0.75 
AJ BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior Prot. M QIAamp DNA blood midi*  50 0.5-0.75 
P BM smear day 0 Invitrogen Forensic 18 0.75 
 BM prior Prot. M QIAamp DNA blood midi*  50 0.5-0.75 
AK BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 35 QIAamp DNA blood midi*  50 0.5-0.75 
AL PB day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
E BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
DF BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
O PB day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior Prot. M QIAamp DNA blood midi*  50 0.5-0.75 
AM BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
AN BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
AO BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior Prot. M QIAamp DNA blood midi*  50 0.5-0.75 
AP BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
DG BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
AQ BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior Prot. M QIAamp DNA blood midi*  50 0.5-0.75 
C pleural effusion 
frozen cells in 
DMSO  
PeqLab E.Z.N.A. Blood 111 0.75 
 BM day 0 QIAamp DNA blood midi*  50 0.75-1 
 BM day 33 QIAamp DNA blood midi*  50 0.75-1 
G BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
AR BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior Prot. M QIAamp DNA blood midi*  50 0.5-0.75 
DH BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
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case type of sample DNA preparation kit DNA 
concentration 
[ng/µl] 
DNA amount as 
template for 
PCR [ng 
AS BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
AT BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
A BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior Prot. M QIAamp DNA blood midi*  50 0.5-0.75 
AU BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33  QIAamp DNA blood midi*  50 0.5-0.75 
AV BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior 2nd HR QIAamp DNA blood midi*  50 0.5-0.75 
AW BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
AX BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior Prot. M QIAamp DNA blood midi*  50 0.5-0.75 
AY BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
AZ BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
BA PB day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior 2nd HR QIAamp DNA blood midi*  50 0.5-0.75 
BB BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior Prot. M QIAamp DNA blood midi*  50 0.5-0.75 
BC BM smear (Tu) Invitrogen Forensic 30 0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
BD BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
DI BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
BE BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 44 QIAamp DNA blood midi*  50 0.5-0.75 
BF BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
DJ BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
DK BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior 3rd HR QIAamp DNA blood midi*  50 0.5-0.75 
BG BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
DL BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
BH BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 52 QIAamp DNA blood midi*  50 0.5-0.75 
BI BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day Prot. M QIAamp DNA blood midi*  50 0.5-0.75 
BJ BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
BK BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
DM BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior 3rd HR QIAamp DNA blood midi*  50 0.5-0.75 
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case type of sample DNA preparation kit DNA 
concentration 
[ng/µl] 
DNA amount as 
template for 
PCR [ng 
BL PB day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
BM BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
BN BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
BO PB day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 52 QIAamp DNA blood midi*  50 0.5-0.75 
DN BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior 1st HR QIAamp DNA blood midi*  50 0.5-0.75 
BP PB day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
BQ BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
B BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 37 QIAamp DNA blood midi*  50 0.5-0.75 
DO BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
BR BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
BS BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
I BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
BT BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
BU BM smear day 0 Invitrogen Forensic 63 0.75 
 PB prior Prot. III QIAamp DNA blood midi*  50 0.5-0.75 
BV PB day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 52 QIAamp DNA blood midi*  50 0.5-0.75 
BW BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
BX BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior Prot. M QIAamp DNA blood midi*  50 0.5-0.75 
DP BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 52 QIAamp DNA blood midi*  50 0.5-0.75 
DQ BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior Prot. M QIAamp DNA blood midi*  50 0.5-0.75 
BY BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
BZ BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
J BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior Prot. M QIAamp DNA blood midi*  50 0.5-0.75 
CA BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior Prot. M QIAamp DNA blood midi*  50 0.5-0.75 
M BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
CB BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
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case type of sample DNA preparation kit DNA 
concentration 
[ng/µl] 
DNA amount as 
template for 
PCR [ng 
CC PB day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
DR BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
F BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
CD BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
H BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
CE BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 52 QIAamp DNA blood midi*  50 0.5-0.75 
CF BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 52 QIAamp DNA blood midi*  50 0.5-0.75 
DS BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM smear prior to 
1st HR 
Invitrogen Forensic 19 0.75 
 BM day 52 QIAamp DNA blood midi*  50 0.5-0.75 
CG BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
DT BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior 1st HR QIAamp DNA blood midi*  50 0.5-0.75 
DU BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
CH BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
K BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior Prot. M QIAamp DNA blood midi*  50 0.5-0.75 
CI BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
CJ BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
CK BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
DV PB day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 prior SCT QIAamp DNA blood midi*  50 0.5-0.75 
CL BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior Prot. M QIAamp DNA blood midi*  50 0.5-0.75 
CM BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
CN BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior Prot. M QIAamp DNA blood midi*  50 0.5-0.75 
CO BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
CP BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 41 QIAamp DNA blood midi*  50 0.5-0.75 
CQ BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
CR PB day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
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case type of sample DNA preparation kit DNA 
concentration 
[ng/µl] 
DNA amount as 
template for 
PCR [ng 
CS BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
CT PB day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33  QIAamp DNA blood midi*  50 0.5-0.75 
CU PB day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior 1st HR QIAamp DNA blood midi*  50 0.5-0.75 
CV PB day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
CW PB day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
CX BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
L PB day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
CY BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior Prot. M QIAamp DNA blood midi*  50 0.5-0.75 
CZ BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
DA BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 52 QIAamp DNA blood midi*  50 0.5-0.75 
N BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM prior Prot. M  QIAamp DNA blood midi*  50 0.5-0.75 
DW BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
DB BM day 0 QIAamp DNA blood midi*  50 0.5-0.75 
 BM day 33 QIAamp DNA blood midi*  50 0.5-0.75 
 
* All DNA preparations using the QIAamp DNA blood midi kit were performed by the staff of the 
ALL-BFM Study center in Hannover/Kiel. Forty microliter aliquots with 50 ng DNA/µl were 
provided by the ALL-BFM study center.
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8.5 Results of LOH analyses in T-LBL patients 
Each column represents the results for one individual patient; each line represents the results for one particular marker. The markers are shown in 
centromere to telomere direction as indicated in Figure IX. 
 
 
             T-LBL with relapse     T-LBL without relapse  
markers  
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8.6 Results of LOH analyses in T-ALL patients 
Each column represents the results for one individual patient; each line represents the results for one particular marker. The markers are shown in 
centromere to telomere direction as indicated in Figure IX. 
 
 
             T-ALL with relapse     T-ALL without relapse  
markers
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